<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Betaferon, INN-recombinant interferon beta-1b</title>

<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Latha;
	panose-1:2 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Segoe UI Emoji";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI Symbol";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:BISansCond;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;}
@font-face
	{font-family:"Bahnschrift Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Bahnschrift;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight SemiConde";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold SemiConden";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Candara;
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Candara Light";
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:Constantia;
	panose-1:2 3 6 2 5 3 6 3 3 3;}
@font-face
	{font-family:Corbel;
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"Corbel Light";
	panose-1:2 11 3 3 2 2 4 2 2 4;}
@font-face
	{font-family:Ebrima;
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Franklin Gothic Medium";
	panose-1:2 11 6 3 2 1 2 2 2 4;}
@font-face
	{font-family:Gabriola;
	panose-1:4 4 6 5 5 16 2 2 13 2;}
@font-face
	{font-family:Gadugi;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Georgia;
	panose-1:2 4 5 2 5 4 5 2 3 3;}
@font-face
	{font-family:Impact;
	panose-1:2 11 8 6 3 9 2 5 2 4;}
@font-face
	{font-family:"Ink Free";
	panose-1:3 8 4 2 0 5 0 0 0 0;}
@font-face
	{font-family:"Javanese Text";
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Leelawadee UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Leelawadee UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Lucida Console";
	panose-1:2 11 6 9 4 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Unicode";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Malgun Gothic";
	panose-1:2 11 5 3 2 0 0 2 0 4;}
@font-face
	{font-family:"\@Malgun Gothic";}
@font-face
	{font-family:"Malgun Gothic Semilight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Malgun Gothic Semilight";}
@font-face
	{font-family:"Microsoft Himalaya";
	panose-1:1 1 1 0 1 1 1 1 1 1;}
@font-face
	{font-family:"Microsoft JhengHei";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei";}
@font-face
	{font-family:"Microsoft JhengHei UI";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI";}
@font-face
	{font-family:"Microsoft JhengHei Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei Light";}
@font-face
	{font-family:"Microsoft JhengHei UI Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI Light";}
@font-face
	{font-family:"Microsoft New Tai Lue";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft PhagsPa";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft Sans Serif";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Microsoft Tai Le";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft YaHei";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei";}
@font-face
	{font-family:"Microsoft YaHei UI";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei UI";}
@font-face
	{font-family:"Microsoft YaHei Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei Light";}
@font-face
	{font-family:"Microsoft YaHei UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei UI Light";}
@font-face
	{font-family:"Microsoft Yi Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:MingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU-ExtB";}
@font-face
	{font-family:PMingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@PMingLiU-ExtB";}
@font-face
	{font-family:MingLiU_HKSCS-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU_HKSCS-ExtB";}
@font-face
	{font-family:"Mongolian Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"MS UI Gothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS UI Gothic";}
@font-face
	{font-family:"MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS PGothic";}
@font-face
	{font-family:"MV Boli";
	panose-1:2 0 5 0 3 2 0 9 0 0;}
@font-face
	{font-family:"Myanmar Text";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Segoe Print";
	panose-1:2 0 6 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe Script";
	panose-1:3 11 5 4 2 0 0 0 0 3;}
@font-face
	{font-family:"Segoe UI Black";
	panose-1:2 11 10 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Historic";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semibold";
	panose-1:2 11 7 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:NSimSun;
	panose-1:2 1 6 9 3 1 1 1 1 1;}
@font-face
	{font-family:"\@NSimSun";}
@font-face
	{font-family:SimSun-ExtB;
	panose-1:2 1 6 9 6 1 1 1 1 1;}
@font-face
	{font-family:"\@SimSun-ExtB";}
@font-face
	{font-family:"Sitka Small";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Text";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Subheading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Heading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Display";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Banner";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;}
@font-face
	{font-family:Webdings;
	panose-1:5 3 1 2 1 5 9 6 7 3;}
@font-face
	{font-family:"\@Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Yu Gothic UI";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI";}
@font-face
	{font-family:"Yu Gothic UI Semibold";
	panose-1:2 11 7 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semibold";}
@font-face
	{font-family:"Yu Gothic Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Light";}
@font-face
	{font-family:"Yu Gothic UI Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Light";}
@font-face
	{font-family:"Yu Gothic Medium";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Medium";}
@font-face
	{font-family:"Yu Gothic UI Semilight";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semilight";}
@font-face
	{font-family:"HoloLens MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Agency FB";
	panose-1:2 11 5 3 2 2 2 2 2 4;}
@font-face
	{font-family:Algerian;
	panose-1:4 2 7 5 4 10 2 6 7 2;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 6 6 2 2 2 3 2 4;}
@font-face
	{font-family:"Arial Rounded MT Bold";
	panose-1:2 15 7 4 3 5 4 3 2 4;}
@font-face
	{font-family:"Baskerville Old Face";
	panose-1:2 2 6 2 8 5 5 2 3 3;}
@font-face
	{font-family:"Bauhaus 93";
	panose-1:4 3 9 5 2 11 2 2 12 2;}
@font-face
	{font-family:"Bell MT";
	panose-1:2 2 5 3 6 3 5 2 3 3;}
@font-face
	{font-family:"Bernard MT Condensed";
	panose-1:2 5 8 6 6 9 5 2 4 4;}
@font-face
	{font-family:"Bodoni MT";
	panose-1:2 7 6 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Black";
	panose-1:2 7 10 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Condensed";
	panose-1:2 7 6 6 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Poster Compressed";
	panose-1:2 7 7 6 8 6 1 5 2 4;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;}
@font-face
	{font-family:"Bradley Hand ITC";
	panose-1:3 7 4 2 5 3 2 3 2 3;}
@font-face
	{font-family:"Britannic Bold";
	panose-1:2 11 9 3 6 7 3 2 2 4;}
@font-face
	{font-family:"Berlin Sans FB";
	panose-1:2 14 6 2 2 5 2 2 3 6;}
@font-face
	{font-family:"Berlin Sans FB Demi";
	panose-1:2 14 8 2 2 5 2 2 3 6;}
@font-face
	{font-family:Broadway;
	panose-1:4 4 9 5 8 11 2 2 5 2;}
@font-face
	{font-family:"Brush Script MT";
	panose-1:3 6 8 2 4 4 6 7 3 4;}
@font-face
	{font-family:"Bookshelf Symbol 7";
	panose-1:5 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Californian FB";
	panose-1:2 7 4 3 6 8 11 3 2 4;}
@font-face
	{font-family:"Calisto MT";
	panose-1:2 4 6 3 5 5 5 3 3 4;}
@font-face
	{font-family:Castellar;
	panose-1:2 10 4 2 6 4 6 1 3 1;}
@font-face
	{font-family:"Century Schoolbook";
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:Centaur;
	panose-1:2 3 5 4 5 2 5 2 3 4;}
@font-face
	{font-family:Chiller;
	panose-1:4 2 4 4 3 16 7 2 6 2;}
@font-face
	{font-family:"Colonna MT";
	panose-1:4 2 8 5 6 2 2 3 2 3;}
@font-face
	{font-family:"Cooper Black";
	panose-1:2 8 9 4 4 3 11 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Bold";
	panose-1:2 14 7 5 2 2 6 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Light";
	panose-1:2 14 5 7 2 2 6 2 4 4;}
@font-face
	{font-family:"Curlz MT";
	panose-1:4 4 4 4 5 7 2 2 2 2;}
@font-face
	{font-family:Dubai;
	panose-1:2 11 5 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Light";
	panose-1:2 11 3 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Medium";
	panose-1:2 11 6 3 3 4 3 3 2 4;}
@font-face
	{font-family:Elephant;
	panose-1:2 2 9 4 9 5 5 2 3 3;}
@font-face
	{font-family:"Engravers MT";
	panose-1:2 9 7 7 8 5 5 2 3 4;}
@font-face
	{font-family:"Eras Bold ITC";
	panose-1:2 11 9 7 3 5 4 2 2 4;}
@font-face
	{font-family:"Eras Demi ITC";
	panose-1:2 11 8 5 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Light ITC";
	panose-1:2 11 4 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Medium ITC";
	panose-1:2 11 6 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Felix Titling";
	panose-1:4 6 5 5 6 2 2 2 10 4;}
@font-face
	{font-family:Forte;
	panose-1:3 6 9 2 4 5 2 7 2 3;}
@font-face
	{font-family:"Franklin Gothic Book";
	panose-1:2 11 5 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi";
	panose-1:2 11 7 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi Cond";
	panose-1:2 11 7 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Heavy";
	panose-1:2 11 9 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Medium Cond";
	panose-1:2 11 6 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Freestyle Script";
	panose-1:3 8 4 2 3 2 5 11 4 4;}
@font-face
	{font-family:"French Script MT";
	panose-1:3 2 4 2 4 6 7 4 6 5;}
@font-face
	{font-family:"Footlight MT Light";
	panose-1:2 4 6 2 6 3 10 2 3 4;}
@font-face
	{font-family:Garamond;
	panose-1:2 2 4 4 3 3 1 1 8 3;}
@font-face
	{font-family:Gigi;
	panose-1:4 4 5 4 6 16 7 2 13 2;}
@font-face
	{font-family:"Gill Sans MT";
	panose-1:2 11 5 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans MT Condensed";
	panose-1:2 11 5 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold Condensed";
	panose-1:2 11 10 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold";
	panose-1:2 11 10 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gloucester MT Extra Condensed";
	panose-1:2 3 8 8 2 6 1 1 1 1;}
@font-face
	{font-family:"Gill Sans MT Ext Condensed Bold";
	panose-1:2 11 9 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;}
@font-face
	{font-family:"Goudy Old Style";
	panose-1:2 2 5 2 5 3 5 2 3 3;}
@font-face
	{font-family:"Goudy Stout";
	panose-1:2 2 9 4 7 3 11 2 4 1;}
@font-face
	{font-family:"Harlow Solid Italic";
	panose-1:4 3 6 4 2 15 2 2 13 2;}
@font-face
	{font-family:Harrington;
	panose-1:4 4 5 5 5 10 2 2 7 2;}
@font-face
	{font-family:Haettenschweiler;
	panose-1:2 11 7 6 4 9 2 6 2 4;}
@font-face
	{font-family:"High Tower Text";
	panose-1:2 4 5 2 5 5 6 3 3 3;}
@font-face
	{font-family:"Imprint MT Shadow";
	panose-1:4 2 6 5 6 3 3 3 2 2;}
@font-face
	{font-family:"Informal Roman";
	panose-1:3 6 4 2 3 4 6 11 2 4;}
@font-face
	{font-family:"Blackadder ITC";
	panose-1:4 2 5 5 5 16 7 2 13 2;}
@font-face
	{font-family:"Edwardian Script ITC";
	panose-1:3 3 3 2 4 7 7 13 8 4;}
@font-face
	{font-family:"Kristen ITC";
	panose-1:3 5 5 2 4 2 2 3 2 2;}
@font-face
	{font-family:Jokerman;
	panose-1:4 9 6 5 6 13 6 2 7 2;}
@font-face
	{font-family:"Juice ITC";
	panose-1:4 4 4 3 4 10 2 2 2 2;}
@font-face
	{font-family:"Kunstler Script";
	panose-1:3 3 4 2 2 6 7 13 13 6;}
@font-face
	{font-family:"Wide Latin";
	panose-1:2 10 10 7 5 5 5 2 4 4;}
@font-face
	{font-family:"Lucida Bright";
	panose-1:2 4 6 2 5 5 5 2 3 4;}
@font-face
	{font-family:"Lucida Calligraphy";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Fax";
	panose-1:2 6 6 2 5 5 5 2 2 4;}
@font-face
	{font-family:"Lucida Handwriting";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Sans";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Typewriter";
	panose-1:2 11 5 9 3 5 4 3 2 4;}
@font-face
	{font-family:Magneto;
	panose-1:4 3 8 5 5 8 2 2 13 2;}
@font-face
	{font-family:"Maiandra GD";
	panose-1:2 14 5 2 3 3 8 2 2 4;}
@font-face
	{font-family:"Matura MT Script Capitals";
	panose-1:3 2 8 2 6 6 2 7 2 2;}
@font-face
	{font-family:Mistral;
	panose-1:3 9 7 2 3 4 7 2 4 3;}
@font-face
	{font-family:"Modern No\. 20";
	panose-1:2 7 7 4 7 5 5 2 3 3;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;}
@font-face
	{font-family:"Niagara Engraved";
	panose-1:4 2 5 2 7 7 3 3 2 2;}
@font-face
	{font-family:"Niagara Solid";
	panose-1:4 2 5 2 7 7 2 2 2 2;}
@font-face
	{font-family:"OCR A Extended";
	panose-1:2 1 5 9 2 1 2 1 3 3;}
@font-face
	{font-family:"Old English Text MT";
	panose-1:3 4 9 2 4 5 8 3 8 6;}
@font-face
	{font-family:Onyx;
	panose-1:4 5 6 2 8 7 2 2 2 3;}
@font-face
	{font-family:"MS Outlook";
	panose-1:5 1 1 0 1 0 0 0 0 0;}
@font-face
	{font-family:"Palace Script MT";
	panose-1:3 3 3 2 2 6 7 12 11 5;}
@font-face
	{font-family:Papyrus;
	panose-1:3 7 5 2 6 5 2 3 2 5;}
@font-face
	{font-family:Parchment;
	panose-1:3 4 6 2 4 7 8 4 8 4;}
@font-face
	{font-family:Perpetua;
	panose-1:2 2 5 2 6 4 1 2 3 3;}
@font-face
	{font-family:"Perpetua Titling MT";
	panose-1:2 2 5 2 6 5 5 2 8 4;}
@font-face
	{font-family:Playbill;
	panose-1:4 5 6 3 10 6 2 2 2 2;}
@font-face
	{font-family:"Poor Richard";
	panose-1:2 8 5 2 5 5 5 2 7 2;}
@font-face
	{font-family:Pristina;
	panose-1:3 6 4 2 4 4 6 8 2 4;}
@font-face
	{font-family:"Rage Italic";
	panose-1:3 7 5 2 4 5 7 7 3 4;}
@font-face
	{font-family:Ravie;
	panose-1:4 4 8 5 5 8 9 2 6 2;}
@font-face
	{font-family:"MS Reference Sans Serif";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"MS Reference Specialty";
	panose-1:5 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Rockwell Condensed";
	panose-1:2 6 6 3 5 4 5 2 1 4;}
@font-face
	{font-family:Rockwell;
	panose-1:2 6 6 3 2 2 5 2 4 3;}
@font-face
	{font-family:"Rockwell Extra Bold";
	panose-1:2 6 9 3 4 5 5 2 4 3;}
@font-face
	{font-family:"Script MT Bold";
	panose-1:3 4 6 2 4 6 7 8 9 4;}
@font-face
	{font-family:"Showcard Gothic";
	panose-1:4 2 9 4 2 1 2 2 6 4;}
@font-face
	{font-family:"Snap ITC";
	panose-1:4 4 10 7 6 10 2 2 2 2;}
@font-face
	{font-family:Stencil;
	panose-1:4 4 9 5 13 8 2 2 4 4;}
@font-face
	{font-family:"Tw Cen MT";
	panose-1:2 11 6 2 2 1 4 2 6 3;}
@font-face
	{font-family:"Tw Cen MT Condensed";
	panose-1:2 11 6 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Tw Cen MT Condensed Extra Bold";
	panose-1:2 11 8 3 2 2 2 2 2 4;}
@font-face
	{font-family:"Tempus Sans ITC";
	panose-1:4 2 4 4 3 13 7 2 2 2;}
@font-face
	{font-family:"Viner Hand ITC";
	panose-1:3 7 5 2 3 5 2 2 2 3;}
@font-face
	{font-family:Vivaldi;
	panose-1:3 2 6 2 5 5 6 9 8 4;}
@font-face
	{font-family:"Vladimir Script";
	panose-1:3 5 4 2 4 4 7 7 3 5;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;}
@font-face
	{font-family:"Wingdings 3";
	panose-1:5 4 1 2 1 8 7 7 7 7;}
@font-face
	{font-family:AngsanaUPC;}
@font-face
	{font-family:CordiaUPC;}
@font-face
	{font-family:Abadi;}
@font-face
	{font-family:"Abadi Extra Light";}
@font-face
	{font-family:Aharoni;}
@font-face
	{font-family:Aldhabi;}
@font-face
	{font-family:Aparajita;}
@font-face
	{font-family:"Arabic Typesetting";}
@font-face
	{font-family:"Arial Nova";}
@font-face
	{font-family:"Arial Nova Cond";}
@font-face
	{font-family:"Arial Nova Cond Light";}
@font-face
	{font-family:"Arial Nova Light";}
@font-face
	{font-family:"Avenir Next LT Pro";}
@font-face
	{font-family:"Avenir Next LT Pro Light";}
@font-face
	{font-family:BatangChe;}
@font-face
	{font-family:Bembo;}
@font-face
	{font-family:Biome;}
@font-face
	{font-family:"Biome Light";}
@font-face
	{font-family:"Browallia New";}
@font-face
	{font-family:BrowalliaUPC;}
@font-face
	{font-family:Cavolini;}
@font-face
	{font-family:Dante;}
@font-face
	{font-family:DaunPenh;}
@font-face
	{font-family:David;}
@font-face
	{font-family:Daytona;}
@font-face
	{font-family:"Daytona Condensed";}
@font-face
	{font-family:"Daytona Condensed Light";}
@font-face
	{font-family:"Daytona Light";}
@font-face
	{font-family:"DengXian Light";}
@font-face
	{font-family:DilleniaUPC;}
@font-face
	{font-family:DokChampa;}
@font-face
	{font-family:DotumChe;}
@font-face
	{font-family:"Elephant Pro";}
@font-face
	{font-family:EucrosiaUPC;}
@font-face
	{font-family:Euphemia;}
@font-face
	{font-family:FangSong;}
@font-face
	{font-family:FrankRuehl;}
@font-face
	{font-family:FreesiaUPC;}
@font-face
	{font-family:"Georgia Pro";}
@font-face
	{font-family:"Georgia Pro Black";}
@font-face
	{font-family:"Georgia Pro Cond";}
@font-face
	{font-family:"Georgia Pro Cond Black";}
@font-face
	{font-family:"Georgia Pro Cond Light";}
@font-face
	{font-family:"Georgia Pro Cond Semibold";}
@font-face
	{font-family:"Georgia Pro Light";}
@font-face
	{font-family:"Georgia Pro Semibold";}
@font-face
	{font-family:"Gill Sans Nova";}
@font-face
	{font-family:"Gill Sans Nova Cond";}
@font-face
	{font-family:"Gill Sans Nova Cond Lt";}
@font-face
	{font-family:"Gill Sans Nova Cond Ultra Bold";}
@font-face
	{font-family:"Gill Sans Nova Cond XBd";}
@font-face
	{font-family:"Gill Sans Nova Light";}
@font-face
	{font-family:"Gill Sans Nova Ultra Bold";}
@font-face
	{font-family:Gisha;}
@font-face
	{font-family:Grotesque;}
@font-face
	{font-family:"Grotesque Light";}
@font-face
	{font-family:GulimChe;}
@font-face
	{font-family:Gungsuh;}
@font-face
	{font-family:GungsuhChe;}
@font-face
	{font-family:"Hadassah Friedlaender";}
@font-face
	{font-family:HGGothicE;}
@font-face
	{font-family:HGMaruGothicMPRO;}
@font-face
	{font-family:HGMinchoE;}
@font-face
	{font-family:HGPGothicE;}
@font-face
	{font-family:HGPMinchoE;}
@font-face
	{font-family:HGPSoeiKakugothicUB;}
@font-face
	{font-family:HGSGothicE;}
@font-face
	{font-family:HGSMinchoE;}
@font-face
	{font-family:HGSoeiKakugothicUB;}
@font-face
	{font-family:HGSSoeiKakugothicUB;}
@font-face
	{font-family:IrisUPC;}
@font-face
	{font-family:"Iskoola Pota";}
@font-face
	{font-family:JasmineUPC;}
@font-face
	{font-family:KaiTi;}
@font-face
	{font-family:Kalinga;}
@font-face
	{font-family:Kartika;}
@font-face
	{font-family:"Khmer UI";}
@font-face
	{font-family:Kigelia;}
@font-face
	{font-family:"Kigelia Arabic";}
@font-face
	{font-family:"Kigelia Arabic Light";}
@font-face
	{font-family:"Kigelia Light";}
@font-face
	{font-family:KodchiangUPC;}
@font-face
	{font-family:Kokila;}
@font-face
	{font-family:"Lao UI";}
@font-face
	{font-family:Leelawadee;}
@font-face
	{font-family:"Levenim MT";}
@font-face
	{font-family:LilyUPC;}
@font-face
	{font-family:"Mangal Pro";}
@font-face
	{font-family:Meiryo;}
@font-face
	{font-family:"Meiryo UI";}
@font-face
	{font-family:"Microsoft GothicNeo";}
@font-face
	{font-family:"Microsoft GothicNeo Light";}
@font-face
	{font-family:"Microsoft Uighur";}
@font-face
	{font-family:MingLiU_HKSCS;}
@font-face
	{font-family:Miriam;}
@font-face
	{font-family:"Miriam Fixed";}
@font-face
	{font-family:"Modern Love";}
@font-face
	{font-family:"Modern Love Caps";}
@font-face
	{font-family:"Modern Love Grunge";}
@font-face
	{font-family:MoolBoran;}
@font-face
	{font-family:"MS PMincho";}
@font-face
	{font-family:"MT Extra";}
@font-face
	{font-family:Narkisim;}
@font-face
	{font-family:"Neue Haas Grotesk Text Pro";}
@font-face
	{font-family:"News Gothic MT";}
@font-face
	{font-family:Nyala;}
@font-face
	{font-family:OCRB;}
@font-face
	{font-family:"Plantagenet Cherokee";}
@font-face
	{font-family:Posterama;}
@font-face
	{font-family:"Quire Sans";}
@font-face
	{font-family:"Quire Sans Light";}
@font-face
	{font-family:"Quire Sans Pro Light";}
@font-face
	{font-family:"Rockwell Light";}
@font-face
	{font-family:"Rockwell Nova";}
@font-face
	{font-family:"Rockwell Nova Cond";}
@font-face
	{font-family:"Rockwell Nova Cond Light";}
@font-face
	{font-family:"Rockwell Nova Extra Bold";}
@font-face
	{font-family:"Rockwell Nova Light";}
@font-face
	{font-family:Rod;}
@font-face
	{font-family:"Sabon Next LT";}
@font-face
	{font-family:"Sagona Book";}
@font-face
	{font-family:"Sagona ExtraLight";}
@font-face
	{font-family:"Sakkal Majalla";}
@font-face
	{font-family:"Sanskrit Text";}
@font-face
	{font-family:Selawik;}
@font-face
	{font-family:"Selawik Light";}
@font-face
	{font-family:"Selawik Semibold";}
@font-face
	{font-family:"Shonar Bangla";}
@font-face
	{font-family:"Simplified Arabic";}
@font-face
	{font-family:"Simplified Arabic Fixed";}
@font-face
	{font-family:"Sitka Banner Semibold";}
@font-face
	{font-family:"Sitka Display Semibold";}
@font-face
	{font-family:"Sitka Heading Semibold";}
@font-face
	{font-family:"Sitka Small Semibold";}
@font-face
	{font-family:"Sitka Subheading Semibold";}
@font-face
	{font-family:"Sitka Text Semibold";}
@font-face
	{font-family:"Source Sans Pro";}
@font-face
	{font-family:"Source Sans Pro Black";}
@font-face
	{font-family:"Source Sans Pro ExtraLight";}
@font-face
	{font-family:"Source Sans Pro Light";}
@font-face
	{font-family:"Source Sans Pro SemiBold";}
@font-face
	{font-family:"Speak Pro";}
@font-face
	{font-family:"Speak Pro Light";}
@font-face
	{font-family:STCaiyun;}
@font-face
	{font-family:STFangsong;}
@font-face
	{font-family:STHupo;}
@font-face
	{font-family:STKaiti;}
@font-face
	{font-family:STXihei;}
@font-face
	{font-family:STXingkai;}
@font-face
	{font-family:STXinwei;}
@font-face
	{font-family:STZhongsong;}
@font-face
	{font-family:"TH SarabunPSK";}
@font-face
	{font-family:"The Hand";}
@font-face
	{font-family:"The Hand Black";}
@font-face
	{font-family:"The Hand Extrablack";}
@font-face
	{font-family:"The Hand Light";}
@font-face
	{font-family:"The Serif Hand";}
@font-face
	{font-family:"The Serif Hand Black";}
@font-face
	{font-family:"The Serif Hand Extrablack";}
@font-face
	{font-family:"The Serif Hand Light";}
@font-face
	{font-family:"Tisa Offc Serif Pro";}
@font-face
	{font-family:"Tisa Offc Serif Pro Thin";}
@font-face
	{font-family:"Trade Gothic Next";}
@font-face
	{font-family:"Trade Gothic Next Cond";}
@font-face
	{font-family:"Trade Gothic Next Cond Hv";}
@font-face
	{font-family:"Trade Gothic Next Heavy";}
@font-face
	{font-family:"Trade Gothic Next Light";}
@font-face
	{font-family:"Traditional Arabic";}
@font-face
	{font-family:"UD Digi Kyokasho N-B";}
@font-face
	{font-family:"UD Digi Kyokasho N-R";}
@font-face
	{font-family:"UD Digi Kyokasho NK-B";}
@font-face
	{font-family:"UD Digi Kyokasho NK-R";}
@font-face
	{font-family:"UD Digi Kyokasho NP-B";}
@font-face
	{font-family:"UD Digi Kyokasho NP-R";}
@font-face
	{font-family:Univers;}
@font-face
	{font-family:"Univers Condensed";}
@font-face
	{font-family:"Univers Condensed Light";}
@font-face
	{font-family:"Univers Light";}
@font-face
	{font-family:"Urdu Typesetting";}
@font-face
	{font-family:Utsaah;}
@font-face
	{font-family:Vani;}
@font-face
	{font-family:"Verdana Pro";}
@font-face
	{font-family:"Verdana Pro Black";}
@font-face
	{font-family:"Verdana Pro Cond";}
@font-face
	{font-family:"Verdana Pro Cond Black";}
@font-face
	{font-family:"Verdana Pro Cond Light";}
@font-face
	{font-family:"Verdana Pro Cond SemiBold";}
@font-face
	{font-family:"Verdana Pro Light";}
@font-face
	{font-family:"Verdana Pro SemiBold";}
@font-face
	{font-family:Vijaya;}
@font-face
	{font-family:"Walbaum Display";}
@font-face
	{font-family:"Walbaum Display Heavy";}
@font-face
	{font-family:"Walbaum Display Light";}
@font-face
	{font-family:"Walbaum Display SemiBold";}
@font-face
	{font-family:"Walbaum Heading";}
@font-face
	{font-family:"Walbaum Text";}
@font-face
	{font-family:"Yu Mincho";}
@font-face
	{font-family:"Yu Mincho Demibold";}
@font-face
	{font-family:"Yu Mincho Light";}
@font-face
	{font-family:"TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:PraxisCom-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EUAlbertina;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"\@TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"\@Batang";
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@BatangChe";}
@font-face
	{font-family:"\@Gungsuh";}
@font-face
	{font-family:"\@GungsuhChe";}
@font-face
	{font-family:"\@DengXian Light";}
@font-face
	{font-family:"\@Gulim";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@GulimChe";}
@font-face
	{font-family:"\@Dotum";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@DotumChe";}
@font-face
	{font-family:"\@Meiryo";}
@font-face
	{font-family:"\@Meiryo UI";}
@font-face
	{font-family:"\@MingLiU";
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:"\@PMingLiU";
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"\@MingLiU_HKSCS";}
@font-face
	{font-family:"\@MS PMincho";}
@font-face
	{font-family:"\@STXingkai";}
@font-face
	{font-family:"\@STZhongsong";}
@font-face
	{font-family:"\@Yu Mincho";}
@font-face
	{font-family:"\@Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Times-Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:CourierNewPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"SAS Monospace";}
@font-face
	{font-family:"Bookshelf Symbol 3";}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
h1
	{margin-top:22.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:43.1pt;
	text-indent:-43.1pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h2
	{margin-top:11.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:50.45pt;
	text-indent:-50.45pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h3
	{margin-top:11.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:57.55pt;
	text-indent:-57.55pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h4
	{margin-top:11.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:64.9pt;
	text-indent:-64.9pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h5
	{margin-top:11.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:1.0in;
	text-indent:-1.0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h6
	{margin-top:11.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:76.55pt;
	text-indent:-76.55pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{margin-top:11.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:85.6pt;
	text-indent:-85.6pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{margin-top:11.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:94.95pt;
	text-indent:-94.95pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{margin-top:11.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:104.05pt;
	text-indent:-104.05pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoIndex1, li.MsoIndex1, div.MsoIndex1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:12.0pt;
	text-indent:-12.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex2, li.MsoIndex2, div.MsoIndex2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:24.0pt;
	text-indent:-12.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex3, li.MsoIndex3, div.MsoIndex3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:.5in;
	text-indent:-12.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex4, li.MsoIndex4, div.MsoIndex4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:48.0pt;
	text-indent:-12.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex5, li.MsoIndex5, div.MsoIndex5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:60.0pt;
	text-indent:-12.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex6, li.MsoIndex6, div.MsoIndex6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:1.0in;
	text-indent:-12.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex7, li.MsoIndex7, div.MsoIndex7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:84.0pt;
	text-indent:-12.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex8, li.MsoIndex8, div.MsoIndex8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:96.0pt;
	text-indent:-12.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex9, li.MsoIndex9, div.MsoIndex9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:1.5in;
	text-indent:-12.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin-top:8.0pt;
	margin-right:78.8pt;
	margin-bottom:4.0pt;
	margin-left:18.45pt;
	text-indent:-18.45pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:78.8pt;
	margin-bottom:4.0pt;
	margin-left:42.55pt;
	text-indent:-24.1pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:78.8pt;
	margin-bottom:4.0pt;
	margin-left:53.05pt;
	text-indent:-34.6pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{margin-top:0in;
	margin-right:78.8pt;
	margin-bottom:4.0pt;
	margin-left:61.55pt;
	text-indent:-43.1pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{margin-top:0in;
	margin-right:78.8pt;
	margin-bottom:4.0pt;
	margin-left:70.9pt;
	text-indent:-52.45pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{margin-top:0in;
	margin-right:78.8pt;
	margin-bottom:4.0pt;
	margin-left:80.8pt;
	text-indent:-62.35pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{margin-top:0in;
	margin-right:78.8pt;
	margin-bottom:4.0pt;
	margin-left:89.9pt;
	text-indent:-71.45pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{margin-top:0in;
	margin-right:78.8pt;
	margin-bottom:4.0pt;
	margin-left:99.8pt;
	text-indent:-81.35pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{margin-top:0in;
	margin-right:78.8pt;
	margin-bottom:4.0pt;
	margin-left:109.15pt;
	text-indent:-90.7pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNormalIndent, li.MsoNormalIndent, div.MsoNormalIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:35.4pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:22.7pt;
	text-indent:-22.7pt;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-link:"Comment Text Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndexHeading, li.MsoIndexHeading, div.MsoIndexHeading
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:77.95pt;
	text-indent:-77.95pt;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoTof, li.MsoTof, div.MsoTof
	{margin-top:0in;
	margin-right:78.8pt;
	margin-bottom:11.0pt;
	margin-left:42.55pt;
	text-indent:-42.55pt;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoEnvelopeAddress, li.MsoEnvelopeAddress, div.MsoEnvelopeAddress
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:.05pt;
	font-size:12.0pt;
	font-family:"Cambria",serif;}
p.MsoEnvelopeReturn, li.MsoEnvelopeReturn, div.MsoEnvelopeReturn
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	font-size:10.0pt;
	font-family:"Cambria",serif;}
span.MsoFootnoteReference
	{font-family:"Times New Roman",serif;
	position:relative;
	top:-3.0pt;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{mso-style-link:"Endnote Text Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToa, li.MsoToa, div.MsoToa
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:12.0pt;
	text-indent:-12.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMacroText, li.MsoMacroText, div.MsoMacroText
	{mso-style-link:"Macro Text Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoToaHeading, li.MsoToaHeading, div.MsoToaHeading
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.MsoList, li.MsoList, div.MsoList
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpFirst, li.MsoListCxSpFirst, div.MsoListCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpMiddle, li.MsoListCxSpMiddle, div.MsoListCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpLast, li.MsoListCxSpLast, div.MsoListCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpFirst, li.MsoListBulletCxSpFirst, div.MsoListBulletCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpMiddle, li.MsoListBulletCxSpMiddle, div.MsoListBulletCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpLast, li.MsoListBulletCxSpLast, div.MsoListBulletCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber, li.MsoListNumber, div.MsoListNumber
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpFirst, li.MsoListNumberCxSpFirst, div.MsoListNumberCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpMiddle, li.MsoListNumberCxSpMiddle, div.MsoListNumberCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpLast, li.MsoListNumberCxSpLast, div.MsoListNumberCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2, li.MsoList2, div.MsoList2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpFirst, li.MsoList2CxSpFirst, div.MsoList2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpMiddle, li.MsoList2CxSpMiddle, div.MsoList2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpLast, li.MsoList2CxSpLast, div.MsoList2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3, li.MsoList3, div.MsoList3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpFirst, li.MsoList3CxSpFirst, div.MsoList3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpMiddle, li.MsoList3CxSpMiddle, div.MsoList3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpLast, li.MsoList3CxSpLast, div.MsoList3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4, li.MsoList4, div.MsoList4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpFirst, li.MsoList4CxSpFirst, div.MsoList4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpMiddle, li.MsoList4CxSpMiddle, div.MsoList4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpLast, li.MsoList4CxSpLast, div.MsoList4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5, li.MsoList5, div.MsoList5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpFirst, li.MsoList5CxSpFirst, div.MsoList5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpMiddle, li.MsoList5CxSpMiddle, div.MsoList5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpLast, li.MsoList5CxSpLast, div.MsoList5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpFirst, li.MsoListBullet2CxSpFirst, div.MsoListBullet2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpMiddle, li.MsoListBullet2CxSpMiddle, div.MsoListBullet2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpLast, li.MsoListBullet2CxSpLast, div.MsoListBullet2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3, li.MsoListBullet3, div.MsoListBullet3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpFirst, li.MsoListBullet3CxSpFirst, div.MsoListBullet3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpMiddle, li.MsoListBullet3CxSpMiddle, div.MsoListBullet3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpLast, li.MsoListBullet3CxSpLast, div.MsoListBullet3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4, li.MsoListBullet4, div.MsoListBullet4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpFirst, li.MsoListBullet4CxSpFirst, div.MsoListBullet4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpMiddle, li.MsoListBullet4CxSpMiddle, div.MsoListBullet4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpLast, li.MsoListBullet4CxSpLast, div.MsoListBullet4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5, li.MsoListBullet5, div.MsoListBullet5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpFirst, li.MsoListBullet5CxSpFirst, div.MsoListBullet5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpMiddle, li.MsoListBullet5CxSpMiddle, div.MsoListBullet5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpLast, li.MsoListBullet5CxSpLast, div.MsoListBullet5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2, li.MsoListNumber2, div.MsoListNumber2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpFirst, li.MsoListNumber2CxSpFirst, div.MsoListNumber2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpMiddle, li.MsoListNumber2CxSpMiddle, div.MsoListNumber2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpLast, li.MsoListNumber2CxSpLast, div.MsoListNumber2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3, li.MsoListNumber3, div.MsoListNumber3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpFirst, li.MsoListNumber3CxSpFirst, div.MsoListNumber3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpMiddle, li.MsoListNumber3CxSpMiddle, div.MsoListNumber3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpLast, li.MsoListNumber3CxSpLast, div.MsoListNumber3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4, li.MsoListNumber4, div.MsoListNumber4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpFirst, li.MsoListNumber4CxSpFirst, div.MsoListNumber4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpMiddle, li.MsoListNumber4CxSpMiddle, div.MsoListNumber4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpLast, li.MsoListNumber4CxSpLast, div.MsoListNumber4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5, li.MsoListNumber5, div.MsoListNumber5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpFirst, li.MsoListNumber5CxSpFirst, div.MsoListNumber5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpMiddle, li.MsoListNumber5CxSpMiddle, div.MsoListNumber5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpLast, li.MsoListNumber5CxSpLast, div.MsoListNumber5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{mso-style-link:"Title Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:16.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.MsoClosing, li.MsoClosing, div.MsoClosing
	{mso-style-link:"Closing Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:212.6pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoSignature, li.MsoSignature, div.MsoSignature
	{mso-style-link:"Signature Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:212.6pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-link:"Body Text Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{mso-style-link:"Body Text Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue, li.MsoListContinue, div.MsoListContinue
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpFirst, li.MsoListContinueCxSpFirst, div.MsoListContinueCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpMiddle, li.MsoListContinueCxSpMiddle, div.MsoListContinueCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpLast, li.MsoListContinueCxSpLast, div.MsoListContinueCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2, li.MsoListContinue2, div.MsoListContinue2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpFirst, li.MsoListContinue2CxSpFirst, div.MsoListContinue2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpMiddle, li.MsoListContinue2CxSpMiddle, div.MsoListContinue2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpLast, li.MsoListContinue2CxSpLast, div.MsoListContinue2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3, li.MsoListContinue3, div.MsoListContinue3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpFirst, li.MsoListContinue3CxSpFirst, div.MsoListContinue3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpMiddle, li.MsoListContinue3CxSpMiddle, div.MsoListContinue3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpLast, li.MsoListContinue3CxSpLast, div.MsoListContinue3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4, li.MsoListContinue4, div.MsoListContinue4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpFirst, li.MsoListContinue4CxSpFirst, div.MsoListContinue4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpMiddle, li.MsoListContinue4CxSpMiddle, div.MsoListContinue4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpLast, li.MsoListContinue4CxSpLast, div.MsoListContinue4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5, li.MsoListContinue5, div.MsoListContinue5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpFirst, li.MsoListContinue5CxSpFirst, div.MsoListContinue5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpMiddle, li.MsoListContinue5CxSpMiddle, div.MsoListContinue5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpLast, li.MsoListContinue5CxSpLast, div.MsoListContinue5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMessageHeader, li.MsoMessageHeader, div.MsoMessageHeader
	{mso-style-link:"Message Header Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:56.7pt;
	text-indent:-56.7pt;
	background:#CCCCCC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Cambria",serif;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{mso-style-link:"Subtitle Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Cambria",serif;}
p.MsoSalutation, li.MsoSalutation, div.MsoSalutation
	{mso-style-link:"Salutation Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoDate, li.MsoDate, div.MsoDate
	{mso-style-link:"Date Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent, li.MsoBodyTextFirstIndent, div.MsoBodyTextFirstIndent
	{mso-style-link:"Body Text First Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:10.5pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent2, li.MsoBodyTextFirstIndent2, div.MsoBodyTextFirstIndent2
	{mso-style-link:"Body Text First Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	text-indent:10.5pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNoteHeading, li.MsoNoteHeading, div.MsoNoteHeading
	{mso-style-link:"Note Heading Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{mso-style-link:"Body Text 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:200%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{mso-style-link:"Body Text 3 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{mso-style-link:"Body Text Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:200%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{mso-style-link:"Body Text Indent 3 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:0in;
	margin-right:1.0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:#954F72;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	background:navy;
	font-size:10.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{mso-style-link:"Plain Text Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoAutoSig, li.MsoAutoSig, div.MsoAutoSig
	{mso-style-link:"E-mail Signature Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p
	{margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
address
	{mso-style-link:"HTML Address Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
pre
	{mso-style-link:"HTML Preformatted Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	font-size:8.0pt;
	font-family:"Arial",sans-serif;}
p.MsoNoSpacing, li.MsoNoSpacing, div.MsoNoSpacing
	{margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:35.4pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoQuote, li.MsoQuote, div.MsoQuote
	{mso-style-link:"Quote Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;
	font-style:italic;}
p.MsoIntenseQuote, li.MsoIntenseQuote, div.MsoIntenseQuote
	{mso-style-link:"Intense Quote Char";
	margin-top:10.0pt;
	margin-right:.65in;
	margin-bottom:14.0pt;
	margin-left:.65in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
p.MsoBibliography, li.MsoBibliography, div.MsoBibliography
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTocHeading, li.MsoTocHeading, div.MsoTocHeading
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:16.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.1Style, li.1Style, div.1Style
	{mso-style-name:"\#1 Style";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Para0s, li.Para0s, div.Para0s
	{mso-style-name:"Para\:0\:s";
	mso-style-link:"Para\:0\:s Zchn";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.ProductName
	{mso-style-name:"Product Name";
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.list2d, li.list2d, div.list2d
	{mso-style-name:"list\:2\:d";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:1.25in;
	text-indent:-17.85pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.list0d, li.list0d, div.list0d
	{mso-style-name:"list\:0\:d";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:17.85pt;
	text-indent:-17.85pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.list0s, li.list0s, div.list0s
	{mso-style-name:"list\:0\:s";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:2.0pt;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.SAG-Heading1, li.SAG-Heading1, div.SAG-Heading1
	{mso-style-name:"SAG-Heading 1";
	margin-top:22.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Bullet0d, li.Bullet0d, div.Bullet0d
	{mso-style-name:"Bullet\:0\:d";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:17.85pt;
	text-indent:-17.85pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Bullet0s, li.Bullet0s, div.Bullet0s
	{mso-style-name:"Bullet\:0\:s";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:2.0pt;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.list3d, li.list3d, div.list3d
	{mso-style-name:"list\:3\:d";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:1.75in;
	text-indent:-17.85pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.nlist0s, li.nlist0s, div.nlist0s
	{mso-style-name:"nlist\:0\:s";
	margin-top:4.0pt;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:17.85pt;
	text-indent:-17.85pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Bullet1d, li.Bullet1d, div.Bullet1d
	{mso-style-name:"Bullet\:1\:d";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:.75in;
	text-indent:-17.85pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Bullet1s, li.Bullet1s, div.Bullet1s
	{mso-style-name:"Bullet\:1\:s";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:2.0pt;
	margin-left:54.15pt;
	text-indent:-17.85pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Bullet2d, li.Bullet2d, div.Bullet2d
	{mso-style-name:"Bullet\:2\:d";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:1.25in;
	text-indent:-17.85pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Bullet2s, li.Bullet2s, div.Bullet2s
	{mso-style-name:"Bullet\:2\:s";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:2.0pt;
	margin-left:89.85pt;
	text-indent:-17.85pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Smalltext120b, li.Smalltext120b, div.Smalltext120b
	{mso-style-name:"Smalltext12\:0\:b";
	margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Smalltext120, li.Smalltext120, div.Smalltext120
	{mso-style-name:"Smalltext12\:0";
	margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.list1d, li.list1d, div.list1d
	{mso-style-name:"list\:1\:d";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:54.15pt;
	text-indent:-17.85pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.list1s, li.list1s, div.list1s
	{mso-style-name:"list\:1\:s";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:2.0pt;
	margin-left:54.15pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.list2s, li.list2s, div.list2s
	{mso-style-name:"list\:2\:s";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:2.0pt;
	margin-left:89.85pt;
	text-indent:-17.85pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.list3s, li.list3s, div.list3s
	{mso-style-name:"list\:3\:s";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:2.0pt;
	margin-left:125.85pt;
	text-indent:-17.85pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.nlist0d, li.nlist0d, div.nlist0d
	{mso-style-name:"nlist\:0\:d";
	margin-top:4.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:17.85pt;
	text-indent:-17.85pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.nlist1d, li.nlist1d, div.nlist1d
	{mso-style-name:"nlist\:1\:d";
	margin-top:4.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:54.15pt;
	text-indent:-17.85pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.nlist1s, li.nlist1s, div.nlist1s
	{mso-style-name:"nlist\:1\:s";
	margin-top:4.0pt;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:54.15pt;
	text-indent:-17.85pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Para0sb, li.Para0sb, div.Para0sb
	{mso-style-name:"Para\:0\:sb";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Para1s, li.Para1s, div.Para1s
	{mso-style-name:"Para\:1\:s";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Para2s, li.Para2s, div.Para2s
	{mso-style-name:"Para\:2\:s";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:1.0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.SasTitle, li.SasTitle, div.SasTitle
	{mso-style-name:SasTitle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.TOCSas, li.TOCSas, div.TOCSas
	{mso-style-name:TOCSas;
	margin-top:8.0pt;
	margin-right:78.8pt;
	margin-bottom:4.0pt;
	margin-left:.75in;
	text-indent:-.75in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.nlist2s, li.nlist2s, div.nlist2s
	{mso-style-name:"nlist\:2\:s";
	margin-top:4.0pt;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:1.25in;
	text-indent:-17.85pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.nlist2d, li.nlist2d, div.nlist2d
	{mso-style-name:"nlist\:2\:d";
	margin-top:4.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:1.25in;
	text-indent:-17.85pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Legend, li.Legend, div.Legend
	{mso-style-name:Legend;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:77.95pt;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.Hanging2s, li.Hanging2s, div.Hanging2s
	{mso-style-name:"Hanging\:2\:s";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:1.0in;
	text-indent:-1.0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Hanging4s, li.Hanging4s, div.Hanging4s
	{mso-style-name:"Hanging\:4\:s";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:2.0in;
	text-indent:-2.0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Hanging6s, li.Hanging6s, div.Hanging6s
	{mso-style-name:"Hanging\:6\:s";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:3.0in;
	text-indent:-3.0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.centereds, li.centereds, div.centereds
	{mso-style-name:"centered\:s";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:2.0pt;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.centeredd, li.centeredd, div.centeredd
	{mso-style-name:"centered\:d";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.centeredsb, li.centeredsb, div.centeredsb
	{mso-style-name:"centered\:s\:b";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:2.0pt;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.centereddb, li.centereddb, div.centereddb
	{mso-style-name:"centered\:d\:b";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Para0d, li.Para0d, div.Para0d
	{mso-style-name:"Para\:0\:d";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	line-height:200%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Para1d, li.Para1d, div.Para1d
	{mso-style-name:"Para\:1\:d";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:.5in;
	line-height:200%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Para2d, li.Para2d, div.Para2d
	{mso-style-name:"Para\:2\:d";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:1.0in;
	line-height:200%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.ParaKT0s, li.ParaKT0s, div.ParaKT0s
	{mso-style-name:"ParaKT\:0\:s";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.SASMono8, li.SASMono8, div.SASMono8
	{mso-style-name:"SAS Mono\:8";
	margin:0in;
	font-size:8.0pt;
	font-family:"SAS Monospace";}
p.Table120b, li.Table120b, div.Table120b
	{mso-style-name:"Table12\:0\:b";
	margin-top:4.0pt;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Table120, li.Table120, div.Table120
	{mso-style-name:"Table12\:0";
	margin-top:4.0pt;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Smalltext90, li.Smalltext90, div.Smalltext90
	{mso-style-name:"Smalltext9\:0";
	margin:0in;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;}
p.Smalltext100, li.Smalltext100, div.Smalltext100
	{mso-style-name:"Smalltext10\:0";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.ParaKT0sb, li.ParaKT0sb, div.ParaKT0sb
	{mso-style-name:"ParaKT\:0\:sb";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Xspace40, li.Xspace40, div.Xspace40
	{mso-style-name:"Xspace4\:0";
	margin:0in;
	font-size:4.0pt;
	font-family:"Times New Roman",serif;}
p.ReportTitle, li.ReportTitle, div.ReportTitle
	{mso-style-name:ReportTitle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	font-size:14.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Table100, li.Table100, div.Table100
	{mso-style-name:"Table10\:0";
	margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.SAG-Heading2, li.SAG-Heading2, div.SAG-Heading2
	{mso-style-name:"SAG-Heading 2";
	margin-top:11.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.SOP-reportnumber, li.SOP-reportnumber, div.SOP-reportnumber
	{mso-style-name:"SOP-report number";
	margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.SOP-Head, li.SOP-Head, div.SOP-Head
	{mso-style-name:SOP-Head;
	margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Mono8, li.Mono8, div.Mono8
	{mso-style-name:"Mono\:8";
	margin:0in;
	font-size:8.0pt;
	font-family:Courier;}
p.SAG-Heading3, li.SAG-Heading3, div.SAG-Heading3
	{mso-style-name:"SAG-Heading 3";
	margin-top:11.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.SOP-Report-type, li.SOP-Report-type, div.SOP-Report-type
	{mso-style-name:SOP-Report-type;
	margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.SOP-Document-Identity, li.SOP-Document-Identity, div.SOP-Document-Identity
	{mso-style-name:SOP-Document-Identity;
	margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.SOP-Document-page-count, li.SOP-Document-page-count, div.SOP-Document-page-count
	{mso-style-name:SOP-Document-page-count;
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.Bullet2, li.Bullet2, div.Bullet2
	{mso-style-name:Bullet2;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:75.25pt;
	text-indent:-21.25pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.Para0sZchn
	{mso-style-name:"Para\:0\:s Zchn";
	mso-style-link:"Para\:0\:s";}
p.TitleA, li.TitleA, div.TitleA
	{mso-style-name:"Title A";
	margin:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.TitleB, li.TitleB, div.TitleB
	{mso-style-name:"Title B";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.Listenabsatz1, li.Listenabsatz1, div.Listenabsatz1
	{mso-style-name:Listenabsatz1;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:35.4pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.berarbeitung1, li.berarbeitung1, div.berarbeitung1
	{mso-style-name:berarbeitung1;
	margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";
	mso-style-link:"Comment Text";}
span.SalutationChar
	{mso-style-name:"Salutation Char";
	mso-style-link:Salutation;}
span.DateChar
	{mso-style-name:"Date Char";
	mso-style-link:Date;}
span.E-mailSignatureChar
	{mso-style-name:"E-mail Signature Char";
	mso-style-link:"E-mail Signature";}
span.EndnoteTextChar
	{mso-style-name:"Endnote Text Char";
	mso-style-link:"Endnote Text";}
span.NoteHeadingChar
	{mso-style-name:"Note Heading Char";
	mso-style-link:"Note Heading";}
span.ClosingChar
	{mso-style-name:"Closing Char";
	mso-style-link:Closing;}
span.HTMLAddressChar
	{mso-style-name:"HTML Address Char";
	mso-style-link:"HTML Address";
	font-style:italic;}
span.HTMLPreformattedChar
	{mso-style-name:"HTML Preformatted Char";
	mso-style-link:"HTML Preformatted";
	font-family:"Courier New";}
span.IntenseQuoteChar
	{mso-style-name:"Intense Quote Char";
	mso-style-link:"Intense Quote";
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
span.MacroTextChar
	{mso-style-name:"Macro Text Char";
	mso-style-link:"Macro Text";
	font-family:"Courier New";}
span.MessageHeaderChar
	{mso-style-name:"Message Header Char";
	mso-style-link:"Message Header";
	font-family:"Cambria",serif;
	background:#CCCCCC;}
span.PlainTextChar
	{mso-style-name:"Plain Text Char";
	mso-style-link:"Plain Text";
	font-family:"Courier New";}
span.BodyTextChar
	{mso-style-name:"Body Text Char";
	mso-style-link:"Body Text";}
span.BodyText2Char
	{mso-style-name:"Body Text 2 Char";
	mso-style-link:"Body Text 2";}
span.BodyText3Char
	{mso-style-name:"Body Text 3 Char";
	mso-style-link:"Body Text 3";}
span.BodyTextIndent2Char
	{mso-style-name:"Body Text Indent 2 Char";
	mso-style-link:"Body Text Indent 2";}
span.BodyTextIndent3Char
	{mso-style-name:"Body Text Indent 3 Char";
	mso-style-link:"Body Text Indent 3";}
span.BodyTextFirstIndentChar
	{mso-style-name:"Body Text First Indent Char";
	mso-style-link:"Body Text First Indent";}
span.BodyTextIndentChar
	{mso-style-name:"Body Text Indent Char";
	mso-style-link:"Body Text Indent";}
span.BodyTextFirstIndent2Char
	{mso-style-name:"Body Text First Indent 2 Char";
	mso-style-link:"Body Text First Indent 2";}
span.TitleChar
	{mso-style-name:"Title Char";
	mso-style-link:Title;
	font-family:"Cambria",serif;
	font-weight:bold;}
span.SignatureChar
	{mso-style-name:"Signature Char";
	mso-style-link:Signature;}
span.SubtitleChar
	{mso-style-name:"Subtitle Char";
	mso-style-link:Subtitle;
	font-family:"Cambria",serif;}
span.QuoteChar
	{mso-style-name:"Quote Char";
	mso-style-link:Quote;
	color:black;
	font-style:italic;}
span.glossary-term
	{mso-style-name:glossary-term;}
p.BayerBodyTextFull, li.BayerBodyTextFull, div.BayerBodyTextFull
	{mso-style-name:"Bayer Body Text Full";
	mso-style-link:"Bayer Body Text Full Zchn";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BayerBodyTextFullZchn
	{mso-style-name:"Bayer Body Text Full Zchn";
	mso-style-link:"Bayer Body Text Full";
	font-family:"Verdana",sans-serif;}
p.BayerTRDASectionHeading5, li.BayerTRDASectionHeading5, div.BayerTRDASectionHeading5
	{mso-style-name:"Bayer TRD_A_Section Heading 5";
	margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:85.05pt;
	text-indent:-56.7pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Verdana",sans-serif;}
span.msoIns
	{mso-style-name:"";
	text-decoration:underline;
	color:teal;}
span.msoDel
	{mso-style-name:"";
	text-decoration:line-through;
	color:red;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:595.3pt 841.9pt;
	margin:56.7pt 70.85pt 56.7pt 70.85pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink="#954F72" style='word-wrap:break-word'>

<div class=WordSection1>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><b><span
lang=EN-GB style='font-size:11.0pt'>ANNEX I</span></b></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=TitleA>SUMMARY OF PRODUCT CHARACTERISTICS</p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<i><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all>
</span></i>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>1.</span></b><i><span
lang=EN-GB style='font-size:11.0pt'> </span></i><b><span lang=EN-GB
style='font-size:11.0pt'>NAME OF THE MEDICINAL PRODUCT</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Betaferon 250
microgram/ml, powder and solvent for solution for injection</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='font-size:11.0pt;text-transform:uppercase'>2. QUALITATIVE
AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Recombinant
interferon beta-1b<sup>* </sup>250 microgram (8.0 million IU) per ml when
reconstituted.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Betaferon
contains 300 microgram (9.6 million IU) of recombinant interferon beta-1b per
vial.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>For the full
list of excipients, see section 6.1.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoFootnoteText><span class=MsoFootnoteReference><span
style='font-size:11.0pt'>*</span></span><span style='font-size:11.0pt'>
produced by genetic engineering from a strain of <i>Escherichia coli</i>.</span></p>

<p class=Smalltext120><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='font-size:11.0pt'>3. PHARMACEUTICAL FORM</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Powder and
solvent for solution for injection.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Sterile white
to off-white powder.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='font-size:11.0pt;text-transform:uppercase'>4. CLINICAL
PARTICULARS</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='font-size:11.0pt'>4.1 Therapeutic indications</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Betaferon is
indicated for the treatment of </span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>patients with a single
demyelinating event with an active inflammatory process, if it is severe enough
to warrant treatment with intravenous corticosteroids, if alternative diagnoses
have been excluded, and if they are determined to be at high risk of developing
clinically definite multiple sclerosis (see section 5.1).</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>patients with relapsing-remitting
multiple sclerosis and two or more relapses within the last two years. </span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>patients with secondary
progressive multiple sclerosis with active disease, evidenced by relapses. </span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='font-size:11.0pt'>4.2 Posology and method of
administration</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:
line'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>The treatment
with Betaferon should be initiated under the supervision of a physician
experienced in the treatment of the disease.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><u><span lang=EN-GB style='font-size:11.0pt'>Posology</span></u></p>

<p class=Smalltext120><i><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=Smalltext120><i><span lang=EN-GB style='font-size:11.0pt'>Adults</span></i></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>The recommended
dose of Betaferon is 250 microgram (8.0 million IU), contained in 1 ml of the
reconstituted solution (see section 6.6), to be injected subcutaneously every
other day.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><i><span lang=EN-GB style='font-size:11.0pt'>Paediatric
population </span></i></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>No formal
clinical trials or pharmacokinetic studies have been conducted in children or
adolescents. However, limited published data suggest that the safety profile in
adolescents from 12&nbsp;to 16&nbsp;years of age receiving Betaferon 8.0
million IU subcutaneously every other day is similar to that seen in adults.
There is no information on the use of Betaferon in children under 12 years of
age. Therefore Betaferon should not be used in this population. </span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Generally, dose
titration is recommended at the start of treatment.</span></p>

<p class=Smalltext120><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Patients should
be started at 62.5 microgram (0.25 ml) subcutaneously every other day, and
increased slowly to a dose of 250 microgram (1.0 ml) every other day (see Table
A). The titration period may be adjusted, if any significant adverse reaction
occurs. In order to obtain adequate efficacy, a dose of 250 microgram (1.0 ml)
every other day should be reached.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>A titration
pack composed of four triple packs is available for the titration period and
the patients initial treatment with Betaferon. This package meets the
patients needs for the first 12 injections. The triple packs are highlighted
in different colours (see section 6.5).</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Table A:
Schedule for dose titration*</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:3.5pt;border-collapse:collapse;border:none'>
 <tr style='height:16.0pt'>
  <td width=189 valign=top style='width:141.75pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:16.0pt'>
  <p class=Smalltext120 align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:11.0pt'>treatment day</span></b></p>
  </td>
  <td width=208 colspan=2 valign=top style='width:155.95pt;border:none;
  border-top:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt;height:16.0pt'>
  <p class=Smalltext120 align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:11.0pt'>dose</span></b></p>
  </td>
  <td width=208 colspan=2 valign=top style='width:155.9pt;border:none;
  border-top:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt;height:16.0pt'>
  <p class=Smalltext120 align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:11.0pt'>volume </span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:16.0pt'>
  <td width=189 valign=top style='width:141.75pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:16.0pt'>
  <p class=Smalltext120 align=center style='margin-left:28.35pt;text-align:
  center;text-indent:-28.35pt'><span lang=EN-GB style='font-size:11.0pt'>1, 3,
  5</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:16.0pt'>
  <p class=Smalltext120 align=right style='text-align:right'><span lang=EN-GB
  style='font-size:11.0pt'>62.5 </span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:16.0pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>microgram</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:16.0pt'>
  <p class=Smalltext120 align=right style='text-align:right'><span lang=EN-GB
  style='font-size:11.0pt'>0.25</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:16.0pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>ml</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:16.0pt'>
  <td width=189 valign=top style='width:141.75pt;border:none;padding:0in 3.5pt 0in 3.5pt;
  height:16.0pt'>
  <p class=Smalltext120 align=center style='margin-left:28.35pt;text-align:
  center;text-indent:-28.35pt'><span lang=EN-GB style='font-size:11.0pt'>7, 9,
  11</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border:none;padding:0in 3.5pt 0in 3.5pt;
  height:16.0pt'>
  <p class=Smalltext120 align=right style='text-align:right'><span lang=EN-GB
  style='font-size:11.0pt'>125</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border:none;padding:0in 3.5pt 0in 3.5pt;
  height:16.0pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>microgram</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;padding:0in 3.5pt 0in 3.5pt;
  height:16.0pt'>
  <p class=Smalltext120 align=right style='text-align:right'><span lang=EN-GB
  style='font-size:11.0pt'>0.5 </span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border:none;padding:0in 3.5pt 0in 3.5pt;
  height:16.0pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>ml</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:16.0pt'>
  <td width=189 valign=top style='width:141.75pt;border:none;padding:0in 3.5pt 0in 3.5pt;
  height:16.0pt'>
  <p class=Smalltext120 align=center style='margin-left:28.35pt;text-align:
  center;text-indent:-28.35pt'><span lang=EN-GB style='font-size:11.0pt'>13,
  15, 17</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border:none;padding:0in 3.5pt 0in 3.5pt;
  height:16.0pt'>
  <p class=Smalltext120 align=right style='text-align:right'><span lang=EN-GB
  style='font-size:11.0pt'>187.5</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border:none;padding:0in 3.5pt 0in 3.5pt;
  height:16.0pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>microgram</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;padding:0in 3.5pt 0in 3.5pt;
  height:16.0pt'>
  <p class=Smalltext120 align=right style='text-align:right'><span lang=EN-GB
  style='font-size:11.0pt'>0.75</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border:none;padding:0in 3.5pt 0in 3.5pt;
  height:16.0pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>ml</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:16.0pt'>
  <td width=189 valign=top style='width:141.75pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt;height:16.0pt'>
  <p class=Smalltext120 align=center style='margin-left:28.35pt;text-align:
  center;text-indent:-28.35pt'><span lang=EN-GB style='font-size:11.0pt'>19,
  21, 23 et seq.</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:16.0pt'>
  <p class=Smalltext120 align=right style='text-align:right'><span lang=EN-GB
  style='font-size:11.0pt'>250</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:16.0pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>microgram</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:16.0pt'>
  <p class=Smalltext120 align=right style='text-align:right'><span lang=EN-GB
  style='font-size:11.0pt'>1.0</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:16.0pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>ml</span></p>
  </td>
 </tr>
</table>

<p class=Smalltext120 style='margin-right:-1.45pt'><span lang=EN-GB
style='font-size:11.0pt'>* The titration period may be adjusted, if any
significant adverse reaction occurs.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>The optimal
dose has not been fully clarified.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>At the present
time, it is not known how long the patient should be treated for. There are
follow-up data under controlled clinical conditions for patients with
relapsing-remitting MS for up to 5 years and for patients with secondary
progressive MS for up to 3 years. For relapsing-remitting MS, efficacy has been
demonstrated for therapy for the first two years. The available data for the
additional three years are consistent with sustained treatment efficacy of
Betaferon over the whole time period.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>In patients
with a single clinical event suggestive of multiple sclerosis, the progression
to clinically definite multiple sclerosis was significantly delayed over a
period of five years.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Treatment is
not recommended in patients with relapsing-remitting multiple sclerosis who
have experienced less than 2 relapses in the previous 2 years or in patients
with secondary-progressive multiple sclerosis who have had no active disease in
the previous 2 years.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>If the patient
fails to respond, for example a steady progression in EDSS for 6 months occurs
or treatment with at least 3 courses of ACTH or corticosteroids during a one
year period is required despite Betaferon therapy, treatment with Betaferon
should be stopped.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><u><span lang=EN-GB style='font-size:11.0pt'>Method of
administration</span></u></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>For
subcutaneous injection.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>For
instructions on reconstitution of the medicinal product before administration,
see section 6.6.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='font-size:11.0pt'>4.3 Contraindications</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Patients with a history
of hypersensitivity to natural or recombinant interferon beta, human albumin or
to any of the excipients listed in section 6.1.</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Patients with current
severe depression and/or suicidal ideation (see sections 4.4 and 4.8).</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Patients with
decompensated liver disease (see sections 4.4, 4.5 and 4.8).</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:avoid'><b><span lang=EN-GB style='font-size:11.0pt'>4.4 Special
warnings and precautions for use</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:
line'>&nbsp;</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Traceability</span></u></p>

<p class=Smalltext120><span style='font-size:11.0pt'>In order to improve traceability
of biological medicinal products, the name and the batch number of the
administered product should be clearly recorded.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:
line'>&nbsp;</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Immune system disorders</span></u></p>

<p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>The administration of cytokines to patients with a
pre-existing monoclonal gammopathy has been associated with the development of
systemic capillary leak syndrome with shock-like symptoms and fatal outcome.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:
line'>&nbsp;</span></p>

<p class=Smalltext120><u><span lang=EN-GB style='font-size:11.0pt'>Gastrointestinal
disorders</span></u></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>In rare cases,
pancreatitis was observed with Betaferon use, often associated with
hypertriglyceridaemia.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Nervous system disorders</span></u></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Betaferon
should be administered with caution to patients with previous or current
depressive disorders, in particular to those with antecedents of suicidal
ideation (see section 4.3). Depression and suicidal ideation are known to occur
with increased frequency in the multiple sclerosis population and in
association with interferon use. Patients treated with Betaferon should be
advised to report any symptoms of depression and/or suicidal ideation to their
prescribing physician immediately. Patients exhibiting depression should be
monitored closely during therapy with Betaferon and treated appropriately.
Cessation of therapy with Betaferon should be considered (see also sections 4.3
and 4.8).</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:
line'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:
line'>Betaferon should be administered with caution to patients with a history
of seizures and </span><span lang=EN-GB style='font-size:11.0pt'>to those
receiving treatment with anti-epileptics, particularly if their epilepsy is not
adequately controlled with anti-epileptics (see sections 4.5 and 4.8)<span
style='layout-grid-mode:line'>. </span></span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>This product
contains human albumin and hence carries a potential risk for transmission of
viral diseases. A risk for transmission of Creutzfeld-Jacob disease (CJD)
cannot be excluded.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Laboratory test</span></u></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Thyroid
function tests are recommended regularly in patients with a history of thyroid
dysfunction or as clinically indicated. </span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>In addition to
those laboratory tests normally required for monitoring patients with multiple
sclerosis, complete blood and differential white blood cell counts, platelet
counts, and blood chemistries, including liver function tests (e.g. AST (SGOT),
ALT (SGPT) and </span><span lang=EN-GB style='font-size:11.0pt;font-family:
Symbol'>g</span><span lang=EN-GB style='font-size:11.0pt'>-GT), are recommended
prior to initiation and at regular intervals following introduction of
Betaferon therapy, and then periodically thereafter in the absence of clinical
symptoms. </span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Patients with
anaemia, thrombocytopenia, leukopenia (alone or in any combination) may require
more intensive monitoring of complete blood cell counts, with differential and
platelet counts. Patients who develop neutropenia should be monitored closely
for the development of fever or infection. There have been reports of
thrombocytopenia, with profound decreases in platelet count.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Hepatobiliary disorders</span></u></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:
line'>Asymptomatic elevations of serum transaminases, in most cases mild and
transient, occurred very commonly in patients treated with Betaferon during
clinical trials. As for other beta interferons, severe hepatic injury,
including cases of hepatic failure, has been reported rarely in patients treated
with Betaferon. The most serious events often occurred in patients exposed to
other drugs or substances known to be associated with hepatotoxicity or in the
presence of comorbid medical conditions (e.g. metastasising malignant disease,
severe infection and sepsis, alcohol abuse).</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Patients should
be monitored for signs of hepatic injury. The occurrence of elevations in serum
transaminases should lead to close monitoring and investigation. Withdrawal of
Betaferon should be considered if the levels significantly increase or if they
are associated with clinical symptoms such as jaundice. In the absence of
clinical evidence for liver damage and after normalisation of liver enzymes a
reintroduction of therapy could be considered with appropriate follow-up of
hepatic functions.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Renal and urinary disorders</span></u></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:
line'>Caution should be used and close monitoring considered when administering
interferon beta to patients with severe renal failure.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:
line'>&nbsp;</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Nephrotic Syndrome</span></u></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Cases of
nephrotic syndrome with different underlying nephropathies including collapsing
focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD),
membranoproliferative glomerulonephritis (MPGN) and membranous glomerulopathy
(MGN) have been reported during treatment with interferon beta products. Events
were reported at various time points during treatment and may occur after
several years of treatment with interferon beta. Periodic monitoring of early
signs or symptoms, e.g. oedema, proteinuria and impaired renal function is
recommended, especially in patients at higher risk of renal disease. Prompt
treatment of nephrotic syndrome is required and discontinuation of treatment
with Betaferon should be considered.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Cardiac disorders</span></u></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Betaferon
should also be used with caution in patients who suffer from pre-existing
cardiac disorders. <span style='layout-grid-mode:line'>Patients with
pre-existing significant cardiac disease, such as congestive heart failure,
coronary artery disease or arrhythmia, should be monitored for worsening of
their cardiac condition, particularly during initiation of treatment with
Betaferon. </span></span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:
line'>While Betaferon does not have any known direct-acting cardiac toxicity,
symptoms of the flu-like syndrome associated with beta interferons may prove
stressful to patients with pre-existing significant cardiac disease. During the
post-marketing period very rare reports have been received of worsening of
cardiac status in patients with pre-existing significant cardiac disease
temporarily associated with the initiation of Betaferon therapy.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Rare cases of
cardiomyopathy have been reported. If this occurs and a relationship to
Betaferon is suspected, treatment should be discontinued.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Thrombotic microangiopathy (TMA)</span><span
lang=EN-GB> </span></u><u><span lang=EN-GB style='font-size:11.0pt'>and
Haemolytic anaemia (HA)</span></u></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Cases of
thrombotic microangiopathy, manifested as thrombotic thrombocytopenic purpura
(TTP) or haemolytic uraemic syndrome (HUS), including fatal cases, have been
reported with interferon beta products. Early clinical features include
thrombocytopenia, new onset hypertension, fever, central nervous system
symptoms (e.g. confusion, paresis) and impaired renal function. Laboratory
findings suggestive of TMA include decreased platelet counts, increased serum
lactate dehydrogenase (LDH) due to haemolysis and schistocytes (erythrocyte
fragmentation) on a blood film. Therefore if clinical features of TMA are
observed, further testing of blood platelet levels, serum LDH, blood films and
renal function is recommended. </span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Additionally,
cases of HA not associated with TMA, including immune HA, have been reported
with interferon beta products. Life-threatening and fatal cases have been
reported. Cases of TMA</span><span lang=EN-GB> </span><span lang=EN-GB
style='font-size:11.0pt'>and/or HA have been reported at various time points
during treatment and may occur several weeks to several years after starting
treatment with interferon beta.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>If TMA</span><span
lang=EN-GB> </span><span lang=EN-GB style='font-size:11.0pt'>and/or HA is
diagnosed and a relationship to Betaferon is suspected, prompt treatment is
required (in case of TMA considering plasma exchange) and immediate
discontinuation of Betaferon is recommended.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>General disorders and administration site conditions</span></u></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Serious
hypersensitivity reactions (rare but severe acute reactions such as
bronchospasm, anaphylaxis and urticaria) may occur. If reactions are severe,
Betaferon should be discontinued and appropriate medical intervention
instituted. </span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Injection site
necrosis has been reported in patients using Betaferon (see section 4.8). It
can be extensive and may involve muscle fascia as well as fat and therefore can
result in scar formation. Occasionally debridement and, less often, skin
grafting are required, and healing may take up to 6&nbsp;months.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>If the patient
experiences any break in the skin, which may be associated with swelling or
drainage of fluid from the injection site, the patient should be advised to
consult with his/her physician before continuing injections with Betaferon. </span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>If the patient
has multiple lesions Betaferon should be discontinued until healing has
occurred. Patients with single lesions may continue on Betaferon provided the
necrosis is not too extensive, as some patients have experienced healing of
injection site necrosis whilst on Betaferon.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>To minimise the
risk of injection site necrosis patients should be advised to:</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>use an aseptic
injection technique</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>rotate the injection
sites with each dose.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>The incidence
of injection site reactions may be reduced by the use of an autoinjector. In
the pivotal study of patients with a single clinical event suggestive of
multiple sclerosis an autoinjector was used in the majority of patients.
Injection site reactions as well as injection site necroses were observed less
frequently in this study than in the other pivotal studies.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>The procedure
for the self-administration by the patient should be reviewed periodically
especially if injection site reactions have occurred.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Immunogenicity</span></u></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:
line'>As with all therapeutic proteins, there is a potential for
immunogenicity. Serum samples in controlled clinical trials were collected
every 3 months for monitoring of development of antibodies to Betaferon. </span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>In the <span
style='layout-grid-mode:line'>different controlled clinical trials in
relapsing-remitting multiple sclerosis and secondary progressive multiple
sclerosis</span>, between 23% and 41% of the patients developed serum
interferon beta-1b neutralising activity confirmed by at least two consecutive
positive titres; of these patients, between 43% and 55% <span style='layout-grid-mode:
line'>converted to a stable antibody negative status (based on two consecutive
negative titres)</span> during the subsequent observational period of the
respective study. </span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>The development
of neutralising activity in these studies is associated with a reduction in
clinical efficacy only with regard to relapse activity. Some analyses suggest
that this effect might be larger in patients with higher titre levels of
neutralising activity. </span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>In the study of
patients with a single clinical event suggestive of multiple sclerosis,
neutralising activity measured every 6 months <span style='layout-grid-mode:
line'>was observed at least once in 32% (89) of the patients treated
immediately with Betaferon; of these, 60% (53) returned to negative status
based on the last available assessment within the 5 year period. Within this
period, the development of neutralising activity was associated with a
significant increase in newly active lesions and T2 lesion volume on magnetic
resonance imaging. However, this did not seem to be associated with a reduction
in clinical efficacy (with regard to time to clinically definite multiple
sclerosis (CDMS), time to confirmed EDSS progression and relapse rate). </span></span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>New adverse
events have not been associated with the development of neutralising activity. </span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>It has been
demonstrated <i>in vitro </i>that Betaferon cross-reacts with natural
interferon beta. However, this has not been investigated <i>in vivo </i>and its
clinical significance is uncertain.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>There are
sparse and inconclusive data on patients who have developed neutralising
activity and have completed Betaferon therapy.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:
line'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:
line'>The decision to continue or discontinue treatment should be based on all
aspects of the patients disease status rather than on neutralising activity
status alone.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:
line'>&nbsp;</span></p>

<p class=Smalltext120><u><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:
line'>Excipients</span></u></p>

<p class=Smalltext120><span style='font-size:11.0pt;layout-grid-mode:line'>This
medicinal product contains less than 1 mmol sodium (23 mg) per ml, that is to
say essentially sodium-free.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='font-size:11.0pt'>4.5 Interaction with other medicinal
products and other forms of interaction</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>No interaction
studies have been performed.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>The effect of
alternate-day administration of 250 microgram (8.0 million IU) of Betaferon on
drug metabolism in multiple sclerosis patients is unknown. Corticosteroid or
ACTH treatment of relapses for periods of up to 28 days has been well tolerated
in patients receiving Betaferon.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Due to the lack
of clinical experience in multiple sclerosis patients, the use of Betaferon
together with immunomodulators other than corticosteroids or ACTH is not
recommended.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Interferons
have been reported to reduce the activity of hepatic cytochrome P450-dependent
enzymes in humans and animals. Caution should be exercised when Betaferon is
administered in combination with medicinal products that have a narrow
therapeutic index and are largely dependent on the hepatic cytochrome P450
system for clearance, e.g. anti-epileptics. Additional caution should be
exercised with any co-medication which has an effect on the haematopoietic system.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>No interaction
studies with anti-epileptics have been carried out.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:avoid'><b><span lang=EN-GB style='font-size:11.0pt'>4.6 Fertility,
pregnancy and lactation</span></b></p>

<p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Pregnancy</span></u></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none'><span
style='font-size:11.0pt'>A large amount of data (more than 1000 pregnancy
outcomes) from interferon beta registries, national registries and
post-marketing experience indicates no increased risk of major congenital
anomalies after pre-conception exposure or exposure during the first trimester
of pregnancy. However, the duration of exposure during the first trimester is
uncertain, because data were collected when interferon beta use was
contraindicated during pregnancy, and treatment likely interrupted when
pregnancy was detected and/or confirmed. Experience with exposure during the
second and third trimester is very limited.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>Based on animal data (see
section 5.3), there is a possibly increased risk for spontaneous abortion. The
risk of spontaneous abortions in pregnant women exposed to interferon beta
cannot adequately be evaluated based on the currently available data, but the
data do not suggest an increased risk so far.</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span style='font-size:
11.0pt'>If clinically needed, the use of Betaferon may be considered during
pregnancy.</span></p>

<p class=Smalltext120><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Smalltext120 style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Breast-feeding</span></u></p>

<p class=Smalltext120 style='page-break-after:avoid'><span style='font-size:
11.0pt'>Limited information available on the transfer of interferon beta-1b
into breast milk, together with the chemical / physiological characteristics of
interferon beta, suggests that levels of interferon beta-1b excreted in human
milk are negligible. No harmful effects on the breastfed newborn/infant are
anticipated.</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span style='font-size:
11.0pt;color:black'>Betaferon can be used during breast-feeding.</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Fertility</span></u></p>

<p class=Smalltext120><span style='font-size:11.0pt'>No investigations on
fertility have been conducted (see section</span><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span><span style='font-size:11.0pt'>5.3).</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><b><span lang=EN-GB style='font-size:11.0pt'>4.7 Effects on ability
to drive and use machines</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>No studies of
the effects on the ability to drive and use machines have been performed.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Central nervous
system-related adverse events associated with the use of Betaferon might
influence the ability to drive and use machines in susceptible patients.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='font-size:11.0pt'>4.8 Undesirable effects</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><u><span lang=EN-GB style='font-size:11.0pt'>Summary of
the safety profile</span></u></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>At the
beginning of treatment adverse reactions are common but in general they subside
with further treatment. The most frequently observed adverse reactions are a
flu-like symptom complex (fever, chills, arthralgia, malaise, sweating,
headache, or myalgia), which is mainly due to the pharmacological effects of
the medicinal product, and injection site reactions. Injection site reactions
occurred frequently after administration of Betaferon. Redness, swelling,
discolouration, inflammation, pain, hypersensitivity, necrosis and non-specific
reactions were significantly associated with 250&nbsp;microgram (8.0 million
IU) Betaferon treatment. </span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>The most
serious adverse reactions reported include thrombotic microangiopathy (TMA) and
haemolytic anaemia (HA).</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Generally, dose
titration is recommended at the start of treatment in order to increase
tolerability to Betaferon (see section 4.2). Flu-like symptoms may also be
reduced by administration of non-steroidal anti-inflammatory drugs. The
incidence of injection site reactions may be reduced by the use of an
autoinjector.</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:avoid'><u><span lang=EN-GB style='font-size:11.0pt'>Tabulated
list of adverse reactions</span></u></p>

<p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>The following adverse event listing is based on
reports from clinical trials <i>(Table 1, adverse events and laboratory
abnormalities) </i>and from the post-marketing surveillance <i>(Table 2, <span
style='letter-spacing:-.2pt;layout-grid-mode:line'>frequencies  where known-
based on pooled clinical trials </span>(very common &#8805;1/10, common
&#8805;1/100 to &lt;1/10, uncommon &#8805;&nbsp;1/1,000 to &lt; 1/100, rare
&#8805;1/10,000 to &lt;1/1,000, very rare &lt; 1/10,000))<span
style='letter-spacing:-.2pt;layout-grid-mode:line'> </span></i>of Betaferon
use. Experience with Betaferon in patients with MS is limited, consequently
those adverse events which occur very rarely may not yet have been observed.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><i><u><span lang=EN-GB style='font-size:11.0pt'>Table 1:</span></u></i><i><span
lang=EN-GB style='font-size:11.0pt'> Adverse events and laboratory
abnormalities with incidence rates </span></i><b><span lang=EN-GB
style='font-size:11.0pt'>&#8805; </span></b><i><span lang=EN-GB
style='font-size:11.0pt'>10% and the respective percentages under placebo;
significantly associated side effects &lt; 10% based on reports from clinical
trials </span></i></p>

<p class=Smalltext120><i><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></i></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width=170 rowspan=2 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>System
   Organ Class</span></b></p>
   <p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>
   <p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>Adverse
   Event</span></b></p>
   <p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>and Laboratory
   Abnormalities</span></b></p>
   </td>
   <td width=109 valign=top style='width:81.5pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=Smalltext120 align=center style='text-align:center'><b><span
   lang=EN-GB style='font-size:11.0pt'>Single Event suggestive of Multiple
   Sclerosis</span></b></p>
   <p class=Smalltext120 align=center style='text-align:center'><b><span
   lang=EN-GB style='font-size:11.0pt'>(BENEFIT) </span></b><sup><span
   lang=EN-GB style='font-size:11.0pt'>#</span></sup></p>
   </td>
   <td width=109 valign=top style='width:81.5pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=Smalltext120 align=center style='text-align:center'><b><span
   lang=EN-GB style='font-size:11.0pt'>Secondary Progressive Multiple Sclerosis</span></b></p>
   <p class=Smalltext120 align=center style='text-align:center'><b><span
   lang=EN-GB style='font-size:11.0pt'>(European Study)</span></b></p>
   </td>
   <td width=109 valign=top style='width:81.5pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=Smalltext120 align=center style='text-align:center'><b><span
   lang=EN-GB style='font-size:11.0pt'>Secondary Progressive Multiple Sclerosis</span></b></p>
   <p class=Smalltext120 align=center style='text-align:center'><b><span
   lang=EN-GB style='font-size:11.0pt'>(North American Study)</span></b></p>
   </td>
   <td width=109 valign=top style='width:81.5pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=Smalltext120 align=center style='margin-right:-5.4pt;text-align:
   center'><b><span lang=EN-GB style='font-size:11.0pt'>Relapsing-Remitting
   Multiple Sclerosis</span></b></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=Smalltext120 align=center style='text-align:center'><b><span
   lang=EN-GB style='font-size:11.0pt'>Betaferon</span></b></p>
   <p class=Smalltext120 align=center style='text-align:center'><b><span
   lang=EN-GB style='font-size:11.0pt'>250 microgram (Placebo)</span></b></p>
   <p class=Smalltext120 align=center style='text-align:center'><b><span
   lang=EN-GB style='font-size:11.0pt'>n=292 (n=176)</span></b></p>
   </td>
   <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=Smalltext120 align=center style='text-align:center'><b><span
   lang=EN-GB style='font-size:11.0pt'>Betaferon</span></b></p>
   <p class=Smalltext120 align=center style='text-align:center'><b><span
   lang=EN-GB style='font-size:11.0pt'>250 microgram (Placebo)</span></b></p>
   <p class=Smalltext120 align=center style='text-align:center'><b><span
   lang=EN-GB style='font-size:11.0pt'>n=360 (n=358)</span></b></p>
   </td>
   <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=Smalltext120 align=center style='text-align:center'><b><span
   lang=EN-GB style='font-size:11.0pt'>Betaferon</span></b></p>
   <p class=Smalltext120 align=center style='margin-top:0in;margin-right:-2.85pt;
   margin-bottom:0in;margin-left:-2.85pt;margin-bottom:.0001pt;text-align:center'><b><span
   lang=EN-GB style='font-size:11.0pt'>250 microgram (Placebo)</span></b></p>
   <p class=Smalltext120 align=center style='margin-top:0in;margin-right:-2.85pt;
   margin-bottom:0in;margin-left:-2.85pt;margin-bottom:.0001pt;text-align:center'><b><span
   lang=EN-GB style='font-size:11.0pt'>n=317 (n=308)</span></b></p>
   </td>
   <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=Smalltext120 align=center style='text-align:center'><b><span
   lang=EN-GB style='font-size:11.0pt'>Betaferon</span></b></p>
   <p class=Smalltext120 align=center style='text-align:center'><b><span
   lang=EN-GB style='font-size:11.0pt'>250 microgram (Placebo)</span></b></p>
   <p class=Smalltext120 align=center style='text-align:center'><b><span
   lang=EN-GB style='font-size:11.0pt'>n=124 (n=123)</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>Infections
  and infestations</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Infection</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>6% (3%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>13% (11%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>11% (10%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>14% (13%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.7pt'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.7pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Abscess</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.7pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>0% (1%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.7pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>4% (2%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.7pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>4% (5%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.7pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>1% (6%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>Blood and lymphatic
  system disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:4.25pt'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:4.25pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Lymphocyte
  count decreased (&lt;1,500/mm) </span><sup><span lang=EN-GB
  style='font-size:11.0pt;font-family:Symbol'></span></sup><sup><span
  lang=EN-GB style='font-size:11.0pt'> </span></sup><sup><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Bookshelf Symbol 3"'>L</span></sup><sup><span
  lang=EN-GB style='font-size:11.0pt'> </span></sup><span lang=EN-GB
  style='font-size:11.0pt'></span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:4.25pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>79% (45%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:4.25pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>53% (28%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:4.25pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>88% (68%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:4.25pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>82% (67%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Absolute
  neutrophil count decreased (&lt;1,500/mm) </span><sup><span lang=EN-GB
  style='font-size:11.0pt;font-family:Symbol'></span></sup><sup><span
  lang=EN-GB style='font-size:11.0pt'> </span></sup><sup><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Bookshelf Symbol 3"'>L</span></sup><sup><span
  lang=EN-GB style='font-size:11.0pt'> </span></sup><span lang=EN-GB
  style='font-size:11.0pt'>*  </span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>11% (2%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>18% (5%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>4% (10%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>18% (5%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>White blood
  cell count decreased (&lt;3,000/mm) </span><sup><span lang=EN-GB
  style='font-size:11.0pt;font-family:Symbol'></span></sup><sup><span
  lang=EN-GB style='font-size:11.0pt'> </span></sup><sup><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Bookshelf Symbol 3"'>L</span></sup><sup><span
  lang=EN-GB style='font-size:11.0pt'> </span></sup><span lang=EN-GB
  style='font-size:11.0pt'>*  </span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>11% (2%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>13% (4%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>13% (4%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>16% (4%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Lymphadenopathy</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>1% (1%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>3% (1%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>11% (5%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>14% (11%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 style='margin-right:102.6pt'><b><span lang=EN-GB
  style='font-size:11.0pt;layout-grid-mode:line'>Metabolism and nutrition
  disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Blood glucose
  decreased (&lt;55&nbsp;mg/dl) </span><sup><span lang=EN-GB style='font-size:
  11.0pt;font-family:Symbol'></span></sup></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>3% (5%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>27% (27%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>5% (3%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>15% (13%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>Psychiatric
  disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Depression</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>10% (11%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>24% (31%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>44% (41%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>25% (24%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.7pt'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.7pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Anxiety</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.7pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>3% (5%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.7pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>6% (5%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.7pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>10% (11%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.7pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>15% (13%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>Nervous
  system disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Headache </span><sup><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Bookshelf Symbol 3"'>L</span></sup></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>27% (17%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>47% (41%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>55% (46%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>84% (77%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Dizziness</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>3% (4%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>14% (14%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>28% (26%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>35% (28%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Insomnia</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>8% (4%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>12% (8%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>26% (25%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>31% (33%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Migraine</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>2% (2%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>4% (3%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>5% (4%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>12% (7%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Paraesthesia</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>16% (17%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>35% (39%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>40% (43%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>19% (21%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>Eye
  disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Conjunctivitis</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>1% (1%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>2% (3%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>6% (6%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>12% (10%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Abnormal
  vision </span><sup><span lang=EN-GB style='font-size:11.0pt;font-family:"Bookshelf Symbol 3"'>L</span></sup></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>3% (1%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>11% (15%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>11% (11%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>7% (4%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt'>Ear and labyrinth disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Ear pain</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>0% (1%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&lt;1% (1%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>6% (8%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>16% (15%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>Cardiac
  disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Palpitation *</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>1% (1%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>2% (3%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>5% (2%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>8% (2%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>Vascular
  disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Vasodilatation</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>0% (0%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>6% (4%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>13% (8%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>18% (17%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Hypertension
  </span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>2% (0%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>4% (2%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>9% (8%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>7% (2%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>Respiratory,
  thoracic and mediastinal disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Upper
  respiratory infection</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>18% (19%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>3% (2%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Sinusitis</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>4% (6%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>6% (6%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>16% (18%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>36% (26%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Cough
  increased</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>2% (2%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>5% (10%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>11% (15%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>31% (23%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Dyspnoea *</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>0% (0%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>3% (2%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>8% (6%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>8% (2%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>Gastrointestinal
  disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Diarrhoea</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>4% (2%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>7% (10%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>21% (19%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>35% (29%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Constipation</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>1% (1%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>12% (12%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>22% (24%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>24% (18%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Nausea</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>3% (4%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>13% (13%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>32% (30%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>48% (49%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Vomiting </span><sup><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Bookshelf Symbol 3"'>L</span></sup></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>5% (1%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>4% (6%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>10% (12%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>21% (19%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Abdominal
  pain </span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>5% (3%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>11% (6%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>18% (16%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>32% (24%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>Hepatobiliary
  disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Alanine
  aminotransferase increased (SGPT&gt; 5 times baseline) </span><sup><span
  lang=EN-GB style='font-size:11.0pt;font-family:Symbol'></span></sup><sup><span
  lang=EN-GB style='font-size:11.0pt'> </span></sup><sup><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Bookshelf Symbol 3"'>L</span></sup><sup><span
  lang=EN-GB style='font-size:11.0pt'> </span></sup><span lang=EN-GB
  style='font-size:11.0pt'>* </span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>18% (5%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>14% (5%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>4% (2%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>19% (6%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.7pt'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.7pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Aspartate
  aminotransferase increased (SGOT &gt; 5 times baseline) </span><sup><span
  lang=EN-GB style='font-size:11.0pt;font-family:Symbol'></span></sup><sup><span
  lang=EN-GB style='font-size:11.0pt'> </span></sup><sup><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Bookshelf Symbol 3"'>L</span></sup><sup><span
  lang=EN-GB style='font-size:11.0pt'> </span></sup><span lang=EN-GB
  style='font-size:11.0pt'>*  </span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.7pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>6% (1%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.7pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>4% (1%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.7pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>2% (1%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.7pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>4% (0%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>Skin and
  subcutaneous tissue disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Skin disorder</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>1% (0%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>4% (4%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>19% (17%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>6% (8%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Rash </span><sup><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Bookshelf Symbol 3"'>L</span></sup><sup><span
  lang=EN-GB style='font-size:11.0pt'> </span></sup><span lang=EN-GB
  style='font-size:11.0pt'></span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>11% (3%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>20% (12%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>26% (20%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>27% (32%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>Musculoskeletal
  and connective tissue disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Hypertonia</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>2% (1%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>41% (31%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>57% (57%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>26% (24%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Myalgia * </span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>8% (8%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>23% (9%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>19% (29%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>44% (28%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Myasthenia</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>2% (2%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>39% (40%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>57% (60%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>13% (10%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Back pain</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>10% (7%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>26% (24%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>31% (32%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>36% (37%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Pain in
  extremity</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>6% (3%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>14% (12%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>0% (0%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>Renal and
  urinary disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Urinary
  retention</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>1% (1%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>4% (6%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>15% (13%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Urinary
  protein positive (&gt; 1+)</span><sup><span lang=EN-GB style='font-size:11.0pt;
  font-family:Symbol'></span></sup></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>25% (26%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>14% (11%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>5% (5%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>5% (3%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Urinary
  frequency</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>1% (1%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>6% (5%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>12% (11%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>3% (5%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Urinary
  incontinence</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>1% (1%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>8% (15%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>20% (19%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>2% (1%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Urinary
  urgency</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>1% (1%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>8% (7%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>21% (17%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>4% (2%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:15.7pt'>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.7pt'>
  <p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>Reproductive
  system and breast disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.55pt'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.55pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Dysmenorrhoea</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.55pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>2% (0%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.55pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>&lt;1% (&lt;1%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.55pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>6% (5%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.55pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>18% (11%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Menstrual
  disorder *</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>1% (2%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>9% (13%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>10% (8%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>17% (8%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Metrorrhagia</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>2% (0%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>12% (6%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>10% (10%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>15% (8%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Impotence</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>1% (0%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>7% (4%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>10% (11%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>2% (1%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>General
  disorders and administration site conditions</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Injection
  site reaction (various kinds) </span><sup><span lang=EN-GB style='font-size:
  11.0pt;font-family:"Bookshelf Symbol 3"'>L</span></sup><sup><span lang=EN-GB
  style='font-size:11.0pt'> </span></sup><span lang=EN-GB style='font-size:
  11.0pt'>*  <sup></sup></span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>52% (11%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>78% (20%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>89% (37%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>85% (37%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Injection
  site necrosis * </span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>1% (0%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>5% (0%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>6% (0%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>5% (0%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Flu-like
  symptoms <sup>&amp; </sup></span><sup><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Bookshelf Symbol 3"'>L</span></sup><sup><span lang=EN-GB
  style='font-size:11.0pt'> </span></sup><span lang=EN-GB style='font-size:
  11.0pt'>*</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>44% (18%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>61% (40%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>43% (33%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>52% (48%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Fever </span><sup><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Bookshelf Symbol 3"'>L</span></sup><sup><span
  lang=EN-GB style='font-size:11.0pt'> </span></sup><span lang=EN-GB
  style='font-size:11.0pt'>* </span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>13% (5%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>40% (13%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>29% (24%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>59% (41%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Pain</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>4% (4%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>31% (25%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>59% (59%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>52% (48%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Chest pain </span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>1% (0%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>5% (4%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>15% (8%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>15% (15%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Peripheral
  oedema</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>0% (0%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>7% (7%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>21% (18%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>7% (8%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Asthenia *</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>22% (17%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>63% (58%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>64% (58%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>49% (35%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Chills </span><sup><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Bookshelf Symbol 3"'>L</span></sup><sup><span
  lang=EN-GB style='font-size:11.0pt'> </span></sup><span lang=EN-GB
  style='font-size:11.0pt'>*  </span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>5% (1%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>23% (7%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>22% (12%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>46% (19%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Sweating *</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>2% (1%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>6% (6%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>10% (10%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>23% (11%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=170 valign=top style='width:127.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Malaise *</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>0% (1%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>8% (5%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>6% (2%)</span></p>
  </td>
  <td width=109 valign=top style='width:81.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Smalltext120 align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'>15% (3%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.25in'>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.25in'>
  <p class=Smalltext120 style='margin-left:15.9pt;text-indent:-15.9pt'><sup><span
  lang=EN-GB style='font-size:11.0pt;font-family:Symbol'></span></sup><sup><span
  lang=EN-GB style='font-size:11.0pt'> </span></sup><span lang=EN-GB
  style='font-size:11.0pt'>Laboratory abnormality </span></p>
  <p class=Smalltext120 style='margin-left:15.9pt;text-indent:-15.9pt'><sup><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Bookshelf Symbol 3"'>L</span></sup><sup><span
  lang=EN-GB style='font-size:11.0pt'> </span></sup><span lang=EN-GB
  style='font-size:11.0pt'>Significantly associated with Betaferon treatment
  for patients with first event suggestive of MS, p&nbsp;&lt; 0.05</span></p>
  <p class=Smalltext120 style='margin-left:15.9pt;text-indent:-15.9pt'><span
  lang=EN-GB style='font-size:11.0pt'>* Significantly associated with
  Betaferon treatment for RRMS, p &lt; 0.05</span></p>
  <p class=Smalltext120 style='margin-left:15.9pt;text-indent:-15.9pt'><span
  lang=EN-GB style='font-size:11.0pt'> Significantly associated with Betaferon
  treatment for SPMS, p &lt; 0.05</span></p>
  <p class=Smalltext120 style='margin-left:15.9pt;text-indent:-15.9pt'><span
  lang=EN-GB style='font-size:11.0pt'> Injection site reaction (various
  kinds) comprises all adverse events occurring at the injection site, i.e. the
  following terms: injection site haemorrhage, injection site hypersensitivity,
  injection site inflammation, injection site mass, injection site necrosis,
  injection site pain, injection site reaction, injection site oedema, and
  injection site atrophy</span></p>
  <p class=Smalltext120 style='margin-left:15.9pt;text-indent:-15.9pt'><span
  lang=EN-GB style='font-size:11.0pt'>&amp; Flu-like symptom complex denotes
  flu syndrome and/or a combination of at least two AEs from fever, chills, myalgia,
  malaise, sweating.</span></p>
  <p class=Smalltext120 style='margin-left:15.9pt;text-indent:-15.9pt'><sup><span
  lang=EN-GB style='font-size:11.0pt'>#</span></sup><span lang=EN-GB
  style='font-size:11.0pt'> During the BENEFIT follow-up study, no change in
  the known risk profile of Betaferon was observed.</span></p>
  </td>
 </tr>
</table>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>The most
appropriate MedDRA term is used to describe a certain reaction <span
style='layout-grid-mode:line'>and its </span>synonyms and related conditions.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Para0s style='margin-bottom:0in;page-break-after:avoid'><i><u><span
lang=EN-GB style='font-size:11.0pt'>Table 2:<span style='layout-grid-mode:line'>
</span></span></u></i><i><span lang=EN-GB style='font-size:11.0pt;color:black'>Adverse
drug reactions (ADRs) identified during post-marketing surveillance</span></i><span
lang=EN-GB style='font-size:11.0pt;color:black'> (</span><i><span lang=EN-GB
style='font-size:11.0pt;letter-spacing:-.2pt;layout-grid-mode:line'>frequencies
- where known - calculated based on pooled clinical trial data N= 1093)</span></i></p>

<p class=Para0s style='margin-bottom:0in;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=635
 style='width:476.0pt;margin-left:3.5pt;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td valign=top style='border:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
   <p class=Smalltext120 style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;letter-spacing:-.2pt'>System Organ Class </span></b></p>
   <p class=Smalltext90 style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;letter-spacing:-.2pt'>&nbsp;</span></b></p>
   </td>
   <td valign=top style='border:solid windowtext 1.0pt;border-left:none;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=Smalltext120 style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;letter-spacing:-.2pt'>Very common</span></b></p>
   <p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
   style='font-size:11.0pt;letter-spacing:-.2pt'>(</span><span lang=EN-GB
   style='font-size:11.0pt;font-family:Symbol;letter-spacing:-.2pt'></span><span
   lang=EN-GB style='font-size:11.0pt;letter-spacing:-.2pt'> <b>1/10) <sup>1</sup>
   </b></span></p>
   </td>
   <td valign=top style='border:solid windowtext 1.0pt;border-left:none;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=Smalltext120 style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;letter-spacing:-.2pt'>Common</span></b></p>
   <p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
   style='font-size:11.0pt;letter-spacing:-.2pt'>( </span><span lang=EN-GB
   style='font-size:11.0pt;font-family:Symbol;letter-spacing:-.2pt'></span><span
   lang=EN-GB style='font-size:11.0pt;letter-spacing:-.2pt'> <b>1/100 to </b></span></p>
   <p class=Smalltext120 style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;letter-spacing:-.2pt'>&lt; 1/10) <sup>1</sup></span></b></p>
   </td>
   <td valign=top style='border:solid windowtext 1.0pt;border-left:none;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=Smalltext120 style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;letter-spacing:-.2pt'>Uncommon</span></b></p>
   <p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
   style='font-size:11.0pt;letter-spacing:-.2pt'>(</span><span lang=EN-GB
   style='font-size:11.0pt;font-family:Symbol;letter-spacing:-.2pt'></span><span
   lang=EN-GB style='font-size:11.0pt;letter-spacing:-.2pt'> <b>1/1,000 to </b></span></p>
   <p class=Smalltext120 style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;letter-spacing:-.2pt'>&lt; 1/100) <sup>1</sup></span></b></p>
   </td>
   <td valign=top style='border:solid windowtext 1.0pt;border-left:none;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=Smalltext120 style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;letter-spacing:-.2pt'>Rare</span></b></p>
   <p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
   style='font-size:11.0pt;letter-spacing:-.2pt'>( </span><span lang=EN-GB
   style='font-size:11.0pt;font-family:Symbol;letter-spacing:-.2pt'></span><span
   lang=EN-GB style='font-size:11.0pt;letter-spacing:-.2pt'> <b>1/10,000 to
   &lt;&nbsp;1/1,000) <sup>1</sup></b></span></p>
   </td>
   <td valign=top style='border:solid windowtext 1.0pt;border-left:none;
   padding:0in 3.5pt 0in 3.5pt'>
   <p class=Smalltext120 style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;letter-spacing:-.2pt'>Frequency</span></b></p>
   <p class=Smalltext120 style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;letter-spacing:-.2pt'>not known</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td valign=top style='border:solid windowtext 1.0pt;border-top:none;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>Blood and lymphatic system disorders</span></b></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'></span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>Anaemia</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Thrombocytopenia</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;color:black;
  letter-spacing:-.2pt'>Thrombotic microangiopathy<b><i><sup>5</sup></i> </b>including
  thrombotic thrombocytopenic purpura/ haemolytic uraemic syndrome</span><b><i><sup><span
  lang=EN-GB style='font-size:11.0pt;color:black'>3</span></sup></i></b></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;color:black;
  letter-spacing:-.2pt'>Haemolytic anaemia</span><i><sup><span lang=EN-GB
  style='font-size:11.0pt'>2, <span style='color:black;letter-spacing:-.2pt'>5</span></span></sup></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td valign=top style='border:solid windowtext 1.0pt;border-top:none;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext90><b><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>Immune system disorders</span></b></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>Anaphylactic reactions</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;color:black;
  layout-grid-mode:line'>Capillary leak syndrome in pre-existing monoclonal gammopathy</span><b><i><sup><span
  lang=EN-GB style='font-size:11.0pt'>2</span></sup></i></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td valign=top style='border:solid windowtext 1.0pt;border-top:none;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext90><b><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>Endocrine <span style='layout-grid-mode:line'>disorders</span></span></b></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Hypothyroidism</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt;layout-grid-mode:line'>Hyperthyroidism,</span></p>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt;layout-grid-mode:line'>Thyroid disorders</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt;layout-grid-mode:line'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td valign=top style='border:solid windowtext 1.0pt;border-top:none;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext90><b><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>Metabolism and nutrition disorders</span></b></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>Weight increased,</span></p>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>Weight decreased</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>Blood triglycerides increased</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt;layout-grid-mode:line'>Anorexia</span><b><i><sup><span lang=EN-GB
  style='font-size:11.0pt'>2</span></sup></i></b></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt;layout-grid-mode:line'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td valign=top style='border:solid windowtext 1.0pt;border-top:none;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext90><b><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>Psychiatric disorders</span></b></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>Confusional state </span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt;layout-grid-mode:line'>Suicide attempt (see also section 4.4), </span></p>
  <p class=Smalltext90><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt;layout-grid-mode:line'>Emotional lability</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt;layout-grid-mode:line'>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt;layout-grid-mode:line'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td valign=top style='border:solid windowtext 1.0pt;border-top:none;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext90><b><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>Nervous system disorders</span></b></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt;layout-grid-mode:line'>Convulsion</span></p>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt;layout-grid-mode:line'>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt;layout-grid-mode:line'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td valign=top style='border:solid windowtext 1.0pt;border-top:none;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext90><b><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>Cardiac disorders</span></b></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>Tachycardia</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt;layout-grid-mode:line'>Cardiomyopathy</span><b><i><sup><span
  lang=EN-GB style='font-size:11.0pt'>2</span></sup></i></b></p>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt;layout-grid-mode:line'>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt;layout-grid-mode:line'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.45pt'>
  <td valign=top style='border:solid windowtext 1.0pt;border-top:none;
  padding:0in 3.5pt 0in 3.5pt;height:44.45pt'>
  <p class=Smalltext90><b><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>Respiratory, thoracic and mediastinal disorders</span></b></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt;height:44.45pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt;height:44.45pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt;height:44.45pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt;height:44.45pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt;layout-grid-mode:line'>Bronchospasm</span><b><i><sup><span lang=EN-GB
  style='font-size:11.0pt'>2</span></sup></i></b></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt;height:44.45pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt;layout-grid-mode:line'>Pulmonary arterial hypertension</span><b><i><sup><span
  lang=EN-GB style='font-size:11.0pt'>4</span></sup></i></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td valign=top style='border:solid windowtext 1.0pt;border-top:none;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext90><b><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>Gastrointestinal disorders</span></b></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>Pancreatitis</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt;layout-grid-mode:line'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td valign=top style='border:solid windowtext 1.0pt;border-top:none;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext90><b><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>Hepatobiliary disorders</span></b></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>Blood bilirubin increased</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>Gamma-glutamyl-transferase increased,</span></p>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>Hepatitis</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;color:black;
  layout-grid-mode:line'>Hepatic injury (including hepatitis), Hepatic failure</span><b><i><sup><span
  lang=EN-GB style='font-size:11.0pt'>2</span></sup></i></b></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt;layout-grid-mode:line'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.45pt'>
  <td valign=top style='border:solid windowtext 1.0pt;border-top:none;
  padding:0in 3.5pt 0in 3.5pt;height:44.45pt'>
  <p class=Smalltext90><b><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>Skin and subcutaneous tissue disorders</span></b></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt;height:44.45pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt;height:44.45pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt;layout-grid-mode:line'>Urticaria,</span></p>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt;layout-grid-mode:line'>Pruritus,</span></p>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt;layout-grid-mode:line'>Alopecia</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt;height:44.45pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>Skin discolouration</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt;height:44.45pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt;layout-grid-mode:line'>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt;height:44.45pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt;layout-grid-mode:line'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td valign=top style='border:solid windowtext 1.0pt;border-top:none;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext90><b><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>Musculoskeletal and connective tissue disorders</span></b></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Arthralgia</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>Drug-induced lupus erythematosus</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td valign=top style='border:solid windowtext 1.0pt;border-top:none;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext90><b><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>Renal and urinary disorders</span></b></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt;layout-grid-mode:line'>Nephrotic syndrome, glomerulosclerosis (see
  section 4.4)<b><i><sup>2, 3</sup></i></b></span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:4.0pt'>
  <td valign=top style='border:solid windowtext 1.0pt;border-top:none;
  padding:0in 3.5pt 0in 3.5pt;height:4.0pt'>
  <p class=Smalltext90><b><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>Reproductive system and breast disorders</span></b></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt;height:4.0pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt;height:4.0pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>Menorrhagia</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt;height:4.0pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt;height:4.0pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt'>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt;height:4.0pt'>
  <p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;letter-spacing:
  -.2pt;layout-grid-mode:line'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td colspan=6 valign=top style='border:solid windowtext 1.0pt;border-top:
  none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=Smalltext120 style='margin-left:17.8pt;text-indent:-17.8pt'><b><i><sup><span
  lang=EN-GB style='font-size:11.0pt;letter-spacing:-.2pt;layout-grid-mode:
  line'>1</span></sup></i></b><i><span lang=EN-GB style='font-size:11.0pt;
  letter-spacing:-.2pt;layout-grid-mode:line'> frequencies based on pooled
  clinical trials </span></i><i><span lang=EN-GB style='font-size:11.0pt'>(very
  common &#8805;1/10, common &#8805;1/100 to &lt;1/10, uncommon
  &#8805;&nbsp;1/1,000 to &lt; 1/100, rare &#8805;1/10,000 to &lt;1/1,000, very
  rare &lt; 1/10,000).</span></i></p>
  <p class=Smalltext120 style='margin-left:17.8pt;text-indent:-17.8pt'><b><i><sup><span
  lang=EN-GB style='font-size:11.0pt'>2 </span></sup></i></b><i><span
  lang=EN-GB style='font-size:11.0pt'>ADRs derived only during post-marketing</span></i></p>
  <p class=Smalltext120 style='margin-left:17.8pt;text-indent:-17.8pt'><b><i><sup><span
  lang=EN-GB style='font-size:11.0pt'>3 </span></sup></i></b><i><span
  lang=EN-GB style='font-size:11.0pt'>Class label for interferon beta products
  (see section 4.4).</span></i></p>
  <p class=Smalltext120 style='margin-left:17.8pt;text-indent:-17.8pt'><b><i><sup><span
  lang=EN-GB style='font-size:11.0pt'>4 </span></sup></i></b><i><span
  lang=EN-GB style='font-size:11.0pt'>Class label for interferon products, see
  below Pulmonary arterial hypertension.</span></i></p>
  <p class=Smalltext120 style='margin-left:17.8pt;text-indent:-17.8pt'><b><i><sup><span
  lang=EN-GB style='font-size:11.0pt'>5</span></sup></i></b><i><span
  lang=EN-GB style='font-size:11.0pt'> life-threatening and/or fatal cases
  have been reported.</span></i></p>
  </td>
 </tr>
</table>

<p class=Smalltext90><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:
line'>&nbsp;</span></p>

<p class=Smalltext90><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:
line'>T</span><span lang=EN-GB style='font-size:11.0pt'>he most appropriate
MedDRA term is used to describe a certain reaction and its synonyms and related
conditions.</span></p>

<p class=Smalltext90><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext90><u><span lang=EN-GB style='font-size:11.0pt'>Pulmonary
arterial hypertension</span></u></p>

<p class=Smalltext90><span lang=EN-GB style='font-size:11.0pt'>Cases of
pulmonary arterial hypertension (PAH) have been reported with interferon beta
products. Events were reported at various time points including up to several
years after starting treatment with interferon beta.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><u><span lang=EN-GB style='font-size:11.0pt'>Reporting of
suspected adverse reactions</span></u></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the
medicinal product. Healthcare professionals are asked to report any suspected
adverse reactions <span style='background:lightgrey'>via the national reporting
system listed in</span></span><span lang=EN-GB style='background:lightgrey'> </span><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='font-size:11.0pt;background:lightgrey'>Appendix V</span></a><span
lang=EN-GB style='font-size:11.0pt'>.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='font-size:11.0pt'>4.9 Overdose</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Interferon
beta-1b has been given without serious adverse events compromising vital
functions to adult cancer patients at individual doses as high as 5,500
microgram (176 million IU) intravenously three times a week.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:avoid'><b><span lang=EN-GB style='font-size:11.0pt'>5. PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:avoid'><b><span lang=EN-GB style='font-size:11.0pt'>5.1 Pharmacodynamic
properties</span></b></p>

<p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Pharmacotherapeutic group: Cytokines, Interferons, </span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>ATC Code: L03 AB 08</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><u><span lang=EN-GB style='font-size:11.0pt'>Mechanism of
action</span></u></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Interferons
belong to the family of cytokines, which are naturally occurring proteins.
Interferons have molecular weights ranging from 15,000 to 21,000 Daltons. Three
major classes of interferons have been identified: alpha, beta, and gamma.
Interferon alpha, interferon beta, and interferon gamma have overlapping yet
distinct biologic activities. The activities of interferon beta-1b are
species-restricted and therefore, the most pertinent pharmacological
information on interferon beta-1b is derived from studies of human cells in
culture or in human <i>in vivo </i>studies.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Interferon
beta-1b has been shown to possess both antiviral and immunoregulatory
activities. The mechanisms by which interferon beta-1b exerts its actions in
multiple sclerosis are not clearly understood. However, it is known that the
biologic response-modifying properties of interferon beta&#8209;1b are mediated
through its interactions with specific cell receptors found on the surface of
human cells. The binding of interferon beta-1b to these receptors induces the
expression of a number of gene products that are believed to be the mediators
of the biological actions of interferon beta-1b. A number of these products
have been measured in the serum and cellular fractions of blood collected from patients
treated with interferon beta-1b. Interferon beta-1b both decreases the binding
affinity and enhances the internalisation and degradation of the
interferon-gamma receptor. Interferon beta-1b also enhances the suppressor
activity of peripheral blood mononuclear cells.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>No separate
investigations were performed regarding the influence of Betaferon on the
cardiovascular system, respiratory system and the function of endocrine organs.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><u><span lang=EN-GB style='font-size:11.0pt'>Clinical
efficacy and safety</span></u></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><i><span lang=EN-GB style='font-size:11.0pt'>RR-MS</span></i></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>One controlled
clinical trial with Betaferon in patients with relapsing-remitting multiple
sclerosis and able to walk unaided (baseline EDSS 0 to 5.5) was performed.
Patients receiving Betaferon showed a reduction in frequency (30%) and severity
of clinical relapses, as well as the number of hospitalisations due to disease.
Furthermore, there was a prolongation of the relapse-free interval. There is no
evidence of an effect of Betaferon on the duration of relapses or on symptoms
in between relapses, and no significant effect was seen on the progression of
the disease in relapsing-remitting multiple sclerosis.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><i><span lang=EN-GB style='font-size:11.0pt'>SP-MS</span></i></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Two controlled
clinical trials with Betaferon involving a total of 1,657 patients with
secondary progressive multiple sclerosis (baseline EDSS 3 to 6.5, i.e. patients
were able to walk) were performed. Patients with mild disease and those unable
to walk were not studied. The two studies showed inconsistent results for the
primary endpoint time to confirmed progression, representing delay of
disability progression:</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>One of the two
studies demonstrated a statistically significant delay in the time to
disability progression (Hazard Ratio = 0.69, 95% confidence interval (0.55,
0.86), p=0.0010, corresponding to a 31% risk reduction due to Betaferon) and in
the time to becoming wheelchair bound (Hazard Ratio = 0.61, 95% confidence
interval (0.44, 0.85), p=0.0036, corresponding to a 39% risk reduction due to
Betaferon) in patients who received Betaferon. This effect continued over the
observation period of up to 33 months. The treatment effect occurred in
patients at all levels of disability investigated and independent of relapse
activity.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>In the second
trial of Betaferon in secondary progressive multiple sclerosis, no delay in the
time to disability progression was observed. There is evidence that the
patients included in this study had overall less active disease than in the
other study in secondary progressive multiple sclerosis.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>In
retrospective meta-analyses including the data of both studies, an overall
treatment effect was found which was statistically significant (p=0.0076; 8.0
million IU Betaferon versus all placebo patients).</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Retrospective
analyses in subgroups showed that a treatment effect on disability progression
is most likely in patients with active disease before treatment commences
(Hazard Ratio 0.72, 95% confidence interval (0.59, 0.88), p=0.0011,
corresponding to a 28 % risk reduction due to Betaferon in patients with
relapses or pronounced EDSS progression, 8.0 million IU Betaferon versus all
placebo patients). </span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>From these
retrospective subgroup analyses there was evidence to suggest that relapses as
well as pronounced EDSS progression (EDSS &gt;1 point or &gt;0.5 point for EDSS
&#8805;6 in the previous two years) can help to identify patients with active
disease.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>In both trials
secondary progressive multiple sclerosis patients receiving Betaferon showed a
reduction in frequency (30%) of clinical relapses. There is no evidence of
Betaferon having an effect on the duration of relapses.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt'>Single clinical event suggestive of MS</span></i></p>

<p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>One controlled clinical trial with Betaferon was
performed in patients with a single clinical event and MRI features suggestive
of multiple sclerosis (at least two clinically silent lesions on the
T2-weighted MRI). Patients with monofocal or multifocal onset of the disease
were included (i.e. patients with clinical evidence for a single or at least
two lesions, respectively, of the central nervous system). Any disease other
than multiple sclerosis that could better explain signs and symptoms of the
patient had to be excluded. This study consisted of two phases, a
placebo-controlled phase followed by a pre-planned follow-up phase. The
placebo-controlled phase lasted for 2 years or until the patient developed
clinically definite multiple sclerosis (CDMS), whichever came first. After the
placebo-controlled phase, patients entered a pre-planned follow-up phase with
Betaferon to evaluate the effects of immediate versus delayed start of
Betaferon treatment, comparing patients initially randomized to Betaferon (&quot;immediate
treatment group&quot;) or to placebo (&quot;delayed treatment group&quot;).
Patients and investigators remained blinded to the initial treatment
allocation.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><i><u><span lang=EN-GB
style='font-size:11.0pt'>Table 3:</span></u></i><span lang=EN-GB
style='font-size:11.0pt'> <i>Primary efficacy results of the BENEFIT and the
BENEFIT Follow-up study</i></span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=151 valign=top style='width:113.4pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=154 colspan=2 valign=top style='width:115.7pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:double windowtext 1.5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:4.8pt;margin-right:0in;
  margin-bottom:4.8pt;margin-left:0in;text-align:center'><b><span lang=EN-GB
  style='font-size:11.0pt'>Year 2 results<br>
  Placebo-controlled phase</span></b></p>
  </td>
  <td width=154 colspan=2 valign=top style='width:115.75pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:4.8pt;margin-right:0in;
  margin-bottom:4.8pt;margin-left:0in;text-align:center'><b><span lang=EN-GB
  style='font-size:11.0pt'>Year 3 results<br>
  Open-label follow-up</span></b></p>
  </td>
  <td width=154 colspan=2 valign=top style='width:115.75pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:4.8pt;margin-right:0in;
  margin-bottom:4.8pt;margin-left:0in;text-align:center'><b><span lang=EN-GB
  style='font-size:11.0pt'>Year 5 results<br>
  Open-label follow-up</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=151 valign=top style='width:113.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=77 valign=top style='width:57.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:4.8pt;margin-right:0in;
  margin-bottom:4.8pt;margin-left:0in;text-align:center'><b><span lang=EN-GB
  style='font-size:11.0pt'>Betaferon 250 mcg<br>
  <br>
  n=292</span></b></p>
  </td>
  <td width=77 valign=top style='width:57.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:double windowtext 1.5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:4.8pt;margin-right:0in;
  margin-bottom:4.8pt;margin-left:0in;text-align:center'><b><span lang=EN-GB
  style='font-size:11.0pt'>Placebo<br>
  <br>
  n=176</span></b></p>
  </td>
  <td width=77 valign=top style='width:57.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:4.8pt;margin-right:0in;
  margin-bottom:4.8pt;margin-left:0in;text-align:center'><b><span lang=EN-GB
  style='font-size:11.0pt'>Imme-diate Betaferon 250 mcg<br>
  <br>
  n=292</span></b></p>
  </td>
  <td width=77 valign=top style='width:57.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:4.8pt;margin-right:0in;
  margin-bottom:4.8pt;margin-left:0in;text-align:center'><b><span lang=EN-GB
  style='font-size:11.0pt'>Delayed<br>
  Betaferon 250 mcg<br>
  <br>
  n=176</span></b></p>
  </td>
  <td width=77 valign=top style='width:57.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:4.8pt;margin-right:0in;
  margin-bottom:4.8pt;margin-left:0in;text-align:center'><b><span lang=EN-GB
  style='font-size:11.0pt'>Imme-diate Betaferon 250 mcg<br>
  <br>
  n=292</span></b></p>
  </td>
  <td width=77 valign=top style='width:57.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:4.8pt;margin-right:0in;
  margin-bottom:4.8pt;margin-left:0in;text-align:center'><b><span lang=EN-GB
  style='font-size:11.0pt'>Delayed<br>
  Betaferon 250 mcg<br>
  <br>
  n=176</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=151 valign=top style='width:113.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt'>Number of
  patients completed the trial phase </span></p>
  </td>
  <td width=77 valign=top style='width:57.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt'><br>
  271 (93%)</span></p>
  </td>
  <td width=77 valign=top style='width:57.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:double windowtext 1.5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt'><br>
  166 (94%)</span></p>
  </td>
  <td width=77 valign=top style='width:57.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:4.8pt;margin-right:0in;
  margin-bottom:4.8pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'><br>
  249 (85%)</span></p>
  </td>
  <td width=77 valign=top style='width:57.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:4.8pt;margin-right:0in;
  margin-bottom:4.8pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'><br>
  143 (81%)</span></p>
  </td>
  <td width=77 valign=top style='width:57.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:4.8pt;margin-right:0in;
  margin-bottom:4.8pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'><br>
  235 (80%)</span></p>
  </td>
  <td width=77 valign=top style='width:57.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:4.8pt;margin-right:0in;
  margin-bottom:4.8pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'><br>
  123 (70%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=7 valign=top style='width:460.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><b><span lang=EN-GB style='font-size:11.0pt'>Primary
  efficacy variables</span></b></p>
  </td>
 </tr>
 <tr style='height:17.05pt'>
  <td width=614 colspan=7 valign=top style='width:460.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.05pt'>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><b><span lang=EN-GB style='font-size:11.0pt'>Time to
  CDMS</span></b></p>
  </td>
 </tr>
 <tr style='height:16.25pt'>
  <td width=151 valign=top style='width:113.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.25pt'>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><b><span lang=EN-GB style='font-size:11.0pt'>Kaplan-Meier
  estimates</span></b></p>
  </td>
  <td width=77 valign=top style='width:57.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.25pt'>
  <p class=MsoNormal align=center style='margin-top:4.8pt;margin-right:0in;
  margin-bottom:4.8pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>28%</span></p>
  </td>
  <td width=77 valign=top style='width:57.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:double windowtext 1.5pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.25pt'>
  <p class=MsoNormal align=center style='margin-top:4.8pt;margin-right:0in;
  margin-bottom:4.8pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>45%</span></p>
  </td>
  <td width=77 valign=top style='width:57.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.25pt'>
  <p class=MsoNormal align=center style='margin-top:4.8pt;margin-right:0in;
  margin-bottom:4.8pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>37%</span></p>
  </td>
  <td width=77 valign=top style='width:57.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.25pt'>
  <p class=MsoNormal align=center style='margin-top:4.8pt;margin-right:0in;
  margin-bottom:4.8pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>51%</span></p>
  </td>
  <td width=77 valign=top style='width:57.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.25pt'>
  <p class=MsoNormal align=center style='margin-top:4.8pt;margin-right:0in;
  margin-bottom:4.8pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>46%</span></p>
  </td>
  <td width=77 valign=top style='width:57.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.25pt'>
  <p class=MsoNormal align=center style='margin-top:4.8pt;margin-right:0in;
  margin-bottom:4.8pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>57%</span></p>
  </td>
 </tr>
 <tr style='height:112.85pt'>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:112.85pt'>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><b><span lang=EN-GB style='font-size:11.0pt'>Risk reduction<br>
  <br>
  </span></b></p>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><b><span lang=EN-GB style='font-size:11.0pt'>Hazard
  ratio with 95% confidence interval</span></b></p>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><b><span lang=EN-GB style='font-size:11.0pt'>log-rank
  test</span></b></p>
  </td>
  <td width=154 colspan=2 valign=top style='width:115.7pt;border:none;
  border-right:double windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt;height:112.85pt'>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt'>47% versus
  placebo<br>
  <br>
  </span></p>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt'>HR = 0.53
  [0.39, 0.73]<br>
  <br>
  </span></p>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt'>p &lt;
  0.0001<br>
  <br>
  Betaferon prolonged the time to CDMS by 363 days, from 255 days in the
  placebo group to 618 days in the Betaferon group (based on the 25th
  percentiles)</span></p>
  </td>
  <td width=154 colspan=2 valign=top style='width:115.75pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:112.85pt'>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt'>41% versus
  delayed Betaferon</span></p>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt'>HR = 0.59
  [0.42, 0.83]<br>
  <br>
  </span></p>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt'>p = 0.0011</span></p>
  </td>
  <td width=154 colspan=2 valign=top style='width:115.75pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:112.85pt'>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt'>37% versus
  delayed Betaferon</span></p>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt'>HR = 0.63
  [0.48, 0.83]<br>
  <br>
  </span></p>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt'>p = 0.0027</span></p>
  </td>
 </tr>
 <tr style='height:17.05pt'>
  <td width=614 colspan=7 valign=top style='width:460.6pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:17.05pt'>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><b><span lang=EN-GB style='font-size:11.0pt'>Time to
  McDonald MS</span></b><span lang=EN-GB style='font-size:11.0pt'> </span></p>
  </td>
 </tr>
 <tr style='height:16.25pt'>
  <td width=151 valign=top style='width:113.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.25pt'>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><b><span lang=EN-GB style='font-size:11.0pt'>Kaplan-Meier
  estimates</span></b></p>
  </td>
  <td width=77 valign=top style='width:57.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.25pt'>
  <p class=MsoNormal align=center style='margin-top:4.8pt;margin-right:0in;
  margin-bottom:4.8pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>69%</span></p>
  </td>
  <td width=77 valign=top style='width:57.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:double windowtext 1.5pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.25pt'>
  <p class=MsoNormal align=center style='margin-top:4.8pt;margin-right:0in;
  margin-bottom:4.8pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>85%</span></p>
  </td>
  <td width=154 colspan=2 valign=top style='width:115.75pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.25pt'>
  <p class=MsoNormal align=center style='margin-top:4.8pt;margin-right:0in;
  margin-bottom:4.8pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>No primary endpoint</span></p>
  </td>
  <td width=154 colspan=2 valign=top style='width:115.75pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.25pt'>
  <p class=MsoNormal align=center style='margin-top:4.8pt;margin-right:0in;
  margin-bottom:4.8pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>No primary endpoint</span></p>
  </td>
 </tr>
 <tr style='height:78.05pt'>
  <td width=151 valign=top style='width:113.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:78.05pt'>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><b><span lang=EN-GB style='font-size:11.0pt'>Risk reduction<br>
  <br>
  </span></b></p>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><b><span lang=EN-GB style='font-size:11.0pt'>Hazard
  ratio with 95% confidence interval</span></b></p>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><b><span lang=EN-GB style='font-size:11.0pt'>log-rank
  test</span></b></p>
  </td>
  <td width=154 colspan=2 valign=top style='width:115.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:double windowtext 1.5pt;
  padding:0in 5.4pt 0in 5.4pt;height:78.05pt'>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt'>43% versus
  placebo<br>
  <br>
  </span></p>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt'>HR = 0.57
  [0.46, 0.71]<br>
  <br>
  </span></p>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt'>p &lt;
  0.00001</span></p>
  </td>
  <td width=154 colspan=2 valign=top style='width:115.75pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:78.05pt'>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=154 colspan=2 valign=top style='width:115.75pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:78.05pt'>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:17.05pt'>
  <td width=614 colspan=7 valign=top style='width:460.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.05pt'>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><b><span lang=EN-GB style='font-size:11.0pt'>Time to
  confirmed EDSS progression</span></b></p>
  </td>
 </tr>
 <tr style='height:16.25pt'>
  <td width=151 valign=top style='width:113.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.25pt'>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><b><span lang=EN-GB style='font-size:11.0pt'>Kaplan-Meier
  estimates</span></b></p>
  </td>
  <td width=154 colspan=2 rowspan=2 valign=top style='width:115.7pt;border-top:
  none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:double windowtext 1.5pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.25pt'>
  <p class=MsoNormal align=center style='margin-top:4.8pt;margin-right:0in;
  margin-bottom:4.8pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>No primary endpoint</span></p>
  </td>
  <td width=77 valign=top style='width:57.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.25pt'>
  <p class=MsoNormal align=center style='margin-top:4.8pt;margin-right:0in;
  margin-bottom:4.8pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>16%</span></p>
  </td>
  <td width=77 valign=top style='width:57.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.25pt'>
  <p class=MsoNormal align=center style='margin-top:4.8pt;margin-right:0in;
  margin-bottom:4.8pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>24%</span></p>
  </td>
  <td width=77 valign=top style='width:57.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.25pt'>
  <p class=MsoNormal align=center style='margin-top:4.8pt;margin-right:0in;
  margin-bottom:4.8pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>25%</span></p>
  </td>
  <td width=77 valign=top style='width:57.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.25pt'>
  <p class=MsoNormal align=center style='margin-top:4.8pt;margin-right:0in;
  margin-bottom:4.8pt;margin-left:0in;text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>29%</span></p>
  </td>
 </tr>
 <tr style='height:78.05pt'>
  <td width=151 valign=top style='width:113.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:78.05pt'>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><b><span lang=EN-GB style='font-size:11.0pt'>Risk
  reduction<br>
  <br>
  </span></b></p>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><b><span lang=EN-GB style='font-size:11.0pt'>Hazard
  ratio with 95% confidence interval</span></b></p>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><b><span lang=EN-GB style='font-size:11.0pt'>log-rank
  test</span></b></p>
  </td>
  <td width=154 colspan=2 valign=top style='width:115.75pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:78.05pt'>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt'>40% versus
  delayed Betaferon</span></p>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt'>HR = 0.60
  [0.39, 0.92]<br>
  <br>
  </span></p>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt'>p = 0.022</span></p>
  </td>
  <td width=154 colspan=2 valign=top style='width:115.75pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:78.05pt'>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt'>24% versus
  delayed Betaferon</span></p>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt'>HR = 0.76
  [0.52, 1.11]<br>
  <br>
  </span></p>
  <p class=MsoNormal style='margin-top:4.8pt;margin-right:0in;margin-bottom:
  4.8pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt'>p=0.177</span></p>
  </td>
 </tr>
</table>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none'><span
lang=EN-GB style='font-size:11.0pt'>In the placebo-controlled phase, Betaferon
delayed the progression from the first clinical event to CDMS in a
statistically significant and clinically meaningful manner. The robustness of
the treatment effect was also shown by the delay of progression to multiple
sclerosis according to McDonald criteria (Table 3). </span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Subgroup
analyses according to baseline factors demonstrated evidence of efficacy on
progression to CDMS in all subgroups evaluated. The <span style='layout-grid-mode:
line'>risk for progression to CDMS within 2&nbsp;years was higher in monofocal
patients with at least 9&nbsp;T2-lesions or Gd-enhancement on brain MRI at
baseline. In multifocal patients, the risk for CDMS was independent from MRI
findings at baseline, indicating a<u> </u>high risk for CDMS because of the
dissemination of the disease based on clinical findings. For the time being
there is no well-established definition of a high risk patient, although a more
conservative approach is to accept at least nine T2 hyperintense lesions on the
initial scan and at least one new T2 or one new Gd-enhancing lesion on a
follow-up scan taken at least 1 month after the initial scan. In any case,
treatment should only be considered for patients classified as high risk.</span></span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Therapy with
Betaferon was well accepted as indicated by a high rate of trial completion
(93% in the Betaferon group). To increase tolerability of Betaferon, a dose
titration was applied and non-steroidal anti-inflammatory drugs were
administered at start of therapy. Moreover, an autoinjector was used by the
majority of patients throughout the study.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>In the
open-label follow-up phase, the treatment effect on CDMS was still evident
after 3 and 5 years (Table 3) even though the majority of patients from the
placebo-group were treated with Betaferon at least from the second year
onwards. EDSS progression (confirmed increase in EDSS of at least one point
compared to baseline) was lower in the immediate treatment group (Table 3,
significant effect after 3 years, no significant effect after 5 years). The
majority of patients in both treatment groups had no disability progression
over the 5-year period. Robust evidence for benefit on this outcome parameter
could not be demonstrated for 'immediate' treatment. No benefit, attributable
to immediate Betaferon treatment, in quality of life (as measured by FAMS -
Functional Assessment of MS: Treatment Outcomes Index) was seen.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt'>RR-MS, SP-MS and single clinical event suggestive of
MS</span></i></p>

<p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Betaferon was effective in all multiple sclerosis
studies to reduce disease activity (acute inflammation in the central nervous
system and permanent tissue alterations) as measured by magnetic resonance
imaging (MRI). The relation of multiple sclerosis disease activity as measured
by MRI and clinical outcome is currently not fully understood.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:avoid'><b><span lang=EN-GB style='font-size:11.0pt'>5.2 Pharmacokinetic
properties</span></b></p>

<p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Betaferon serum levels were followed in patients and
volunteers by means of a not completely specific bioassay. Maximum serum levels
of about 40 IU/ml were found 1-8 hours after subcutaneous injection of 500
microgram (16.0 million IU) interferon beta-1b. From various studies mean
clearance rates and half&#8209;lives of disposition phases from serum were
estimated to be at most 30 mlmin<sup>-1</sup>kg<sup>-1 </sup>and 5 hours,
respectively. </span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Betaferon
injections given every other day do not lead to serum level increases, and the
pharmacokinetics does not seem to change during therapy.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>The absolute
bioavailability of subcutaneously administered interferon beta-1b was
approximately 50%.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='font-size:11.0pt'>5.3 Preclinical safety data</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>No acute
toxicity studies have been carried out. As rodents do not react to human
interferon beta, repeated dose studies were carried out with rhesus monkeys.
Transitory hyperthermia was observed, as well as a significant rise in
lymphocytes and a significant decrease in thrombocytes and segmented
neutrophils. </span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>No long-term
studies have been conducted. Reproduction studies with rhesus monkeys revealed
maternal toxicity and an increased rate of abortion, resulting in prenatal
mortality. No malformations have been observed in the surviving animals. </span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>No
investigations on fertility have been conducted. No influence on the monkey
oestrous cycle has been observed. Experience with other interferons suggests a
potential for impairment of male and female fertility.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>In one single
genotoxicity study (Ames test), no mutagenic effect has been observed.
Carcinogenicity studies have not been performed. An <i>in vitro</i> cell
transformation test gave no indication of tumorigenic potential. </span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>6. PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='font-size:11.0pt'>6.1 List of excipients:</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><u><span lang=EN-GB style='font-size:11.0pt'>Vial (with
powder for solution for injection):</span></u></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Human albumin </span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Mannitol</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><u><span lang=EN-GB style='font-size:11.0pt'>Solvent
(sodium chloride solution 5.4 mg/ml (0.54% w/v)):</span></u></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Sodium chloride</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Water for
injection</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='font-size:11.0pt'>6.2 Incompatibilities</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>This medicinal
product must not be mixed with other medicinal products except for the supplied
solvent mentioned in section 6.6.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='font-size:11.0pt'>6.3 Shelf life</span></b></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>2 years. </span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>After
reconstitution, immediate use is recommended. However, the in-use stability has
been demonstrated for 3 hours at 2-8 C.</span></p>

<p class=Smalltext120><i><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='font-size:11.0pt'>6.4 Special precautions for storage</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Do not store
above 25C. </span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Do not freeze.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>For storage
conditions of the reconstituted medicinal product, see section 6.3.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='font-size:11.0pt'>6.5 Nature and contents of container</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><u><span lang=EN-GB style='font-size:11.0pt'>Vial (with
powder for solution for injection):</span></u></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>3 ml clear vial
(type I glass) with a butyl rubber stopper (type I) and aluminium overseal and </span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><u><span lang=EN-GB style='font-size:11.0pt'>Solvent
(with sodium chloride solution 5.4 mg/ml (0.54% </span></u><span lang=EN-GB
style='font-size:11.0pt'>w/v<u>)):</u></span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>2.25 ml
pre-filled syringe (type I glass) with 1.2 ml solvent.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><u><span lang=EN-GB style='font-size:11.0pt'>Pack sizes</span></u></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Pack with 5 single packs,
each containing 1 vial with powder, 1 pre-filled syringe with solvent, 1 vial
adapter with needle, 2 alcohol wipes or</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Pack with 15 single
packs, each containing 1 vial with powder, 1 pre-filled syringe with solvent, 1
vial adapter with needle, 2 alcohol wipes or </span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Pack with 14 single
packs, each containing 1 vial with powder, 1 pre-filled syringe with solvent, 1
vial adapter with needle, 2 alcohol wipes or</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Pack with 12 single
packs, each containing 1 vial with powder, 1 pre-filled syringe with solvent, 1
vial adapter with needle, 2 alcohol wipes or</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>2-month pack with 2x14
single packs, each containing 1 vial with powder, 1 pre-filled syringe with
solvent, 1 vial adapter with needle, 2 alcohol wipes or</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>3-month pack with 3x14
single packs, each containing 1 vial with powder, 1 pre-filled syringe with
solvent, 1 vial adapter with needle, 2 alcohol wipes or</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>3-month pack with 3x15
single packs, each containing 1 vial with powder, 1 pre-filled syringe with
solvent, 1 vial adapter with needle, 2 alcohol wipes or</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Titration pack for dose
titration with 4 differently coloured and numbered triple packs:</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'> -
yellow, with number 1(treatment days 1, 3 and 5; 0.25-ml syringe marking), </span></p>

<p class=Smalltext120 style='text-indent:28.35pt'><span lang=EN-GB
style='font-size:11.0pt'>- red, with number 2 (treatment days 7, 9 and 11;
0.5-ml syringe marking), </span></p>

<p class=Smalltext120 style='text-indent:28.35pt'><span lang=EN-GB
style='font-size:11.0pt'>- green, with number 3 (treatment days 13, 15 and
17; 0.75-ml syringe marking),</span></p>

<p class=Smalltext120 style='margin-left:28.35pt'><span lang=EN-GB
style='font-size:11.0pt'>- blue, with number 4 (treatment days 19, 21 and 23;
0.25, 0.5, 0.75 and 1-ml syringe marking)</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:.15pt'><span
lang=EN-GB style='font-size:11.0pt'>Each triple pack contains 3 vials with
powder, 3 pre-filled syringes with solvent, 3 vial adapters with pre-attached
needle and 6 alcohol wipes for skin and vial cleaning.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Not all pack
sizes may be marketed.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='font-size:11.0pt'>6.6 Special precautions for disposal
and other handling</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><u><span lang=EN-GB style='font-size:11.0pt'>Reconstitution:</span></u></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>To reconstitute
lyophilised interferon beta-1b for injection, connect the vial adapter with the
attached needle on the vial. Connect the pre-filled syringe with solvent to the
vial adapter and inject the 1.2&nbsp;ml of the solvent (sodium chloride
solution, 5.4 mg/ml (0.54% w/v)) into the Betaferon vial. Dissolve the powder
completely without shaking. </span></p>

<p class=MsoNormal style='margin-bottom:6.0pt;text-autospace:none'><span
lang=EN-GB style='font-size:11.0pt'>After reconstitution, draw 1.0 ml from the
vial into the syringe for the administration of 250&nbsp;microgram Betaferon.<span
style='color:red'> </span>For the dose titration at the start of treatment,
draw the respective volume as given in section 4.2.</span></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none'><span
lang=EN-GB style='font-size:11.0pt'>Remove the vial with the vial adapter from
the pre-filled syringe before injection. </span></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none'><span
lang=EN-GB style='font-size:11.0pt'>Betaferon may also be administered with a
suitable autoinjector.</span></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB style='font-size:11.0pt'>Inspection prior to use</span></u></p>

<p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Inspect the reconstituted product visually before use.
The reconstituted product is colourless to light yellow and slightly opalescent
to opalescent. </span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Discard the product before use if it contains
particulate matter or is discoloured.</span></p>

<p class=Smalltext120><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><u><span lang=EN-GB
style='font-size:11.0pt'>Disposal</span></u></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Any unused
medicinal product or waste material should be disposed of in accordance with
local requirements.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='font-size:11.0pt'>7. MARKETING AUTHORISATION HOLDER</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Bayer AG</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>51368
Leverkusen</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Germany</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>8. MARKETING
AUTHORISATION NUMBERS</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=DE style='font-size:11.0pt'>EU/1/95/003/005</span></p>

<p class=Smalltext120><span lang=DE style='font-size:11.0pt'>EU/1/95/003/006</span></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none'><span lang=DE
style='font-size:11.0pt'>EU/1/95/003/007</span></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none'><span lang=DE
style='font-size:11.0pt'>EU/1/95/003/008</span></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none'><span lang=DE
style='font-size:11.0pt'>EU/1/95/003/009</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>EU/1/95/003/010</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>EU/1/95/003/011</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>EU/1/95/003/012</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:avoid'><b><span lang=EN-GB style='font-size:11.0pt'>9. DATE
OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Date of first authorisation: 30 November 1995</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Date of last renewal: 31 January 2006</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='font-size:11.0pt'>10. DATE OF REVISION OF THE TEXT</span></b></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Detailed
information on this medicinal product is available on the website of the
European Medicines Agency </span><a href="http://www.ema.europa.eu/"><span
lang=DA style='font-size:11.0pt'>http://www.ema.europa.eu</span></a><span
lang=EN-GB style='font-size:11.0pt'>.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><b><span
lang=EN-GB style='font-size:11.0pt'>ANNEX II</span></b></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:56.7pt;margin-bottom:
0in;margin-left:42.55pt;margin-bottom:.0001pt;text-indent:-.25in'><b><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman Bold",serif;
text-transform:uppercase'>A.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB style='font-size:11.0pt'>MANUFACTURER OF
THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE</span></b></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:56.7pt;margin-bottom:
0in;margin-left:42.55pt;margin-bottom:.0001pt'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:56.7pt;margin-bottom:
0in;margin-left:42.55pt;margin-bottom:.0001pt;text-indent:-.25in'><b><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman Bold",serif;
text-transform:uppercase'>B.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB style='font-size:11.0pt'>CONDITIONS OR
RESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:56.7pt;margin-bottom:
0in;margin-left:42.55pt;margin-bottom:.0001pt'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:56.7pt;margin-bottom:
0in;margin-left:42.55pt;margin-bottom:.0001pt;text-indent:-.25in'><b><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman Bold",serif;
text-transform:uppercase'>C.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>OTHER CON</span></b><b><span lang=EN-GB
style='font-size:11.0pt'>DITIONS AND REQUIREMENTS OF THE MARKETING
AUTHORISATION</span></b></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:56.7pt;margin-bottom:
0in;margin-left:42.55pt;margin-bottom:.0001pt'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:56.7pt;margin-bottom:
0in;margin-left:42.55pt;margin-bottom:.0001pt;text-indent:-.25in'><b><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman Bold",serif;
text-transform:uppercase'>D.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB style='font-size:11.0pt'>CONDITIONS OR
RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=TitleB>A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND
MANUFACTURER RESPONSIBLE FOR BATCH RELEASE</p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><u><span lang=EN-GB style='font-size:11.0pt'>Name and
address of the manufacturers of the biological active substance</span></u></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=DE style='font-size:11.0pt'>Boehringer
Ingelheim RCV GmbH &amp; Co KG</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Dr.-Boehringer-Gasse
5-11 </span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>A-1121 Vienna </span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Austria</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><u><span lang=EN-GB style='font-size:11.0pt'>Name and
address of the manufacturer responsible for batch release</span></u></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Bayer AG</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Mllerstrae
178</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>13353 Berlin</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Germany</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=TitleB>B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE</p>

<p class=Smalltext120 style='margin-right:28.3pt'><i><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Medicinal
product subject to restricted medical prescription (See Annex I: Summary of
Product Characteristics, section 4.2).</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=TitleB>C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING
AUTHORISATION</p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;text-indent:-.5in;line-height:13.0pt'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:11.0pt'>Periodic safety update
reports (PSURs)</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span style='font-size:11.0pt'>The requirements for
submission of</span><span style='font-size:11.0pt'> </span><span lang=EN-GB
style='font-size:11.0pt'>PSURs for this </span><span style='font-size:11.0pt'>medicinal
</span><span lang=EN-GB style='font-size:11.0pt'>product are set out in the
list of Union reference dates (EURD list) </span><span lang=EN-GB
style='font-size:11.0pt'>provided for under Article 107c(7) of Directive
2001/83/EC and </span><span style='font-size:11.0pt'>any subsequent updates</span><span
style='font-size:11.0pt'> <span lang=EN-GB>published on the European medicines
web-portal.</span></span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=TitleB>D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND
EFFECTIVE USE OF THE MEDICINAL PRODUCT</p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;text-indent:-.5in;line-height:13.0pt'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:11.0pt'>Risk management plan
(RMP)</span></b></p>

<p class=Smalltext120 style='margin-right:28.35pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:28.35pt'><span style='font-size:11.0pt'>The
marketing</span><span style='font-size:11.0pt'> authorisation holder (MAH)
shall perform the required pharmacovigilance activities and interventions
detailed in the agreed RMP presented in Module 1.8.2 of the marketing
authorisation and any agreed subsequent updates of the RMP.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span style='font-size:11.0pt'>An
updated RMP should be submitted:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;text-indent:-.25in'><span style='font-size:11.0pt;
font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>At the request of the European
Medicines Agency;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-10.35pt'><span style='font-size:11.0pt;
font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>Whenever the risk management
system is modified, especially as the result of new information being received
that may lead to a significant change to the benefit/risk profile or as the
result of an important (pharmacovigilance or risk minimisation) milestone being
reached.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><b><span
lang=EN-GB style='font-size:11.0pt'>ANNEX III</span></b></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><b><span
lang=EN-GB style='font-size:11.0pt'>LABELLING AND PACKAGE LEAFLET</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=TitleA>A. LABELLING</p>

<p class=TitleA><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=Smalltext120 style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=Smalltext120 style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Smalltext120 style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>CARTON OF MULTIPACK (INCLUDING BLUE BOX)</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Betaferon 250 microgram/ml, powder and solvent for solution for
injection </span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>interferon beta-1b</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>2. STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>1 ml contains 250 microgram (8.0 million IU) interferon beta-1b when
reconstituted.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>3. LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Excipients: Human albumin, mannitol</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>4. PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>Multipack comprising 15 single packs, each containing:</span></b></p>

<p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
style='font-size:11.0pt;background:lightgrey'>Multipack comprising 5 single
packs, each containing:</span></b></p>

<p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
style='font-size:11.0pt;background:lightgrey'>Multipack comprising 14 single
packs, each containing:</span></b></p>

<p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
style='font-size:11.0pt;background:lightgrey'>Multipack comprising 12 single
packs, each containing:</span></b></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;text-autospace:none'><b><span
lang=EN-GB style='font-size:11.0pt'>I. 1 vial with powder for solution
for injection </span></b><span lang=EN-GB style='font-size:11.0pt'>contains 300
microgram (9.6 million IU). After reconstitution, 1 ml contains 250 microgram
(8.0 million IU) interferon beta-1b*.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;text-autospace:none'><b><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;text-autospace:none'><b><span
lang=EN-GB style='font-size:11.0pt'>II. 1 pre-filled syringe with 1.2 ml
solvent for reconstitution </span></b><span lang=EN-GB style='font-size:11.0pt'>contains
sodium chloride solution 5.4&nbsp;mg/ml.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;text-autospace:none'><b><span
lang=EN-GB style='font-size:11.0pt'>III. 1 vial adapter with needle + 2
alcohol wipes</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none'><span
lang=EN-GB style='font-size:11.0pt'>*Betaferon is formulated to contain a
calculated overfill of 20 %.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>5. METHOD AND ROUTE OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>For subcutaneous injection after reconstitution with 1.2 ml of solvent.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Single use.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>6. SPECIAL WARNING THAT THE MEDICINAL
PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Keep out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>7. OTHER SPECIAL WARNING(S), IF
NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;page-break-after:avoid;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>8. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>EXP</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>After reconstitution, immediate use is recommended. In-use stability
demonstrated for 3 hours at 2-8C.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>9. SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Do not store above 25C. </span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Do not freeze.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>11. NAME AND ADDRESS OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt'>Bayer AG</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt'>51368 Leverkusen</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt'>Germany</span></p>

<p class=MsoFooter><span lang=DE style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=DE style='font-size:11.0pt'>12. MARKETING AUTHORISATION NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt'>EU/1/95/003/005</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt;background:lightgrey'>EU/1/95/003/006</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt;background:lightgrey'>EU/1/95/003/009</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt;background:lightgrey'>EU/1/95/003/011</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>13. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Lot</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>14. GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>15. INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>16. INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>Betaferon</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>17. UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt;
background:lightgrey'>2D barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>18. UNIQUE IDENTIFIER - HUMAN READABLE
DATA</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt'>PC</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt'>SN</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt'>NN</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 1.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-bottom:0in;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>CARTON OF MULTI-MONTH PACK (INCLUDING BLUE
BOX)</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Betaferon 250 microgram/ml, powder and solvent for solution for
injection </span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>interferon beta-1b</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>2. STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>1 ml contains 250 microgram (8.0 million IU) interferon beta-1b when
reconstituted.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>3. LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Excipients: Human albumin, mannitol</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>4. PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>3-month pack comprising 45 (3x15) single packs, each
containing:</span></b></p>

<p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
style='font-size:11.0pt;background:lightgrey'>3-month pack comprising 42 (3x14)
single packs, each containing:</span></b></p>

<p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
style='font-size:11.0pt;background:lightgrey'>2-month pack comprising 28 (2x14)
single packs, each containing:</span></b></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;text-autospace:none'><b><span
lang=EN-GB style='font-size:11.0pt'>I. 1 vial with powder for solution
for injection </span></b><span lang=EN-GB style='font-size:11.0pt'>contains 300
microgram (9.6 million IU). After reconstitution, 1 ml contains 250 microgram
(8.0 million IU) interferon beta-1b*.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;text-autospace:none'><b><span
lang=EN-GB style='font-size:11.0pt'>II. 1 pre-filled syringe with 1.2 ml
solvent for reconstitution </span></b><span lang=EN-GB style='font-size:11.0pt'>contains
sodium chloride solution 5.4&nbsp;mg/ml.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;text-autospace:none'><b><span
lang=EN-GB style='font-size:11.0pt'>III. 1 vial adapter with needle + 2
alcohol wipes</span></b></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none'><span
lang=EN-GB style='font-size:11.0pt'>*Betaferon is formulated to contain a
calculated overfill of 20 %.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt;background:yellow'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>5. METHOD AND ROUTE OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>For subcutaneous injection after reconstitution with 1.2 ml of solvent.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Single use.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>6. SPECIAL WARNING THAT THE MEDICINAL
PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Keep out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>7. OTHER SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt;background:yellow'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;page-break-after:avoid;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>8. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>EXP</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>After reconstitution, immediate use is recommended. In-use stability
demonstrated for 3 hours at 2-8 C.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>9. SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Do not store above 25C. </span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Do not freeze.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>11. NAME AND ADDRESS OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt'>Bayer AG</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt'>51368 Leverkusen</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt'>Germany</span></p>

<p class=MsoFooter><span lang=DE style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=DE style='font-size:11.0pt'>12. MARKETING AUTHORISATION NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt'>EU/1/95/003/007</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt;background:lightgrey'>EU/1/95/003/010</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt;background:lightgrey'>EU/1/95/003/012</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>13. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Lot</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt;background:yellow'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>14. GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>15. INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>16. INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>Betaferon</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>17. UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt;
background:lightgrey'>2D barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>18. UNIQUE IDENTIFIER - HUMAN READABLE
DATA</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt'>PC</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt'>SN</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt'>NN</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
background:yellow'><br clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 1.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-bottom:0in;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>CARTON OF MULTIPACK AS AN INTERMEDIATE PACK
OF MULTI-MONTH PACK (WITHOUT BLUE BOX)</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Betaferon 250 microgram/ml, powder and solvent for solution for
injection </span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>interferon beta-1b</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>2. STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>1 ml contains 250 microgram (8.0 million IU) interferon beta-1b when
reconstituted.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>3. LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Excipients: Human albumin, mannitol</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>4. PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none'><b><span
lang=EN-GB style='font-size:11.0pt'>Pack comprising 15 single packs, part of a
3-month pack containing 45 (3 x 15) single packs. No individual sale of single
packs.</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none'><b><span
lang=EN-GB style='font-size:11.0pt;background:lightgrey'>Pack comprising 14
single packs, part of a 3-month pack containing 42 (3 x 14) single packs. No
individual sale of single packs.</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none'><b><span
lang=EN-GB style='font-size:11.0pt;background:lightgrey'>Pack comprising 14
single packs, part of a 2-month pack containing 28 (2 x 14) single packs. No
individual sale of single packs.</span></b></p>

<p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>Each single pack contains:</span></b></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in;text-autospace:none'><b><span lang=EN-GB
style='font-size:11.0pt'>I. 1 vial with powder for solution for injection </span></b><span
lang=EN-GB style='font-size:11.0pt'>contains 300 microgram (9.6 million IU).
After reconstitution, 1 ml contains 250 microgram (8.0 million IU) interferon
beta-1b*.</span></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none'><b><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.25in;text-indent:-.25in;text-autospace:none'><b><span lang=EN-GB
style='font-size:11.0pt'>II. 1 pre-filled syringe with 1.2 ml solvent for
reconstitution </span></b><span lang=EN-GB style='font-size:11.0pt'>contains
sodium chloride solution 5.4&nbsp;mg/ml.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none'><b><span
lang=EN-GB style='font-size:11.0pt'>III. 1 vial adapter with needle + 2
alcohol wipes</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none'><span
lang=EN-GB style='font-size:11.0pt'>*Betaferon is formulated to contain a
calculated overfill of 20 %.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>5. METHOD AND ROUTE OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt;background:yellow'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>For subcutaneous injection after reconstitution with 1.2 ml of solvent.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Single use.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>6. SPECIAL WARNING THAT THE MEDICINAL
PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Keep out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>7. OTHER SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>8. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>EXP</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>After reconstitution, immediate use is recommended. In-use stability
demonstrated for 3 hours at 2-8 C.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>9. SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Do not store above 25C. </span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Do not freeze.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>11. NAME AND ADDRESS OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt'>Bayer AG</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt'>51368 Leverkusen</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt'>Germany</span></p>

<p class=MsoFooter><span lang=DE style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=DE style='font-size:11.0pt'>12. MARKETING AUTHORISATION NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt'>EU/1/95/003/007</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt;background:lightgrey'>EU/1/95/003/010</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt;background:lightgrey'>EU/1/95/003/012</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>13. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Lot</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>14. GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Medicinal product subject to medical prescription.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>15. INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>16. INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>Betaferon</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>17. UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>18. UNIQUE IDENTIFIER - HUMAN READABLE
DATA</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
background:yellow'><br clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 1.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-bottom:0in;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>CARTON OF THE SINGLE PACK AS AN
INTERMEDIATE PACK OF MULTIPACKS OR MULTI-MONTH PACKS (WITHOUT BLUE BOX)</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Betaferon 250 microgram/ml, powder and solvent for solution for
injection</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>interferon beta-1b</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>2. STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>1 ml contains 250 microgram (8.0 million IU) interferon beta-1b when
reconstituted.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>3. LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Excipients: Human albumin, mannitol</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 4.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>4. PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>Part of a multipack containing 15 single packs. No
individual sale of single packs.</span></b></p>

<p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
style='font-size:11.0pt;background:lightgrey'>Part of a multipack containing 5
single packs. No individual sale of single packs.</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none'><b><span
lang=EN-GB style='font-size:11.0pt;background:lightgrey'>Part of a pack
containing 15 single packs in a 3-month pack of 3x15 single packs. No
individual sale of single packs.</span></b></p>

<p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
style='font-size:11.0pt;background:lightgrey'>Part of a multipack containing 14
single packs. No individual sale of single packs.</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none'><b><span
lang=EN-GB style='font-size:11.0pt;background:lightgrey'>Part of a pack
containing 14 single packs in a 3-month pack of 3x14 single packs. No
individual sale of single packs.</span></b></p>

<p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
style='font-size:11.0pt;background:lightgrey'>Part of a multipack containing 12
single packs. No individual sale of single packs.</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none'><b><span
lang=EN-GB style='font-size:11.0pt;background:lightgrey'>Part of a pack
containing 14 single packs in a 2-month pack of 2x14 single packs. No
individual sale of single packs.</span></b></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>1 vial with powder: 300 microgram (9.6 m IU) per vial. When
reconstituted 250 microgram/ml (8.0 m IU/ml) interferon beta-1b.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>1 pre-filled syringe with 1.2 ml solvent: sodium chloride solution 5.4 mg/ml,</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>1 vial adapter with needle + 2 alcohol wipes</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>5. METHOD AND ROUTE OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>For subcutaneous injection after reconstitution with 1.2 ml of solvent.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Single use.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt;background:yellow'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt;background:yellow'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>6. SPECIAL WARNING THAT THE MEDICINAL
PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Keep out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>7. OTHER SPECIAL WARNING(S), IF
NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>8. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>EXP</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>After reconstitution, immediate use is recommended. In-use stability demonstrated
for 3 hours at 2&#8209;8&nbsp;C.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>9. SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Do not store above 25C. </span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Do not freeze.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt;background:yellow'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>11. NAME AND ADDRESS OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt'>Bayer AG</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt'>51368 Leverkusen</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt'>Germany</span></p>

<p class=MsoFooter><span lang=DE style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=DE style='font-size:11.0pt'>12. MARKETING AUTHORISATION NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt'>EU/1/95/003/005</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt;background:lightgrey'>EU/1/95/003/006</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt;background:lightgrey'>EU/1/95/003/007</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt;background:lightgrey'>EU/1/95/003/009</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt;background:lightgrey'>EU/1/95/003/010</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt;background:lightgrey'>EU/1/95/003/011</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt;background:lightgrey'>EU/1/95/003/012</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=DE style='font-size:11.0pt'>13. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=DE style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Lot</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>14. GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Medicinal product subject to medical prescription.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>15. INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>16. INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>Betaferon</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>17. UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>18. UNIQUE IDENTIFIER - HUMAN READABLE
DATA</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 1.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-bottom:0in;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>TITRATION PACK WITH 4x1 TRIPLE PACK (3
VIALS/3 PRE-FILLED SYRINGES), FOR FIRST 12 INJECTIONS/TREATMENT DAYS (INCLUDING
BLUE BOX)</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Betaferon 250 microgram/ml, powder and solvent for solution for
injection </span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>interferon beta-1b</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>2. STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>1 ml contains 250 microgram (8.0 million IU) interferon beta-1b when
reconstituted.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>3. LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Excipients: Human albumin, mannitol</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>4. PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>Titration pack</span></b></p>

<p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>comprising 4 triple packs, each containing:</span></b></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:30.0pt;text-indent:-30.0pt;text-autospace:none'><b><span
lang=EN-GB style='font-size:11.0pt'>I. 3 Vials with powder for solution
for injection, </span></b><span lang=EN-GB style='font-size:11.0pt'>each
containing 300 microgram (9.6 million IU). After reconstitution, 1 ml contains
250 microgram (8.0 million IU) interferon beta-1b*.</span></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:30.0pt;text-indent:-30.0pt;text-autospace:none'><b><span
lang=EN-GB style='font-size:11.0pt'>II. 3 Pre-filled syringes with solvent
for reconstitution, </span></b><span lang=EN-GB style='font-size:11.0pt'>each<b>
</b>containing 1.2 ml sodium chloride solution, 5.4&nbsp;mg/ml.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none'><b><span
lang=EN-GB style='font-size:11.0pt'>III. 3 Vial adapters with needles + 6
alcohol wipes</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none'><span
lang=EN-GB style='font-size:11.0pt'>*Betaferon is formulated to contain a
calculated overfill of 20 %.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>5. METHOD AND ROUTE OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>For subcutaneous injection after reconstitution with 1.2 ml of solvent.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Single use.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>6. SPECIAL WARNING THAT THE MEDICINAL
PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Keep out of the sight and reach of children</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>7. OTHER SPECIAL WARNING(S), IF
NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;page-break-after:avoid;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>8. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>EXP</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>After reconstitution, immediate use is recommended. In-use stability
demonstrated for 3 hours at 2-8 C.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>9. SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Do not store above 25C. </span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Do not freeze.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>11. NAME AND ADDRESS OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Bayer AG</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>51368 Leverkusen</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Germany</span></p>

<p class=MsoFooter><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>12. MARKETING AUTHORISATION NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>EU/1/95/003/008</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>13. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Lot</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>14. GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>15. INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>Use yellow triple pack No. 1 for treatment days 1, 3 and 5 </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>Use red triple pack No. 2 for treatment days 7, 9 and 11</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>Use green triple pack No. 3 for treatment days 13, 15 and 17</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>Use blue triple pack No. 4 for treatment days 19, 21 and 23</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>16. INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>Betaferon</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 2.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>17. UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt;
background:lightgrey'>2D barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>18. UNIQUE IDENTIFIER - HUMAN READABLE
DATA</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt'>PC</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt'>SN</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt'>NN</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 1.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='margin-bottom:0in;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>CARTON OF THE TRIPLE PACK (3 VIALS/3 PFS)
AS AN INTERMEDIATE PACK OF THE TITRATION PACK (WITHOUT BLUE BOX)</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Betaferon 250 microgram/ml, powder and solvent for solution for
injection</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>interferon beta-1b</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>2. STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>1 ml contains 250 microgram (8.0 million IU) interferon beta-1b when
reconstituted.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>3. LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Excipients: Human albumin, mannitol</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>4. PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Triple pack 1</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>1<sup>st</sup> dosage step (0.25 ml) for treatment days 1, 3, 5</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt;background:lightgrey'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt;background:lightgrey'>Triple pack 2</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt;background:lightgrey'>2<sup>nd</sup> dosage step (0.5 ml) for treatment
days 7, 9, 11</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt;background:lightgrey'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt;background:lightgrey'>Triple pack 3</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt;background:lightgrey'>3<sup>rd</sup> dosage step (0.75 ml) for treatment
days 13, 15, 17</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt;background:lightgrey'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt;background:lightgrey'>Triple pack 4</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt;background:lightgrey'>4<sup>th</sup> dosage step (1.0 ml) for treatment
days 19, 21, 23</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Part of a titration pack. No individual sale.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>3 Vials with powder: 300 microgram (9.6 m IU) per vial. When
reconstituted 250 microgram/ml (8.0&nbsp;m IU/ml) interferon beta-1b.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>3 Pre-filled syringes with 1.2 ml solvent: sodium chloride solution,
5.4 mg/ml,</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>3 Vial adapters with needles + 6 alcohol wipes</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>5. METHOD AND ROUTE OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>For subcutaneous injection after reconstitution with 1.2 ml of solvent.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Single use.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>6. SPECIAL WARNING THAT THE MEDICINAL
PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Keep out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>7. OTHER SPECIAL WARNING(S), IF
NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;page-break-after:avoid;border:none;
padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>8. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>EXP</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>After reconstitution, immediate use is recommended. In-use stability
demonstrated for 3 hours at 2-8&nbsp;C.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>9. SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Do not store above 25C. </span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Do not freeze.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>11. NAME AND ADDRESS OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Bayer AG</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>51368 Leverkusen</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Germany</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>12. MARKETING AUTHORISATION NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>EU/1/95/003/008</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>13. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Lot</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>14. GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Medicinal product subject to medical prescription.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>15. INSTRUCTIONS ON USE</span></b><span
lang=EN-GB> (text for inside the lid)</span></p>

</div>

<p class=MsoNormal style='margin-bottom:3.0pt'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>Dear patient,</span></b></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Triple pack 1 is designed to help you prepare the first 3 injections
(days 1, 3 and 5).</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Use <b>all</b> the<b> </b>solvent in the syringe to dissolve the
Betaferon powder in the vial. </span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Then draw up solution<b> as far as the mark on the syringe:</b></span></p>

<p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>0.25 ml </span></b><span lang=EN-GB style='font-size:
11.0pt'>for first three injections<b> </b>(at day 1, 3 and 5 of therapy).</span></p>

<p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>Discard the vial with the remaining solution.</span></b></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt;background:lightgrey'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt;background:lightgrey'>Dear patient,</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt;background:lightgrey'>Triple pack 2 is
designed to help you prepare the next 3 injections (days 7, 9 and 11).</span></p>

<p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt;background:lightgrey'>Use <b>all </b>the
solvent in the syringe to dissolve the Betaferon powder in the vial. </span></p>

<p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt;background:lightgrey'>Then draw up solution<b>
as far as the mark on the syringe:</b></span></p>

<p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt;background:lightgrey'>0.5 ml </span></b><span
lang=EN-GB style='font-size:11.0pt;background:lightgrey'>for the injections<b> </b>at
day 7, 9 and 11 of therapy.</span></p>

<p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt;background:lightgrey'>Discard the vial with
the remaining solution.</span></b></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt;background:lightgrey'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
style='font-size:11.0pt;background:lightgrey'>Dear patient,</span></b></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt;background:lightgrey'>Triple pack 3 is designed to help you prepare the
next 3 injections (days 13, 15 and 17).</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt;background:lightgrey'>Use <b>all </b>the solvent in the syringe to
dissolve<b> </b>the Betaferon powder in the vial. </span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt;background:lightgrey'>Then draw up solution<b> as far as the mark on the
syringe:</b></span></p>

<p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
style='font-size:11.0pt;background:lightgrey'>0.75 ml </span></b><span
lang=EN-GB style='font-size:11.0pt;background:lightgrey'>for the injections<b> </b>at
day 13, 15 and 17 of therapy.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
style='font-size:11.0pt;background:lightgrey'>Discard the vial with the
remaining solution.</span></b></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt;background:lightgrey'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
style='font-size:11.0pt;background:lightgrey'>Dear patient,</span></b></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt;background:lightgrey'>Triple pack 4 is designed to help you prepare the
next 3 injections (days 19, 21 and 23).</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt;background:lightgrey'>Use <b>all </b>the solvent in the syringe to
dissolve<b> </b>the Betaferon powder in the vial. </span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt;background:lightgrey'>Then draw up solution<b> as far as the 1.0 ml mark
on the syringe:</b></span></p>

<p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
style='font-size:11.0pt;background:lightgrey'>1.0 ml </span></b><span
lang=EN-GB style='font-size:11.0pt;background:lightgrey'>for the injections<b> </b>at
day 19, 21 and 23 of therapy.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
style='font-size:11.0pt;background:lightgrey'>Discard the vial with the
remaining solution.</span></b></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>16. INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>Betaferon</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>17. UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0in;border:none;padding:0in'><b><span
lang=EN-GB style='font-size:11.0pt'>18. UNIQUE IDENTIFIER - HUMAN READABLE
DATA</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span style='font-size:11.0pt'>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=Smalltext120 style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE
PACKAGING UNITS</span></b></p>

<p class=Smalltext120 style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Smalltext120 style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>LABEL OF PRE-FILLED SYRINGE (SOLVENT)</span></b></p>

</div>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt;
border:none;padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION</span></b></p>

</div>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Solvent for
reconstitution of Betaferon</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>1.2 ml sodium
chloride solution 5.4 mg/ml</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt;
border:none;padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt;
border:none;padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>3. EXPIRY
DATE</span></b></p>

</div>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>EXP</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt;
border:none;padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>4. BATCH
NUMBER</span></b></p>

</div>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Lot</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt;
border:none;padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>1.2 ml</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=Smalltext120 style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=Smalltext120 style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE
PACKAGING UNITS</span></b></p>

<p class=Smalltext120 style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Smalltext120 style='border:none;padding:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>LABEL OF VIAL (BETAFERON)</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt;
border:none;padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION</span></b></p>

</div>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Betaferon 250
microgram/ml, powder for solution for injection</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>interferon
beta-1b </span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Subcutaneous
use</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt;
border:none;padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt;
border:none;padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>3. EXPIRY
DATE</span></b></p>

</div>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>EXP</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>After reconst.
immediate use recommended. In-use stability demonstrated for 3 hours at 2-8 C.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt;
border:none;padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>4. BATCH
NUMBER</span></b></p>

</div>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Lot</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt;
border:none;padding:0in'><b><span lang=EN-GB style='font-size:11.0pt'>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>250 mcg
(8&nbsp;m IU) per ml after reconstitution</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=TitleA>B. PACKAGE LEAFLET</p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=Smalltext120 align=center style='text-align:center'><a
name=shelfinjprocedure1></a><a name=shelfinjprocedure3></a><b><span lang=EN-GB
style='font-size:11.0pt'>Package leaflet: Information for the user</span></b></p>

<p class=Smalltext120 align=center style='text-align:center'><b><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Smalltext120 align=center style='text-align:center'><b><span
lang=EN-GB style='font-size:11.0pt'>Betaferon 250 microgram/ml, powder and
solvent for solution for injection</span></b></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>interferon beta-1b</span></p>

<p class=Smalltext120 align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;display:none'>&nbsp;</span></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>Read all of
this leaflet carefully before you start using this medicine because it contains
important information for you.</span></b></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Keep this leaflet. You
may need to read it again.</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>If you have any further
questions, ask your doctor, pharmacist or nurse.</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>This medicine has been
prescribed for you only. Do not pass it on to others. It may harm them, even if
their signs of illness are the same as yours.</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>If you get any side
effects, talk to your doctor, pharmacist or nurse. This includes any possible
side effects not listed in this leaflet. See section 4.</span></p>

<p class=Smalltext120 style='margin-right:-.1pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-right:-.1pt'><b><span lang=EN-GB
style='font-size:11.0pt'>What is in this leaflet</span></b></p>

<p class=Smalltext120 style='margin-right:-.1pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>1. What Betaferon is and what it is
used for</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>2. What you need to know before you
use Betaferon</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>3. How to use Betaferon</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>4. Possible side effects</span></p>

<p class=Smalltext120 style='margin-right:-1.45pt'><span lang=EN-GB
style='font-size:11.0pt'>5. How to store Betaferon</span></p>

<p class=Smalltext120 style='margin-right:-1.45pt'><span lang=EN-GB
style='font-size:11.0pt'>6. Contents of the pack and other information</span></p>

<p class=Smalltext120 style='margin-right:-.1pt'><span lang=EN-GB
style='font-size:11.0pt'> Annex  self injection procedure</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:-.1pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='font-size:11.0pt'>1. What Betaferon is and what it is
used for</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>What Betaferon is</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Betaferon is a
type of medicine known as interferon used to treat multiple sclerosis.
Interferons are proteins produced by the body that help fight against attacks
on the immune system such as viral infections.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>How
Betaferon works</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>Multiple
sclerosis (MS)</span></b><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:
line'> is a long-term condition that affects the central nervous system (CNS),
particularly the functioning of the brain and spinal cord. In MS, inflammation
destroys the protective sheath (called <i>myelin</i>) around the nerves of the
CNS and stops the nerves from working properly. This is called demyelination.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:
line'>The exact cause of MS is unknown. An abnormal response by the body's
immune system is thought to play an important part in the process which damages
the CNS. </span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:
line'>The damage to the CNS</span></b><span lang=EN-GB style='font-size:11.0pt;
layout-grid-mode:line'> can occur within an MS attack <i>(relapse)</i>. It can
cause disability temporarily, such as difficulty walking. Symptoms may
disappear completely or partly.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:
line'>Interferon beta-1b has been shown to change the response of the immune
system and to help to reduce disease activity.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>How Betaferon
helps fight your disease</span></b></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>Single
clinical event indicating a high risk of developing multiple sclerosis:</span></b><span
lang=EN-GB style='font-size:11.0pt'> Betaferon has been shown to delay
progression to definite multiple sclerosis.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>Relapsing-remitting
multiple sclerosis:</span></b><span lang=EN-GB style='font-size:11.0pt'> People
with relapsing-remitting MS have occasional attacks or relapses during which
symptoms become noticeably worse. Betaferon has been shown to cut down the
number of attacks and make them less severe. It reduces the number of hospital
stays due to the disease and prolongs the time without relapses.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>Secondary
progressive multiple sclerosis:</span></b><span lang=EN-GB style='font-size:
11.0pt'> In some cases people with relapsing-remitting MS find that their
symptoms increase and they progress to another form of MS called secondary
progressive MS. With this, people find themselves becoming increasingly
impaired, whether or not they have relapses. Betaferon can reduce the number
and severity of the attacks, and slow the progression of disability.</span></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>What
Betaferon is used for</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>Betaferon is
for use in patients </span></b></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>&nbsp;</span></b></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>&#9658; who have
experienced symptoms for the first time which indicate a high risk of
developing multiple sclerosis.</span></b><span lang=EN-GB style='font-size:
11.0pt;layout-grid-mode:line'> Your doctor will rule out any other reasons
which could explain these symptoms before you are treated.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:
line'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='font-size:11.0pt'>&#9658; who suffer from
relapsing-remitting multiple sclerosis, with at least two relapses within the
last two years</span></b><span lang=EN-GB style='font-size:11.0pt'>.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='font-size:11.0pt'>&#9658; who suffer from secondary
progressive multiple sclerosis with active disease shown by relapses.</span></b><span
lang=EN-GB style='font-size:11.0pt'> </span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-right:-.1pt'><b><span lang=EN-GB
style='font-size:11.0pt'>2. What you need to know before you use
Betaferon</span></b></p>

<p class=Smalltext120 style='margin-right:-.1pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-right:-.1pt'><b><span lang=EN-GB
style='font-size:11.0pt'>Do not use Betaferon</span></b></p>

<p class=Smalltext120 style='margin-right:-.1pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:11.0pt'>if you are allergic</span></b><span
lang=EN-GB style='font-size:11.0pt'> <i>(hypersensitive)</i> to natural or
recombinant interferon beta, human albumin or any of the other ingredients of this
medicine (listed in section 6). </span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:11.0pt'>if you currently
suffer from severe depression and/or suicidal thoughts</span></b><span
lang=EN-GB style='font-size:11.0pt'> (see Warnings and precautions and
section 4 Possible side effects).</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:-.1pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>- <b>if you have severe liver
disease </b>(see Warnings and precautions, Other medicines and Betaferon
and section 4 Possible side effects)<b>.</b></span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:-.1pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:-.1pt;margin-bottom:
0in;margin-left:48.0pt;margin-bottom:.0001pt;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt'>&#9658;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:11.0pt'>Tell your doctor</span></b><span
lang=EN-GB style='font-size:11.0pt'> if any of the above applies to you.</span></p>

<p class=Smalltext120 style='margin-right:-.1pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-right:-.1pt'><b><span lang=EN-GB
style='font-size:11.0pt'>Warnings and precautions</span></b></p>

<p class=Smalltext120 style='margin-right:-.1pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-right:-.1pt'><span lang=EN-GB
style='font-size:11.0pt'>Talk to your doctor before you start using Betaferon:</span></p>

<p class=Smalltext120 style='margin-right:-.1pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:11.0pt'>If you have</span></b><span
lang=EN-GB style='font-size:11.0pt'> <b><i>monoclonal gammopathy</i></b>. This
is<b> a</b> <b>disorder of the immune system where an abnormal protein is found
in the blood</b>. Problems with your small blood vessels <i>(capillaries)</i>
may develop when using medicines like Betaferon <i>(systemic capillary leak
syndrome)</i>. This can lead to shock <i>(collapse)</i> and even be fatal.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:11.0pt'>If you have had
depression or are depressed or previously had thoughts of suicide.</span></b><span
lang=EN-GB style='font-size:11.0pt'> Your doctor will closely monitor you
during treatment. If your depression and/or suicidal thoughts are severe, you
will not be prescribed Betaferon (see also Do not use Betaferon).</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:11.0pt'>If you have ever had
seizures or if you are taking medicines to treat epilepsy </span></b><i><span
lang=EN-GB style='font-size:11.0pt'>(anti-epileptics)</span></i><span
lang=EN-GB style='font-size:11.0pt'>, your doctor will monitor your treatment
carefully (see also Other medicines and Betaferon and section 4. Possible
side effects).</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:11.0pt'>If you have</span></b><span
lang=EN-GB style='font-size:11.0pt'> <b>severe kidney problems</b> your doctor
may monitor your kidney function during treatment.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Your doctor
also needs to know the following <b>whilst you are using Betaferon</b>:</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:11.0pt'>If you experience
symptoms such as itching all over your body, swelling of your face and/or your
tongue or sudden shortness of breath. </span></b><span lang=EN-GB
style='font-size:11.0pt'>These may be symptoms of a serious allergic reaction <i>(hypersensitivity)</i>,
which may become life threatening.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:11.0pt'>If you feel
noticeably more sad or hopeless than before the treatment with Betaferon, or if
you develop thoughts of suicide. </span></b><span lang=EN-GB style='font-size:
11.0pt'>If you become depressed while you are on Betaferon, you may need
special treatment and your doctor will closely monitor you and may also
consider stopping your treatment. If you suffer from severe depression and/or
suicidal thoughts, you will not be treated with Betaferon (see also Do not use
Betaferon).</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:11.0pt'>If you notice any
unusual bruising, excessive bleeding after injury or if you seem to be catching
a lot of infections</span></b><span lang=EN-GB style='font-size:11.0pt'>. These
may be symptoms of a fall in your blood cell count or in the number of
platelets in your blood (cells, which help the blood to clot). You may need
extra monitoring by your doctor.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:11.0pt'>If you have loss of
appetite, fatigue, feeling sick <i>(nausea)</i>, repeated vomiting, especially
if you notice widespread itching, yellowing of the skin or of the whites of the
eyes, or easy bruising.</span></b><span lang=EN-GB style='font-size:11.0pt'>
These symptoms may suggest problems with your liver. Changes to the liver
function values occurred in patients treated with Betaferon during clinical
studies. As for other beta interferons, severe liver damage, including cases of
liver failure, have been reported rarely in patients taking Betaferon. The most
serious were reported in patients taking other medicines or who were suffering
from diseases that can affect the liver (e.g. alcohol abuse, severe infection).</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:11.0pt'>If you experience
symptoms like irregular heartbeat, swelling such as of the ankles or legs, or
shortness of breath. </span></b><span lang=EN-GB style='font-size:11.0pt'>This
may suggest a disease of the heart muscle <i>(cardiomyopathy)</i> which has
been reported rarely in patients using Betaferon.</span></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:11.0pt'>If you notice pain
in your belly which is radiating to your back, and/or you feel sick or have a
fever. </span></b><span lang=EN-GB style='font-size:11.0pt'>This may suggest an
inflammation of the pancreas <i>(pancreatitis)</i>, which has been reported
with Betaferon use. This is often associated with an increase of certain blood
fats <i>(triglycerides)</i>.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:-.1pt;margin-bottom:
0in;margin-left:48.0pt;margin-bottom:.0001pt;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt'>&#9658;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:11.0pt'>Stop using Betaferon
and tell your doctor immediately</span></b><span lang=EN-GB style='font-size:
11.0pt'> if any of these happens to you. </span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>Other things
to consider when using Betaferon</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:11.0pt'>You will need blood
tests </span></b><span lang=EN-GB style='font-size:11.0pt'>to measure the
number of your blood cells, blood chemistry and your liver enzymes. This will
be done <b>before you start using Betaferon, regularly after treatment with
Betaferon has been initiated and periodically whilst you are on it, </b>even if
you have no particular symptoms. These blood tests will be in addition to the
tests, which are normally done to monitor your MS.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:11.0pt'>I<span
style='layout-grid-mode:line'>f you have a heart disease, the flu-like
symptoms, which often occur at the start of treatment, may prove stressful to
you.</span> </span></b><span lang=EN-GB style='font-size:11.0pt'>Betaferon must
be used with caution,<span style='layout-grid-mode:line'> and your doctor will
monitor you for worsening of your heart condition, particularly during the
start of treatment. Betaferon itself does not affect the heart directly.</span></span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol;layout-grid-mode:line'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:
line'>You will have a check of the function of your thyroid gland, </span></b><span
lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>regularly or whenever
thought necessary by your doctor for other reasons.</span></p>

<p class=Smalltext120><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:11.0pt'>Betaferon contains
human albumin and therefore carries</span></b><span lang=EN-GB
style='font-size:11.0pt'> <b>a potential risk for transmission of viral
diseases</b>. A risk of transmission of Creutzfeld-Jacob disease (CJD) cannot
be ruled out.</span></p>

<p class=Smalltext120><i><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:11.0pt'>During treatment
with Betaferon</span></b><span lang=EN-GB style='font-size:11.0pt'> <b>your
body may produce substances called <i>neutralising antibodies, </i></b>which
may react with Betaferon <i>(neutralising activity)</i>. <span
style='layout-grid-mode:line'>It is not yet clear whether these neutralising
antibodies reduce the effectiveness of the treatment. </span>Neutralising
antibodies are not produced in all patients. Currently it is not possible to
predict which patients belong to this group.</span></p>

<p class=Smalltext120><b><i><span lang=EN-GB style='font-size:10.0pt;
font-family:"Century Gothic",sans-serif;color:black'>&nbsp;</span></i></b></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:11.0pt;color:black'>During
treatment with Betaferon, kidney problems that may reduce your kidney function,
including scarring (<i>glomerulosclerosis</i>), may occur. </span></b><span
lang=EN-GB style='font-size:11.0pt;color:black'>Your doctor may perform tests
to check your kidney function.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:11.0pt'>Blood clots in the
small blood vessels may occur during your treatment. </span></b><span
lang=EN-GB style='font-size:11.0pt'>These blood clots could affect your kidneys.
This might happen several weeks to several years after starting Betaferon. Your
doctor may want to check your blood pressure, blood (platelet count) and the
function of your kidney.</span></p>

<p class=MsoListParagraph><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span style='font-size:11.0pt'>Paleness, y</span></b><b><span
lang=EN-GB style='font-size:11.0pt'>ellow skin or dark-colored urine, possibly accompanied
by unusual dizziness, tiredness or shortness of breath may occur during your
treatment</span></b><span lang=EN-GB style='font-size:11.0pt'>. These may be
symptoms of a breakdown of red blood cells.</span><span lang=EN-GB> </span><span
lang=EN-GB style='font-size:11.0pt'>This might happen several weeks to several
years after starting Betaferon.</span><span lang=EN-GB> </span><span
lang=EN-GB style='font-size:11.0pt'>Your doctor may perform blood tests. Inform
your doctor about other medicines that you are taking</span><span lang=EN-GB> </span><a
name="_Hlk46933630"><span lang=EN-GB style='font-size:11.0pt'>at the same time
as Betaferon</span></a><span lang=EN-GB style='font-size:11.0pt'>.</span></p>

<p class=Smalltext120 style='margin-left:28.35pt'><span lang=EN-GB
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='font-size:11.0pt'>Injection site reactions</span></b></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>During
Betaferon treatment you are likely to experience injection site reactions. </span></b><span
lang=EN-GB style='font-size:11.0pt'>Symptoms include redness, swelling, change
in the skin colour, inflammation, pain and hypersensitivity. Skin breakdown and
tissue damage <i>(necrosis) </i>around the injection site are reported less
frequently. Injection site reactions usually become less frequent over time.</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Injection site
skin and tissue breakdown can result in scars forming. If this is severe a
doctor may have to remove foreign matter and dead tissue <i>(debridement)</i>
and, less often, skin grafting is required and healing may take up to 6 months.</span></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>To reduce
the risk of getting injection site reactions you must:</span></b></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>use a sterile <i>(aseptic)</i>
injection technique,</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>rotate the injection
sites with each injection (see Annex Self-injection procedure, Part II, in
the second part of this leaflet).</span></p>

<p class=Smalltext120 style='margin-left:28.35pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='text-indent:-1.65pt'><span lang=EN-GB
style='font-size:11.0pt'>Injection site reactions may occur less frequently, if
you use an auto-injector device. Your doctor or nurse can tell you more about
this.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-right:-.1pt'><b><span lang=EN-GB
style='font-size:11.0pt'>If you experience any break in the skin, which may be
associated with swelling or fluid leaking out from the injection site:</span></b><span
lang=EN-GB style='font-size:11.0pt'> </span></p>

<p class=Smalltext120 style='margin-right:-.1pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:-.1pt;margin-bottom:
0in;margin-left:48.0pt;margin-bottom:.0001pt;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt'>&#9658;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:11.0pt'>Stop injections with
Betaferon</span></b><span lang=EN-GB style='font-size:11.0pt'> and talk to your
doctor</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:-.1pt;margin-bottom:
0in;margin-left:48.0pt;margin-bottom:.0001pt;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt'>&#9658;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:11.0pt'>If you have only one
sore injection site </span></b><span lang=EN-GB style='font-size:11.0pt'>(<i>lesion</i>)<b>
and the tissue damage </b><i>(necrosis)</i><b> is not too extensive you may
continue using Betaferon.</b> </span></p>

<p class=Smalltext120 style='margin-left:30.0pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:-.1pt;margin-bottom:
0in;margin-left:48.0pt;margin-bottom:.0001pt;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt'>&#9658;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:11.0pt'>If you have more
than one sore injection site </span></b><i><span lang=EN-GB style='font-size:
11.0pt'>(multiple lesions)</span></i><b><span lang=EN-GB style='font-size:11.0pt'>
</span></b><span lang=EN-GB style='font-size:11.0pt'>you must stop using
Betaferon until your skin has healed.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>Your doctor
will regularly check the way you inject yourself,</span></b><span lang=EN-GB
style='font-size:11.0pt'> particularly if you have experienced injection site
reactions.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>Children and
adolescents</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-right:-.1pt'><span lang=EN-GB
style='font-size:11.0pt'>There have been no formal clinical trials undertaken
in children or adolescents.</span></p>

<p class=Smalltext120 style='margin-right:-.1pt'><span lang=EN-GB
style='font-size:11.0pt'>However, there is some data available in children and adolescents
from 12 to 16 years. This data suggests that the safety profile from this age
is the same as in adults for use of Betaferon 8.0&nbsp;million IU under the
skin every other day. There is no information on the use of Betaferon in
children under 12 years of age. Therefore Betaferon should not be used in this
population.</span></p>

<p class=Smalltext120 style='margin-right:-.1pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-right:-.1pt;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt'>Other medicines and Betaferon</span></b></p>

<p class=Smalltext120 style='margin-right:-.1pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Tell your doctor or pharmacist if you are using, have
recently used or might use any other medicines, including medicines obtained
without a prescription.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'></span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>No formal
interaction studies have been carried out to find out whether Betaferon affects
other medicines or is affected by them. </span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Using Betaferon
with other medicines that modify the immune system response is not recommended,
except anti-inflammatory medicines called <i>corticosteroid</i>s or the<i>
adrenocorticotropic hormone (ACTH)</i>.</span></p>

<p class=Smalltext120 style='margin-right:-.1pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-right:-.1pt'><span lang=EN-GB
style='font-size:11.0pt'>Betaferon should be used with caution with:</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:-.1pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>- <b>medicines which need a certain
liver enzyme system</b> (known as <i>cytochrome P450 system</i>) for their
removal from the body, for example medicines used to treat epilepsy (like
phenytoin). </span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:-.1pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>- <b>medicines
which affect the production of blood cells.</b></span></p>

<p class=Smalltext120 style='margin-right:-.1pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-right:-.1pt'><b><span lang=EN-GB
style='font-size:11.0pt'>Betaferon with food and drink</span></b></p>

<p class=Smalltext120 style='margin-right:-.1pt'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Betaferon is
injected under the skin so any food or drink you consume is not thought to have
any effect on Betaferon.</span></p>

<p class=Smalltext120 style='margin-right:-.1pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>Pregnancy
and breast-feeding</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>If you are pregnant, think
you may be pregnant or are planning to have a baby, ask your doctor or pharmacist
for advice before taking this medicine.</span></p>

<p class=Smalltext120><span style='font-size:11.0pt'>No harmful effects on the
breastfed newborn/infant are anticipated. Betaferon can be used during
breast-feeding.</span></p>

<p class=Smalltext120 style='margin-right:-.1pt'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Smalltext120 style='margin-right:-.1pt;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt'>Driving and using machines</span></b></p>

<p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Betaferon may cause side effects in the central nervous
system (see section 4. Possible side effects). If you are especially
sensitive, this might affect your ability to drive or use machines.</span></p>

<p class=Smalltext120 style='margin-right:-1.45pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>Betaferon contains mannitol, human albumin and sodium</span></b></p>

<p class=Smalltext120 style='margin-right:-1.45pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-right:-1.45pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>The inactive ingredients of Betaferon
include </span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt;text-indent:-.25in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>small amounts of mannitol, a naturally
occurring sugar and human albumin, a protein.</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-10.35pt;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:11.0pt'>Sodium -</span><span lang=EN-GB> </span><span
lang=EN-GB style='font-size:11.0pt'>this medicine contains less than 1 mmol
sodium (23 mg) per ml, that is to say essentially sodium-free.</span></p>

<p class=Smalltext120 style='margin-right:-1.45pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-right:-1.45pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>If you know that you are allergic <i>(hypersensitive)</i>
to any of the ingredients or if you become so, you must not use Betaferon.</span></p>

<p class=Smalltext120 style='margin-right:-1.45pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-right:-.1pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>3. How to use Betaferon</span></b></p>

<p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Treatment with Betaferon should be started under the
supervision of a doctor who is experienced in the treatment of multiple
sclerosis.</span></p>

<p class=Smalltext120 style='margin-right:-.1pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-right:-.1pt'><span lang=EN-GB
style='font-size:11.0pt'>Always use this medicine exactly as your doctor has
told you. Check with your doctor, pharmacist or nurse if you are not sure.</span></p>

<p class=Smalltext120 style='margin-right:-.1pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>The recommended dose is: </span></b></p>

<p class=Smalltext120 style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Smalltext120 style='margin-right:-.1pt'><b><span lang=EN-GB
style='font-size:11.0pt'>Every other day </span></b><span lang=EN-GB
style='font-size:11.0pt'>(once every two days)<b>,</b> 1.0 ml of the prepared
Betaferon solution (see Annex Self-injection procedure in the second part of
this leaflet) injected under the skin <i>(subcutaneously)</i>. This equals 250
microgram (8.0 million IU) interferon beta-1b.</span></p>

<p class=Smalltext120><b><i><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></i></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:
line'>When starting treatment</span><span lang=EN-GB style='font-size:11.0pt'>
with Betaferon, it is tolerated best by gradually increasing the dose, i.e.
starting with just 0.25 ml of the medication and then increasing, after every 3<sup>rd</sup>
injection, first to <span style='layout-grid-mode:line'>0.5&nbsp;ml</span>,
then to <span style='layout-grid-mode:line'>0.75&nbsp;ml</span> and then
finally to the full dose (1 ml) of Betaferon. </span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:
line'>Your doctor may decide, together with you, to change the time interval
between increases in the dose depending on side effects you may experience at
the start of treatment. To easily increase the dosage during the first 12
injections, you may be given a special <b>titration pack</b>, containing four
differently coloured packs with specially marked syringes and with detailed
instructions on the separate introductory leaflet for titration pack.</span></p>

<p class=Smalltext120 style='margin-right:-.1pt'><u><span lang=EN-GB
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Smalltext120 style='margin-right:-.1pt'><b><span lang=EN-GB
style='font-size:11.0pt'>Preparing the injection</span></b></p>

<p class=Smalltext120 style='margin-right:-.1pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Para0s style='margin-bottom:9.0pt'><b><span lang=EN-GB
style='font-size:11.0pt'>Before injection, the Betaferon solution has to be
prepared</span></b><span lang=EN-GB style='font-size:11.0pt'> from a vial of
Betaferon powder and 1.2&nbsp;ml of liquid from the pre-filled solvent syringe.
This will either be done by your doctor or nurse or by yourself after you have
been carefully trained. For details how the Betaferon solution for injection is
prepared see Annex Self-injection procedure, Part I. </span></p>

<p class=Smalltext120 style='margin-right:-.1pt'><b><span lang=EN-GB
style='font-size:11.0pt'>Detailed instructions for self-injection of Betaferon
under the skin</span></b><span lang=EN-GB style='font-size:11.0pt'> are
provided in Part IE of the Annex Self-injection procedure. </span><span
lang=EN-GB></span></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>The injection
site must be changed regularly.</span></b><span lang=EN-GB style='font-size:
11.0pt'> See section 2. Warnings and precautions and follow the instructions
in Part II Rotating injection sites and Part III (Betaferon Medication
Record) of the Annex Self-injection procedure.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>Duration of
treatment</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>At present it
is not known how long treatment with Betaferon should last. <b>The length of
treatment will be decided by your doctor together with you.</b></span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-right:-.1pt;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt'>If you use more Betaferon than you should</span></b></p>

<p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Giving many times the dose of Betaferon recommended
for the treatment of multiple sclerosis has not led to life-threatening
situations.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:48.0pt;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt'>&#9658;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:11.0pt'>Talk to your doctor</span></b><span
lang=EN-GB style='font-size:11.0pt'> if you injected too much Betaferon or
injected it too often.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>If you forget to use Betaferon</span></b></p>

<p class=Smalltext120 style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>If you have forgotten to give yourself an injection at
the right time do it as soon as you remember and then follow on with the next
one 48 hours later.</span></p>

<p class=Smalltext120 style='margin-right:-.1pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-right:-.1pt'><span lang=EN-GB
style='font-size:11.0pt'>Do not inject a double dose to make up for a forgotten
single dose.</span></p>

<p class=Smalltext120 style='margin-right:-.1pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>If you stop using Betaferon</span></b></p>

<p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Talk to your doctor if you stop or wish to stop
treatment. Stopping Betaferon is not known to lead to acute withdrawal
symptoms.</span></p>

<p class=Smalltext120 style='margin-right:-.1pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:-.1pt;margin-bottom:
0in;margin-left:56.7pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>&#9658; If you have any further
questions on the use of this medicine, ask your doctor, pharmacist or nurse.</span></p>

<p class=Smalltext120 style='margin-right:-.1pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-right:-.1pt'><b><span lang=EN-GB
style='font-size:11.0pt'>4. Possible side effects</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Like all
medicines, this medicine can cause side effects, although not everybody gets
them.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Betaferon may
cause serious side effects. If any of the side effects get serious, or if you
notice any side effects not listed in this leaflet, please tell your doctor,
pharmacist or nurse.</span></p>

<p class=Smalltext120><i><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:-.1pt;margin-bottom:
0in;margin-left:48.0pt;margin-bottom:.0001pt;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt'>&#9658;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:11.0pt'>Tell your doctor immediately
and stop using Betaferon:</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:-.1pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>if you experience<b> </b>symptoms
such as<b> itching all over your body, swelling of your face and/or your tongue
or sudden shortness of breath.</b></span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:-.1pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>if you feel<b>
noticeably more sad or hopeless than before the treatment with Betaferon, or if
you develop thoughts of suicide.</b></span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:-.1pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>if you notice<b> any
unusual bruising, excessive bleeding after injury or if you seem to be catching
a lot of infections.</b></span></p>

<p class=Smalltext120 style='margin-right:-.1pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:-.1pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>if you have<b> loss of
appetite, fatigue, feeling sick , repeated vomiting, especially if you notice
widespread itching, yellowing of the skin or of the whites of the eyes, or easy
bruising.</b></span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:-.1pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>if you experience
symptoms like<b> irregular heartbeat, swelling such as of the ankles or legs,
or shortness of breath.</b></span></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:-.1pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>if you notice<b> pain
in your belly which is radiating to your back, and/or you feel sick or have a
fever.</b></span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:-.1pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:-.1pt;margin-bottom:
0in;margin-left:21.3pt;margin-bottom:.0001pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-size:11.0pt'>&#9658;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:11.0pt'>Tell your doctor
immediately:</span></b></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:-.1pt;margin-bottom:
0in;margin-left:21.3pt;margin-bottom:.0001pt'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>if you get some or all
of these symptoms: <b>foamy urine, fatigue, swelling, particularly in the
ankles and eyelids, and weight gain, </b>as they may be signs of a possible
kidney problem.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>At the
beginning of treatment side effects are common but in general they become less
with further treatment. </span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>The most frequently observed side effects are: </span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Bullet2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:78.0pt;text-indent:-24.0pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&#9658; <b>Flu-like symptoms</b> such as
fever, chills, painful joints, malaise, sweating, headache, or muscular pain.
These symptoms may be reduced by taking paracetamol or non-steroidal
anti-inflammatory medicines such as ibuprofen.</span></p>

<p class=Bullet2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:78.0pt;text-indent:-24.0pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Bullet2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:78.0pt;text-indent:-24.0pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&#9658; <b>Injection site reactions</b>.
Symptoms can be redness, swelling, discolouration, inflammation, pain,
hypersensitivity, tissue damage <i>(necrosis)</i>. See Warnings and
precautions in section 2 for more information and what to do, if you
experience an injection site reaction. These may be reduced by the use of an
auto-injector device. Talk to your doctor, pharmacist or nurse for further
information.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>To reduce side
effects at the start of treatment, your doctor should start you on a low dose
of Betaferon and increase it gradually (see section 3. How to use Betaferon).</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>The
following side effects listing is based on reports from clinical trials with
Betaferon (list&nbsp;1)<i> </i>and from side effects reported on the marketed
product (list&nbsp;2).</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><i><u><span lang=EN-GB style='font-size:11.0pt'>List 1: </span></u></i><span
lang=EN-GB style='font-size:11.0pt'>Very common side effects which have
occurred in clinical trials with Betaferon(at least 10% of the cases) and at a
higher percentage than those observed with placebo. The table also includes
side effects which occurred in less than 10% but were significantly associated
with the treatment.</span></p>

<p class=Smalltext120><i><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>- <b><span
style='layout-grid-mode:line'>infection,</span></b><span style='layout-grid-mode:
line'> abscess</span></span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>- reduced
number of white <b>blood cells</b>, swollen <b>lymph glands </b><i>(lymphadenopathy)</i></span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>- decrease
of <b>sugar in the blood </b><i>(hypoglycaemia)</i></span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>- <b>depression,
anxiety</b></span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>- <b>headache,
dizziness, </b>sleeplessness, migraine, <b>numbness or tingling </b>feeling <i>(paraesthesia)</i></span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>- <b>eye
inflammation </b><i>(conjunctivitis)</i><b>, abnormal vision</b></span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>- <b>e<span
style='layout-grid-mode:line'>ar</span></b><span style='layout-grid-mode:line'>
pain</span></span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>- irregular,
rapid beating or pulsation of the <b>heart</b><span style='layout-grid-mode:
line'> <i>(palpitation)</i></span></span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>- redness and/or facial flushing due
to widening of <b>blood vessels</b><i> (vasodilation)</i>, increased <b>blood
pressure </b><i>(hypertension)</i></span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>- <b>runny
nose</b>, cough, hoarseness due to infection of the upper <b>respiratory tract,
</b></span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'> sinusitis,
cough increased, <b>shortness of breath </b><i>(dyspnoea)</i></span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>- diarrhoea,
constipation, nausea, vomiting, abdominal pain</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>- rises
in the blood levels of <b>liver </b>enzymes (will show up in blood tests)</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>- <b>skin
</b>disorder, rash</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>- <b>muscle</b> stiffness <i>(hypertonia)</i>,
painful muscles <i>(myalgia)</i>, muscular weakness <i>(myasthenia)</i>, <b>back</b>
pain, pain in <b>extremities</b> such as fingers and toes</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>- difficulty urinating <i>(urine
retention)</i>, protein in the <b>urine</b> (will show up in urine tests),
urinary frequency, inability to hold back urination<i> (urinary incontinence)</i>,
urinary urgency</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>- painful periods <i>(dysmenorrhoea)</i>,
<b>menstrual</b> <b>disorder</b>, heavy uterine bleeding <i>(metrorrhagia) </i>especially
between menstrual periods, <b>impotence</b></span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>- <b>i<span style='layout-grid-mode:
line'>njection site</span></b><span style='layout-grid-mode:line'> reaction (</span>including
redness, swelling, discolouration, inflammation, pain, allergic reactions <i>(hypersensitivity)</i>,
skin breakdown and tissue damage <i>(necrosis)</i> at injection site (<span
style='layout-grid-mode:line'>see section 2Warnings and precautions)</span></span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:11.0pt'>flu-like symptoms</span></b><span
lang=EN-GB style='font-size:11.0pt'>, fever, pain, chest pain, <b>accumulation
of fluid</b> in arm, leg or face <i>(peripheral oedema)</i>, <b>lack/loss of
strength </b><i>(asthenia)</i>, chills, sweating, malaise</span></p>

<p class=Smalltext120><i><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=Para0s style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>In addition, the following side effects have been identified during
post-marketing experience</span></p>

<p class=Smalltext120 style='margin-right:28.35pt'><i><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=Smalltext120 style='margin-right:28.35pt;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt'>List 2: </span></i><span lang=EN-GB
style='font-size:11.0pt'>Side effects reported on the marketed product (from
spontaneous reporting<span style='layout-grid-mode:line'>, frequencies  where
known - based on clinical trials)</span></span></p>

<p class=Para0s style='margin-bottom:0in;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:28.35pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt'>&#9658; <b>Very common
(may affect more than 1 in 10<i> </i>users):</b></span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt;layout-grid-mode:line'>- painful joints</span><span
lang=EN-GB style='font-size:11.0pt'> (<i>arthralgia</i><span style='layout-grid-mode:
line'>)</span></span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:28.35pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB style='font-size:11.0pt'>&#9658; Common (may
affect up to 1 in 10 users):</span></b></p>

<p class=Smalltext120 style='margin-right:28.35pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:28.35pt;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>the
number of red cells in the blood may fall</span><span lang=EN-GB
style='font-size:11.0pt'> <i>(anaemia)</i></span></p>

<p class=Smalltext120 style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>the
thyroid gland does not work properly (too little hormone is produced)<i> </i>(<i>hypothyroidism</i>)</span></p>

<p class=Smalltext120 style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>weight
increase or decrease</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:28.35pt;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>confusion</span></p>

<p class=Smalltext120 style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>abnormally
rapid heartbeat </span><i><span lang=EN-GB style='font-size:11.0pt'>(tachycardia)</span></i></p>

<p class=Smalltext120 style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>a
reddish yellow pigment <i>(bilirubin)</i>, which is produced by your liver, may
rise (this will show up in blood tests)</span></p>

<p class=Smalltext120 style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>swollen
and usually itchy patches of skin or mucous membranes (<i>urticaria</i>) </span></p>

<p class=Smalltext120 style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>itching
<i>(pruritus)</i></span></p>

<p class=Smalltext120 style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>loss
of scalp hair <i>(alopecia)</i></span></p>

<p class=Smalltext120 style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>menstrual
disorders <i>(menorrhagia)</i></span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:28.35pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB style='font-size:11.0pt'>&#9658; Uncommon (may
affect up to 1 in 100 users):</span></b></p>

<p class=Smalltext120 style='margin-right:28.35pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:28.35pt;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>the
number of platelets (which help the blood to clot) may fall <i>(t</i></span><i><span
lang=EN-GB style='font-size:11.0pt'>hrombocytopenia)</span></i></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:28.35pt;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>a
certain type of blood fats (<i>triglycerides</i>) may increase (will show up in
blood tests), see section 2 Warnings and precautions</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:28.35pt;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>suicide
attempt</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:28.35pt;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>mood
swings</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:28.35pt;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>convulsion</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:28.35pt;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>a
specific liver enzyme <i>(gamma GT)</i> which is produced by your liver, may
rise (this will show up in blood tests)</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:28.35pt;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>inflammation
of the liver (<i>hepatitis</i>)</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:28.35pt;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>skin
discolouration</span></p>

<p class=Smalltext120 style='margin-right:28.35pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:28.35pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='font-size:11.0pt'>&#9658; Rare (may affect up to 1 in
1,000 users):</span></b></p>

<p class=Smalltext120 style='margin-right:28.35pt'><span lang=EN-GB
style='font-size:11.0pt;layout-grid-mode:line'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-right:28.35pt'><span lang=EN-GB
style='font-size:11.0pt;layout-grid-mode:line'>- serious allergic <i>(anaphylactic</i>)
reactions</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:28.35pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>- the thyroid
gland does not work properly <i>(thyroid disorders),</i> too much hormone is
produced<i> (h<span style='letter-spacing:-.2pt'>yperthyroidism)</span></i></span></p>

<p class=Smalltext120 style='margin-right:28.35pt'><span lang=EN-GB
style='font-size:11.0pt;layout-grid-mode:line'>- inflammation of the
pancreas <i>(pancreatitis</i>), see section 2 Warnings and precautions</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:28.35pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>- blood
clots in the small blood vessels that can affect your kidneys (thrombotic
thrombocytopenic purpura or haemolytic uremic syndrome). Symptoms may include
increased bruising, bleeding, fever, extreme weakness, headache, dizziness or
light-headedness. Your doctor may find changes in your blood and the function
of your kidneys.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:
line'>&nbsp;</span></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:
line'>Side effects derived only during post-marketing:</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:
line'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>- </span><span
lang=EN-GB style='font-size:11.0pt'>breakdown of red blood cells (haemolytic anaemia),
</span><span lang=EN-GB style='font-size:11.0pt'>frequency unknown</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>- kidney
problems including scarring (<i>glomerulosclerosis</i>) that may reduce your
kidney function, uncommon </span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:
line'>- severe loss of appetite leading to weight loss <i>(anorexia)</i>,
rare</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:
line'>- disease of the heart muscle (<i>cardiomyopathy),</i> rare</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:
line'>- sudden shortness of breath <i>(bronchospasm), </i>rare</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>- the
liver does not work properly (<i>hepatic injury</i> (including <i>hepatitis</i>,
<i>hepatic failure</i>), rare</span></p>

<p class=Smalltext120 style='margin-left:30.0pt;text-indent:-30.0pt'><span
lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>- </span><span
lang=EN-GB style='font-size:11.0pt'>problems with your small blood vessels may
develop when using medicines like Betaferon <i>(systemic capillary leak
syndrome)</i>, frequency unknown</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:28.35pt;margin-bottom:
0in;margin-left:30.0pt;margin-bottom:.0001pt;text-indent:-30.0pt'><span
lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>- rash,
redness of the skin in the face, joint pain, fever, weakness and others caused
by the medicine (<i>drug-induced lupus erythematosus</i>), frequency unknown</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:28.35pt;margin-bottom:
0in;margin-left:30.05pt;margin-bottom:.0001pt;text-indent:-30.05pt;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>- severe
narrowing of the blood vessels in the lungs resulting in high blood pressure in
the blood vessels that carry blood from the heart to the lungs (<i>pulmonary
arterial hypertension</i>), frequency unknown. Pulmonary arterial hypertension
has been seen at various time points during treatment, including several years
after starting treatment with Betaferon.</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:28.35pt;margin-bottom:
0in;margin-left:30.0pt;margin-bottom:.0001pt;text-indent:-30.0pt'><span
lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>&nbsp;</span></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>Reporting of
side effects</span></b></p>

<p class=BodytextAgency style='margin-bottom:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>If you
get any side effects, talk to your doctor, pharmacist or nurse.<span
style='color:red'> </span>This includes any possible side effects not listed in
this leaflet.</span><span lang=EN-GB style='font-size:11.0pt'> </span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>You can
also report side effects directly <span style='background:lightgrey'>via the
national reporting system listed in </span></span><span lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;background:lightgrey'>Appendix
V</span></a></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>.
By reporting side effects, you can help provide more information on the safety
of this medicine.</span></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Smalltext120 style='margin-right:-.1pt'><b><span lang=EN-GB
style='font-size:11.0pt'>5. How to store Betaferon</span></b></p>

<p class=Smalltext120 style='margin-right:-.1pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Keep this
medicine out of the sight and reach of children.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Do not use this
medicine after the expiry date which is stated on the pack. The expiry date
refers to the last day of that month.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Do not store
above 25C. Do not freeze. </span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>After preparing
the solution you should use it immediately. However, if you are not able to do
so, it will be suitable for use for 3 hours, if kept at 2-8 C (in a
refrigerator).</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Do not use
Betaferon if you notice it contains particles or is discoloured.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-right:-.1pt'><span lang=EN-GB
style='font-size:11.0pt'>Do not throw away any medicines via wastewater or
household waste. Ask your pharmacist how to throw away medicines you no longer
use. These measures will help protect the environment.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>6. Contents
of the pack and other information</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>What
Betaferon contains</span></b></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>The active
substance is </span></b><span lang=EN-GB style='font-size:11.0pt'>interferon
beta-1b, 250 microgram per millilitre when reconstituted.</span></p>

<p class=Smalltext120 style='margin-left:78.0pt;text-indent:-49.65pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>The other
ingredients are</span></b></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>in the powder: mannitol
and human albumin,</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>in the solvent (sodium
chloride solution 5.4 mg/ml (0.54% w/v)): sodium chloride, water for injection.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>The Betaferon
powder is provided in a <span style='layout-grid-mode:line'>3-millilitre vial,
containing 300 microgram (9.6 million IU) interferon beta-1b per vial. After
reconstitution, each millilitre contains 250 microgram (8.0 million IU) interferon
beta-1b.</span></span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;layout-grid-mode:
line'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>The solvent for Betaferon is provided in a 2.25-millilitre pre-filled
syringe<span style='layout-grid-mode:line'> and contains 1.2&nbsp;ml sodium
chloride solution 5.4 mg/ml (0.54% w/v).</span></span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>What
Betaferon looks like and contents of the pack</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Betaferon is a
sterile white to off-white powder for solution for injection.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Betaferon is available in pack sizes of:</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt;background:yellow'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>multipacks comprising 5
single packs, each containing 1 vial with powder, 1 pre-filled syringe with
solvent, 1 vial adapter with needle, 2 alcohol wipes or</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>multipacks comprising
12 single packs, each containing 1 vial with powder, 1 pre-filled syringe with
solvent, 1 vial adapter with needle, 2 alcohol wipes or</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>multipacks comprising
14 single packs, each containing 1 vial with powder, 1 pre-filled syringe with
solvent, 1 vial adapter with needle, 2 alcohol wipes or</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>multipacks comprising
15 single packs, each containing 1 vial with powder, 1 pre-filled syringe with
solvent, 1 vial adapter with needle, 2 alcohol wipes or</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>2-month packs
comprising 2x14 single packs, each containing 1 vial with powder, 1 pre-filled
syringe with solvent, 1 vial adapter with needle, 2 alcohol wipes or</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>3-month packs
comprising 3x15 single packs, each containing 1 vial with powder, 1 pre-filled
syringe with solvent, 1 vial adapter with needle, 2 alcohol wipes or</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>3-month packs
comprising 3x14 single packs, each containing 1 vial with powder, 1 pre-filled
syringe with solvent, 1 vial adapter with needle, 2 alcohol wipes or</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>titration pack for the
first 12 injections comprising 4 triple packs, each containing 3 vials with
powder, 3 pre-filled syringes with solvent, 3 vial adapters with needle, 6
alcohol wipes</span></p>

<p class=MsoHeader style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoHeader style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:21.0pt;text-indent:-21.0pt'><span lang=EN-GB style='font-size:11.0pt'>Not
all pack sizes may be marketed.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>Marketing Authorisation Holder and Manufacturer</span></b></p>

<p class=Smalltext120 style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Smalltext120 style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Marketing Authorisation Holder</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span lang=DE
style='font-size:11.0pt'>Bayer AG</span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span lang=DE
style='font-size:11.0pt'>51368 Leverkusen </span></p>

<p class=Smalltext120 style='page-break-after:avoid'><span lang=DE
style='font-size:11.0pt'>Germany</span></p>

<p class=Smalltext120><span lang=DE style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=DE style='font-size:11.0pt'>Manufacturer</span></p>

<p class=Smalltext120><span lang=DE style='font-size:11.0pt'>Bayer AG</span></p>

<p class=Smalltext120><span lang=DE style='font-size:11.0pt'>Mllerstrae 178</span></p>

<p class=Smalltext120><span style='font-size:11.0pt'>13353 Berlin</span></p>

<p class=Smalltext120><span style='font-size:11.0pt'>Germany</span></p>

<p class=Smalltext120><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>For any
information about this medicine, please contact the local representative of the
Marketing Authorisation Holder:</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><b><span
  lang=DE style='font-size:11.0pt'>Belgi / Belgique / Belgien</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=DE style='font-size:11.0pt'>Bayer SA&#8209;NV</span></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Tl/Tel: +32&#8209;(0)2&#8209;535 63 11</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:11.0pt'>Lietuva</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>UAB Bayer</span></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Tel. +370 5 23 36 868</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:11.0pt'>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>&#1041;&#1072;&#1081;&#1077;&#1088;
  &#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;
  &#1045;&#1054;&#1054;&#1044;</span></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>&#1058;&#1077;&#1083;. +359 02 4247280</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><b><span
  lang=DE style='font-size:11.0pt'>Luxembourg / Luxemburg</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=DE style='font-size:11.0pt'>Bayer SA&#8209;NV</span></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=DE style='font-size:11.0pt'>Tl/Tel: +32&#8209;(0)2&#8209;535 63 11</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><b><span
  lang=DE style='font-size:11.0pt'>&#268;esk republika</span></b></p>
  <p class=Smalltext120 style='page-break-after:avoid'><span lang=DE
  style='font-size:11.0pt'>Bayer s.r.o.</span></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Tel: +420 266 101 111</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:11.0pt'>Magyarorszg</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Bayer Hungria Kft.</span></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB style='font-size:11.0pt'>Tel.:+36&#8209;14
  87&#8209;41 00</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:11.0pt'>Danmark</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Bayer A/S</span></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Tlf: +45&#8209;45 23 50 00</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB style='font-size:11.0pt'>Malta</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB style='font-size:11.0pt'>Alfred Gera
  and Sons Ltd.</span></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Tel: +356&#8209;21 44 62 05</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><b><span
  lang=DE style='font-size:11.0pt'>Deutschland</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=DE style='font-size:11.0pt'>Bayer Vital GmbH</span></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=DE style='font-size:11.0pt'>Tel: +49&#8209;(0)214&#8209;30 513 48</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><b><span
  lang=DE style='font-size:11.0pt'>Nederland</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=DE style='font-size:11.0pt'>Bayer B.V.</span></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=DE style='font-size:11.0pt'>Tel: +31&#8209;(0)297&#8209;28 06 66</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:11.0pt'>Eesti</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Bayer O</span></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Tel: +372 655 85 65</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>Norge</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>Bayer AS</span></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>Tlf. +47 23 13 05
  00</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:11.0pt'>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Bayer &#917;&#955;&#955;&#940;&#962;
  &#913;&#914;&#917;&#917;</span></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>&#932;&#951;&#955;:+30 210 618 75 00</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><b><span
  lang=DE style='font-size:11.0pt'>sterreich</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=DE style='font-size:11.0pt'>Bayer Austria Ges. m. b. H.</span></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Tel: +43&#8209;(0)1&#8209;711 46&#8209;0</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:11.0pt'>Espaa</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Bayer Hispania S.L.</span></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Tel: +34&#8209;93&#8209;495 65 00</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:11.0pt'>Polska</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Bayer Sp. z o.o.</span></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Tel.: +48&#8209;22&#8209;572 35 00</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:11.0pt'>France</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Bayer HealthCare</span></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Tl (N vert): +33-(0)800 87 54 54</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:11.0pt'>Portugal</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Bayer Portugal, Lda.</span></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Tel: +351&#8209;21&#8209;416 42 00</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><b><span
  lang=DE style='font-size:11.0pt'>Hrvatska</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=DE style='font-size:11.0pt'>Bayer d.o.o.</span></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Tel: +385-(0)1-6599 900</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:11.0pt'>Romnia</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>SC Bayer SRL </span></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Tel: +40 21 528 59 00</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:11.0pt'>Ireland</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Bayer Limited</span></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Tel: +353 1 </span><span lang=DE
  style='font-size:11.0pt;color:#1F497D'>216 3300</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:11.0pt'>Slovenija</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Bayer d. o. o.</span></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Tel.: +386&#8209;(0)1&#8209;58 14 400</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>sland</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in;text-align:justify;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Icepharma<span
  style='layout-grid-mode:line'> hf.</span></span></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt;layout-grid-mode:line'>Smi: +354 540 80
  00</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:11.0pt'>Slovensk republika</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Bayer, spol. s r.o.</span></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Tel: +421 2 59 21 31 11</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:11.0pt'>Italia</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Bayer S.p.A.</span></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Tel: +39&#8209;02&#8209;397 81</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><b><span
  lang=DE style='font-size:11.0pt'>Suomi/Finland</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=DE style='font-size:11.0pt'>Bayer Oy</span></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=DE style='font-size:11.0pt'>Puh/Tel: +358&#8209;20 785 21</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:11.0pt'>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>NOVAGEM Limited</span></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>&#932;&#951;&#955;: +357 22 48 38 58</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:11.0pt'>Sverige</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Bayer AB</span></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Tel: +46&#8209;(0)8&#8209;580&nbsp;223 00
  </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:11.0pt'>Latvija</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>SIA Bayer</span></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Tel: +371 67 84 55 63</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:11.0pt'>United Kingdom</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Bayer plc</span></p>
  <p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Tel: +44 (0)</span><span
  style='font-size:11.0pt'>118 206 3000</span></p>
  </td>
 </tr>
</table>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>This leaflet
was last revised in</span></b></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt'>Other sources of information</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Detailed
information on this medicine is available on the European Medicines Agency
website: </span><a href="http://www.ema.europa.eu">http://www.ema.europa.eu</a><span
lang=EN-GB style='font-size:11.0pt'>.</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>Annex:
SELF-INJECTION PROCEDURE</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Your doctor has
prescribed Betaferon to treat your MS. You will best tolerate Betaferon in the
beginning if you start with a low dose and gradually increase to the full
standard dose (see first part of this leaflet, section 3. How to use
Betaferon). <span style='layout-grid-mode:line'>To easily increase the dosage
during the first 12 injections, you may be given a special titration pack,
containing four differently coloured triple packs with special marked syringes
and with detailed instructions on the separate introductory leaflet for titration
pack. </span>The syringes in this titration pack are marked accordingly with
the appropriate doses (0.25; 0.5; 0.75 or 1.0 ml).</span></p>

<p class=Para0s style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=Para0s style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>The following instructions and pictures explain how to prepare
Betaferon for injection and how to inject Betaferon yourself. Please read the
instructions carefully and follow them step by step. Your doctor or nurse will
help you to learn the process of self-administration. Do not attempt to inject
yourself until you are sure that you understand how to prepare the injection
solution and give the injection to yourself. </span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>PART I:</span></b><span
lang=EN-GB style='font-size:11.0pt'> <b>STEP BY STEP INSTRUCTIONS</b></span></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>The
instructions include the following main steps:</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoHeader style='margin-bottom:0in'><b><span lang=EN-GB
style='font-size:11.0pt;text-transform:uppercase'>A) </span></b><b><span
lang=EN-GB style='font-size:11.0pt'>General advice</span></b></p>

<p class=MsoHeader style='margin-bottom:0in'><b><span lang=EN-GB
style='font-size:11.0pt;text-transform:uppercase'>B) G</span></b><b><span
lang=EN-GB style='font-size:11.0pt'>etting ready to inject</span></b></p>

<p class=MsoHeader style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><b><span lang=EN-GB style='font-size:
11.0pt;text-transform:uppercase'>C) R</span></b><b><span lang=EN-GB
style='font-size:11.0pt'>econstituting the solution<span style='text-transform:
uppercase'>, </span>step by step</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><b><span lang=EN-GB style='font-size:
11.0pt;text-transform:uppercase'>D) </span></b><b><span lang=EN-GB
style='font-size:11.0pt'>Drawing up the injection</span></b></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt;text-transform:
uppercase'>E) </span></b><b><span lang=EN-GB style='font-size:11.0pt'>Making
the injection</span></b></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>F) Quick
review of the process</span></b></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><b><i><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></i></b></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><b><i><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></i></b></p>

<p class=MsoHeader style='margin-bottom:0in'><b><span lang=EN-GB
style='font-size:11.0pt;text-transform:uppercase'>A) </span></b><b><span
lang=EN-GB style='font-size:11.0pt'>General advice</span></b></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&#9658; <b>Get a good start!</b></span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=Para0s style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>You will find that within a few weeks your treatment will become a
natural part of your routine. As you get started, you may find the following
helpful:</span></p>

<p class=Para0s style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=Para0s style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Set up a permanent
storage area in a convenient location out of the sight and reach of children so
your Betaferon and other supplies are always easy to find.<br>
For details on storage conditions, see section 5. How to store Betaferon<b></b>
in the first part of this leaflet.</span></p>

<p class=Para0s style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=Para0s style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Try to give your
injection at the same time of day. This makes it easier to remember and easier
to plan a block of time when you will not be interrupted.</span></p>

<p class=Para0s style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=Para0s style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Prepare each dose only
when you are ready for an injection. After mixing Betaferon, you should give
the injection immediately (if Betaferon is not used immediately, see section 5.
How to store Betaferon in the first part of this leaflet).</span></p>

<p class=MsoHeader style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><a name="_Toc55893549"><span
lang=EN-GB style='font-size:11.0pt'>&#9658; <b>Important tips</b></span></a><b><span
lang=EN-GB style='font-size:11.0pt'> to keep in mind</span></b></p>

<p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Para0s style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Be consistent - use
Betaferon as described in section 3. How to use Betaferon in the first part
of this leaflet. Always double-check your dosage.</span></p>

<p class=Para0s style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Keep your syringes and
syringe disposal unit out of the sight and reach of children; lock the supplies
away if possible.</span></p>

<p class=Para0s style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Never re-use syringes
or needles.</span></p>

<p class=Para0s style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Always use a sterile <i>(aseptic)</i>
technique as described in here.</span></p>

<p class=Para0s style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Always place the used
syringes in the proper disposal unit.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>B) Getting ready to inject</span></b></p>

<p class=MsoNormal style='margin-bottom:0in'><a name="_Toc55893551"><b><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></a></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&#9658; <b>Choosing an injection site</b></span></p>

<p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Before preparing your injection, decide where you are going to inject.
You should inject Betaferon into the fatty layer between the skin and muscle
(that is, subcutaneously, about 8 to 12 mm under the skin). The best places for
injections are where the skin is loose and soft, and away from joints, nerves,
or bones, for example the abdomen, arm, thigh or buttocks. </span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>Important:</span></b><span lang=EN-GB
style='font-size:11.0pt'> Do not use any area where you can feel lumps, bumps,
firm knots, pain or an area that is discoloured, indented, scabbed, or where
the skin is broken. Talk to your doctor or nurse about these or any other
unusual conditions you may find.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>You should rotate the injection site at every injection. If some areas
are too difficult for you to reach, you may need a family member or friend to
help you with these injections. Follow the sequence described in the schedule
at the end of the Annex (see Part II, Rotating injection sites) and you will
come back to your first injection site area after 8 injections (16&nbsp;days).
This will give each injection site a chance to fully recover before receiving
another injection. </span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Please refer to the rotation schedule at the end of this Annex to learn
how to choose an injection site. An example of a medication record is also
included (see Annex Part III). This should give you an idea of how you can keep
track of your injection sites and dates.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&#9658; <b>Checking the content of the pack</b></span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;background:yellow'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>In the
Betaferon pack you will find:</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>1 Betaferon vial (with
powder for solution for injection),</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>1 pre-filled syringe of
solvent for Betaferon (sodium chloride solution 5.4 mg/ml (0.54% <span
style='layout-grid-mode:line'>w/v</span>)),</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>1 vial adapter with a
pre-attached needle,</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>2 alcohol swabs to clean
the skin and vial.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>In addition you
will need a disposal unit for used syringes and needles.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:56.7pt;text-indent:-56.7pt'><span lang=EN-GB style='font-size:11.0pt'>For
skin disinfection use an appropriate disinfectant.</span></p>

<p class=Smalltext120 style='margin-bottom:3.0pt'><span lang=EN-GB
style='font-size:11.0pt'>If you have a Betaferon titration pack you will find 4
differently coloured and numbered triple packs, each containing:</span></p>

<p class=Smalltext120 style='margin-left:28.4pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-size:11.0pt'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>3 Betaferon vials (with
powder for solution for injection)</span></p>

<p class=Smalltext120 style='margin-left:28.4pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-size:11.0pt'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>3 pre-filled syringes
with solvent for the Betaferon powder (sodium chloride solution 5.4 mg/ml
(0.54% w/v))</span></p>

<p class=Smalltext120 style='margin-left:28.4pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-size:11.0pt'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>3 vial adapters with a
pre-attached needle</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:0in;margin-bottom:
6.0pt;margin-left:28.4pt;text-indent:-14.2pt'><span lang=EN-GB
style='font-size:11.0pt'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>6 alcohol wipes for
skin and vial cleaning</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>In addition you
will need a disposal unit for used syringes and needles.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:56.7pt;text-indent:-56.7pt'><span lang=EN-GB style='font-size:11.0pt'>For
skin disinfection use an appropriate disinfectant.</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Start with the <b>yellow
triple pack 1 </b>containing 3 syringes with a 0.25-ml marking, for treatment
days 1, 3 and 5.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Use then the <b>red
triple pack 2 </b>containing 3 syringes with a 0.5-ml marking, for treatment
days 7, 9 and 11.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Continue with
the <b>green triple pack 3</b> containing 3 syringes with a 0.75-ml marking,
for treatment days 13, 15 and 17.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Use the <b>blue
triple pack 4</b> containing 3 syringes with a 0.25; 0.5; 0.75 and 1.0-ml
marking, for treatment days 19, 21 and 23.</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all>
</span></b>

<p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
style='font-size:11.0pt;text-transform:uppercase'>C) </span></b><b><span
lang=EN-GB style='font-size:11.0pt'>Reconstituting the solution, step by step</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><b><span lang=EN-GB style='font-size:
11.0pt;text-transform:uppercase'>&nbsp;</span></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:5.4pt;border-collapse:collapse'>
 <tr>
  <td width=217 colspan=2 valign=top style='width:163.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'><img border=0 width=126 height=142 id="Bild 1"
  src="Betaferon%20II-130%20-%20EN%20PI%20(clean)%20Corr.1_files/image001.png"
  alt="0 wash hands"></span></p>
  </td>
  <td width=394 valign=top style='width:295.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>1 - Wash your hands thoroughly with soap and water
  before beginning this process.</span></p>
  </td>
 </tr>
 <tr>
  <td width=216 valign=top style='width:2.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'><img border=0 width=148 height=132 id="Bild 2"
  src="Betaferon%20II-130%20-%20EN%20PI%20(clean)%20Corr.1_files/image002.png"
  alt="1 Open Vial"></span></p>
  </td>
  <td width=396 colspan=2 valign=top style='width:296.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>2 - Open the Betaferon vial and put it on the table.
  It is best to use your thumb rather than your nail as it could break.</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=216 valign=top style='width:2.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'><img border=0 width=171 height=127 id="Bild 3"
  src="Betaferon%20II-130%20-%20EN%20PI%20(clean)%20Corr.1_files/image003.png"
  alt="2 clean vial"></span></p>
  </td>
  <td width=396 colspan=2 valign=top style='width:296.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>3 - Clean the top of the vial with an alcohol wipe,
  moving the wipe in one direction only. Leave the wipe on top of the vial.</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:54.3pt'>
  <td width=216 valign=top style='width:2.25in;padding:0in 5.4pt 0in 5.4pt;
  height:54.3pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'><img border=0 width=168 height=116 id="Bild 4"
  src="Betaferon%20II-130%20-%20EN%20PI%20(clean)%20Corr.1_files/image004.png"
  alt="3 open blister"></span></p>
  </td>
  <td width=396 colspan=2 valign=top style='width:296.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:54.3pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>4  Open the blister pack containing the vial
  adapter, but leave the vial adapter inside. </span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
  style='font-size:11.0pt'>Do not remove the vial adapter from the blister pack
  at this stage.</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>Do not touch the vial adapter. This is to keep it
  sterile.</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><i><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=216 style='width:2.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'><img border=0 width=168 height=127 id="Bild 5"
  src="Betaferon%20II-130%20-%20EN%20PI%20(clean)%20Corr.1_files/image005.png"
  alt="4 connect adapter to vial"></span></p>
  </td>
  <td width=396 colspan=2 valign=top style='width:296.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>5  Before attaching the adapter remove and discard
  the alcohol wipe and rest the vial on a flat surface.</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'></span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>6 - Hold the blister pack on the outside and place
  it on top of the vial. Push it down firmly until you feel it snap into place
  on the vial.</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=216 valign=top style='width:2.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'><img border=0 width=165 height=143 id="Bild 6"
  src="Betaferon%20II-130%20-%20EN%20PI%20(clean)%20Corr.1_files/image006.png"
  alt="5 take off blister"></span></p>
  </td>
  <td width=396 colspan=2 valign=top style='width:296.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>7 - Remove the blister pack from the vial adapter,
  holding the blister edges. Now you are ready to attach the pre-filled solvent
  syringe to the vial adapter.</span></p>
  </td>
 </tr>
 <tr>
  <td width=216 valign=top style='width:2.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'><img border=0 width=168 height=97 id="Bild 7"
  src="Betaferon%20II-130%20-%20EN%20PI%20(clean)%20Corr.1_files/image007.png"
  alt="6 take off PRTC"></span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=396 colspan=2 valign=top style='width:296.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  0in;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt'>8 - Pick up
  the syringe. Be sure that the orange tip cap is firmly attached to the
  solvent syringe!</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>Remove the tip cap by twisting it off. Throw away
  the tip cap. </span></p>
  <p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=216 valign=top style='width:2.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'><img border=0 width=165 height=124 id="Bild 8"
  src="Betaferon%20II-130%20-%20EN%20PI%20(clean)%20Corr.1_files/image008.png"
  alt="7 connect syringe to adapter"></span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=396 colspan=2 valign=top style='width:296.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>9 - Connect the syringe to the opening on the side
  of the vial adapter by inserting the end of the syringe and tightening
  carefully with a clockwise push and twist motion (see arrow). This will
  form the syringe assembly. </span></p>
  <p class=MsoNormal style='margin-bottom:0in'><i><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=216 valign=top style='width:2.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'><img border=0 width=166 height=132 id="Bild 9"
  src="Betaferon%20II-130%20-%20EN%20PI%20(clean)%20Corr.1_files/image009.png"
  alt="8 dissolve"></span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=396 colspan=2 valign=top style='width:296.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>10 - Hold the syringe assembly at the bottom of the
  vial. Slowly push the plunger of the syringe in all the way to transfer all
  of the solvent into the vial. Release the plunger, which may go back to its
  original position. </span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>This applies also to the titration pack.</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><i><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=216 valign=top style='width:2.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in'><i><span lang=EN-GB
  style='font-size:11.0pt'><img border=0 width=168 height=115 id="Bild 10"
  src="Betaferon%20II-130%20-%20EN%20PI%20(clean)%20Corr.1_files/image010.png"
  alt="9 swirl"></span></i></p>
  </td>
  <td width=396 colspan=2 valign=top style='width:296.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>11 - With the syringe assembly still attached, swirl
  the vial around gently to completely dissolve the dry Betaferon powder.</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
  style='font-size:11.0pt'>Do not shake the vial.</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=216 valign=top style='width:2.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'><img border=0 width=171 height=116 id="Bild 11"
  src="Betaferon%20II-130%20-%20EN%20PI%20(clean)%20Corr.1_files/image011.png"
  alt="10 examine"></span></p>
  </td>
  <td width=396 colspan=2 valign=top style='width:296.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>12 - Examine the solution carefully. It should be
  clear and contain no particles. If the solution is discoloured or contains
  particles, discard it and start again with a new single pack of supplies. If
  foam is present - which can happen if the vial is shaken or swirled too much
   let the vial sit undisturbed until the foam settles.</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=216 style='border:none'></td>
  <td width=1 style='border:none'></td>
  <td width=394 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt;display:none'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
class=MsoCommentReference><span lang=EN-GB style='font-size:11.0pt;text-transform:
uppercase'>&nbsp;</span></span></p>

<span class=MsoCommentReference><b><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif'><br clear=all>
</span></b></span>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
class=MsoCommentReference><b><span lang=EN-GB style='font-size:11.0pt'>D) Drawing
up the injection</span></b></span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><b><i><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></i></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:5.4pt;border-collapse:collapse'>
 <tr>
  <td width=216 valign=top style='width:2.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'><img border=0 width=167 height=125 id="Bild 12"
  src="Betaferon%20II-130%20-%20EN%20PI%20(clean)%20Corr.1_files/image012.png"
  alt="11 redraw solution"></span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=396 valign=top style='width:296.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>13 - If the plunger has moved back to its original
  position push it in again and hold it in place. To prepare your injection,
  turn the assembly over so that the vial is on top, cap side pointing down. Doing
  this allows the solution to flow down into the syringe.</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
  style='font-size:11.0pt'>Keep the syringe horizontal.</span></b><span
  lang=EN-GB style='font-size:11.0pt'> </span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>Slowly pull the plunger back to withdraw all the
  solution out of the vial and into the syringe.</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>With the titration pack, withdraw solution<b> only
  up to the mark on the syringe:</b></span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:3.0pt;
  margin-left:.6pt'><b><span lang=EN-GB style='font-size:11.0pt'>0.25 ml </span></b><span
  lang=EN-GB style='font-size:11.0pt'>for first three injections<b> </b>(at day
  1, 3, 5 of therapy), <b>or</b></span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:3.0pt;
  margin-left:.6pt'><b><span lang=EN-GB style='font-size:11.0pt'>0.5 ml </span></b><span
  lang=EN-GB style='font-size:11.0pt'>for the injections<b> </b>at day 7, 9, 11
  of therapy, <b>or</b></span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:6.0pt;
  margin-left:.6pt'><b><span lang=EN-GB style='font-size:11.0pt'>0.75 ml </span></b><span
  lang=EN-GB style='font-size:11.0pt'>for the injections<b> </b>at day 13, 15,
  17 of therapy.</span></p>
  <p class=MsoNormal style='margin-bottom:3.0pt'><b><span lang=EN-GB
  style='font-size:11.0pt'>Discard the vial with any remaining solution.</span></b></p>
  <p class=MsoNormal style='margin-bottom:3.0pt'><b><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>From day 19 you are injecting the <b>full dose 1.0
  ml.</b></span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:227.25pt'>
  <td width=216 valign=top style='width:2.25in;padding:0in 5.4pt 0in 5.4pt;
  height:227.25pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'><img border=0 width=172 height=140 id="Bild 13"
  src="Betaferon%20II-130%20-%20EN%20PI%20(clean)%20Corr.1_files/image013.jpg"
  alt="12 air bubbles"></span></p>
  </td>
  <td width=396 valign=top style='width:296.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:227.25pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  0in;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt'>14 - After
  drawing up the solution turn the syringe assembly so that the needle is
  pointing up. This allows any air bubbles to rise to the top of the solution.</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>15 - Remove any air bubbles by gently tapping the
  syringe and pushing the plunger to the 1-ml mark, or to the volume prescribed
  by your doctor.</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>If you are injecting less than 1 ml with the
  titration pack there might not be any air bubbles, however for full dose
  injection some air bubbles might turn up. Remove them by gently tapping the
  syringe and pushing the plunger to the respective marking on the syringe.</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>If too much solution enters the vial along with the
  air bubbles, get back into the horizontal position (see pict. 13) and pull
  the plunger back a little to withdraw the solution back into the syringe.</span></p>
  </td>
 </tr>
 <tr style='height:7.6pt'>
  <td width=216 valign=top style='width:2.25in;padding:0in 5.4pt 0in 5.4pt;
  height:7.6pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'><img border=0 width=172 height=127 id="Bild 14"
  src="Betaferon%20II-130%20-%20EN%20PI%20(clean)%20Corr.1_files/image014.png"
  alt="13 take off adapter"></span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=396 rowspan=2 valign=top style='width:296.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.6pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>16 - Next, hold the blue vial adapter with the
  attached vial and remove it from the syringe by twisting it and then pulling
  it down, away from the syringe. </span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
  style='font-size:11.0pt'>Only hold the blue plastic adapter when removing.
  Keep the syringe in a horizontal position and the vial below the syringe.</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Removing the
  vial and adapter from the syringe ensures that the solution will flow out
  from the needle when injected.</span></p>
  </td>
 </tr>
 <tr style='height:7.6pt'>
  <td width=216 valign=top style='width:2.25in;padding:0in 5.4pt 0in 5.4pt;
  height:7.6pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'><img border=0 width=171 height=133 id="Bild 15"
  src="Betaferon%20II-130%20-%20EN%20PI%20(clean)%20Corr.1_files/image015.png"
  alt="14 take off adapter 2"></span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=2 valign=top style='width:458.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>17 - Dispose of the vial and any unused portion of
  the solution in the disposal unit</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=2 valign=top style='width:458.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>18 - You are now ready to inject. </span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>If, for some reason, you are not able to inject the
  Betaferon immediately, you can keep the reconstituted solution in the syringe
  in a refrigerator for up to 3&nbsp;hours before using. Do not freeze the
  solution, and do not wait longer than 3 hours to inject it. If more than
  3&nbsp;hours pass, discard the reconstituted Betaferon solution and prepare a
  new injection. When you use the solution, warm it up in your hands before
  injecting to avoid pain.</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=Smalltext120 style='margin-left:35.45pt;text-indent:-35.45pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='font-size:11.0pt;text-transform:uppercase'>E)  </span></b><b><span
lang=EN-GB style='font-size:11.0pt'>Making the injection</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:5.4pt;border-collapse:collapse'>
 <tr>
  <td width=168 valign=top style='width:1.75in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=432 valign=top style='width:4.5in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>1 - Choose an area for the injection (see advice at
  the start and the diagrams at the end of this Annex), and make a note of it
  in your medication record.</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=168 valign=top style='width:1.75in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'><img border=0 width=148 height=138 id="Bild 16"
  src="Betaferon%20II-130%20-%20EN%20PI%20(clean)%20Corr.1_files/image016.png"
  alt="15 clean injection site"></span></p>
  </td>
  <td width=432 valign=top style='width:4.5in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>2 - Use an alcohol wipe to clean the skin at the
  injection site. Let the skin air-dry. Throw the wipe away.</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>For skin disinfection use an appropriate
  disinfectant.</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=168 valign=top style='width:1.75in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'><img border=0 width=161 height=115 id="Bild 17"
  src="Betaferon%20II-130%20-%20EN%20PI%20(clean)%20Corr.1_files/image017.png"
  alt="16 take off needle cap"></span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=432 valign=top style='width:4.5in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>3 - Remove the cap from the needle by pulling not
  twisting it.</span></p>
  </td>
 </tr>
 <tr>
  <td width=168 rowspan=3 valign=top style='width:1.75in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'><img border=0 width=132 height=133 id="Bild 18"
  src="Betaferon%20II-130%20-%20EN%20PI%20(clean)%20Corr.1_files/image018.png"
  alt="17 inject"></span></p>
  </td>
  <td width=432 valign=top style='width:4.5in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>4 - Gently pinch the skin together around the
  disinfected injection site (to raise it up a little).</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=432 valign=top style='width:4.5in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>5 - Holding the syringe like a pencil or a dart,
  push the needle straight into the skin at a 90&#730; angle with a quick, firm
  motion. Please note: Betaferon can also be administered with an
  auto-injector.</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=432 valign=top style='width:4.5in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>6 - Inject the medicine using a slow, steady push on
  the plunger. (Push the plunger all the way in until the syringe is empty.)</span></p>
  </td>
 </tr>
 <tr>
  <td width=168 valign=top style='width:1.75in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=432 valign=top style='width:4.5in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>7- Discard the syringe in the disposal unit.</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><b><span lang=EN-GB style='font-size:
11.0pt;text-transform:uppercase'>F) </span></b><b><span lang=EN-GB
style='font-size:11.0pt'>Quick review of the process</span></b></p>

<p class=Para0s style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=Para0s style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.5in;text-indent:-.25in'><span lang=EN-GB style='font-size:11.0pt;
font-family:"Verdana",sans-serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Take out the required
content for one injection</span></p>

<p class=Para0s style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.5in;text-indent:-.25in'><span lang=EN-GB style='font-size:11.0pt;
font-family:"Verdana",sans-serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Attach vial adapter to
the vial</span></p>

<p class=Para0s style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.5in;text-indent:-.25in'><span lang=EN-GB style='font-size:11.0pt;
font-family:"Verdana",sans-serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Connect the syringe to
the vial adapter</span></p>

<p class=Para0s style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.5in;text-indent:-.25in'><span lang=EN-GB style='font-size:11.0pt;
font-family:"Verdana",sans-serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Push syringe plunger to
transfer all the solvent into the vial</span></p>

<p class=Para0s style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.5in;text-indent:-.25in'><span lang=EN-GB style='font-size:11.0pt;
font-family:"Verdana",sans-serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Turn the syringe
assembly over and draw up the prescribed amount of the solution</span></p>

<p class=Para0s style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:.5in;text-indent:-.25in'><span lang=EN-GB style='font-size:11.0pt;
font-family:"Verdana",sans-serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Remove vial from
syringe - you are now ready to inject.</span></p>

<p class=Smalltext120><b><i><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></i></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>NOTE: The
injection should be administered immediately after mixing (if the injection is
delayed, refrigerate the solution and inject it within 3 hours). Do not freeze.
</span></p>

<p class=Smalltext120 style='margin-left:35.45pt;text-indent:-35.45pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt;text-transform:
uppercase'>PART II: ROTATING INJECTION SITES</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>You need to
choose a new site for each injection to allow the area time to recover and help
prevent infection. Advice on which areas to choose is given in the first part
of this Annex. It is a good idea to know where you plan to inject before you
prepare your syringe. The schedule shown in the diagram below will help you to
vary the sites appropriately. For example, give the first injection into the
right side of the abdomen, choose the left side for the second injection, then
move to the right thigh for the third, and so on through the diagram until all
suitable areas of the body have been used. Keep a record of where and when you
last gave yourself an injection. One way to do that is to note the injection
site on the enclosed medication record card.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>By following this schedule, you will come back to your first area (e.g.
the right side of the abdomen) after 8 injections (16 days). This is called a
Rotation Cycle. On our example schedule each area is split again into 6
injection sites (which adds up to 48 injection sites all together), left and
right: upper, middle and lower part of each area. If you come back to an area
after one Rotation Cycle, choose the most distant injection site within this
area. If an area becomes sore, talk to your doctor or nurse about choosing
other injection sites.</span></p>

<p class=Para0s style='margin-bottom:0in'><u><span lang=EN-GB style='font-size:
11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Para0s style='margin-bottom:0in'><u><span lang=EN-GB style='font-size:
11.0pt'>Rotation Schedule: </span></u></p>

<p class=Para0s style='margin-bottom:0in'><u><span lang=EN-GB style='font-size:
11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Para0s style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>To help you rotate the injection sites appropriately, we recommend that
you keep a record of the date and location of your injection. You can use the
following rotation schedule. </span></p>

<p class=Para0s style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>Work through each rotation cycle in turn. Each cycle will be 8
injections (16 days), given in area&nbsp;1 through to area&nbsp;8 in turn. By
following this sequence, you will give each area a chance to recover before
receiving another injection. </span></p>

<p class=Para0s style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=Para0s style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:106.2pt;text-indent:-106.2pt'><b><span lang=EN-GB style='font-size:
11.0pt'>Rotation Cycle&nbsp;1:</span></b><span lang=EN-GB style='font-size:
11.0pt'> Upper left section of each area</span></p>

<p class=Para0s style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:106.2pt;text-indent:-106.2pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=Para0s style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:106.2pt;text-indent:-106.2pt'><b><span lang=EN-GB style='font-size:
11.0pt'>Rotation Cycle&nbsp;2:</span></b><span lang=EN-GB style='font-size:
11.0pt'> Lower right section of each area</span></p>

<p class=Para0s style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:106.2pt;text-indent:-106.2pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=Para0s style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:106.2pt;text-indent:-106.2pt'><b><span lang=EN-GB style='font-size:
11.0pt'>Rotation Cycle&nbsp;3:</span></b><span lang=EN-GB style='font-size:
11.0pt'> Middle left section of each area</span></p>

<p class=Para0s style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:106.2pt;text-indent:-106.2pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=Para0s style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:106.2pt;text-indent:-106.2pt'><b><span lang=EN-GB style='font-size:
11.0pt'>Rotation Cycle&nbsp;4:</span></b><span lang=EN-GB style='font-size:
11.0pt'> Upper right section of each area</span></p>

<p class=Para0s style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:106.2pt;text-indent:-106.2pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=Para0s style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:106.2pt;text-indent:-106.2pt'><b><span lang=EN-GB style='font-size:
11.0pt'>Rotation Cycle 5: </span></b><span lang=EN-GB style='font-size:
11.0pt'>Lower left section of each area</span></p>

<p class=Para0s style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:106.2pt;text-indent:-106.2pt'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=Para0s style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:106.2pt;text-indent:-106.2pt'><b><span lang=EN-GB style='font-size:
11.0pt'>Rotation Cycle 6:</span></b><span lang=EN-GB style='font-size:11.0pt'>  Middle
right section of each area</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif'><br
clear=all>
</span>

<p class=Smalltext120></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=614 valign=top style='width:460.5pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
  style='font-size:11.0pt'>ROTATION SCHEDULE:</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:644.8pt'>
  <td width=614 valign=top style='width:460.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:644.8pt'>
  <p class=MsoNormal style='margin-bottom:0in'><span style='position:relative;
  z-index:251658240'><span style='position:absolute;left:160px;top:-17143px;
  width:72px;height:1px'><img width=72 height=1
  src="Betaferon%20II-130%20-%20EN%20PI%20(clean)%20Corr.1_files/image019.png"
  alt="10  15 cm from groin"></span></span><span style='position:relative;
  z-index:251657216'><span style='position:absolute;left:8px;top:-17161px;
  width:520px;height:1px'><img width=520 height=1
  src="Betaferon%20II-130%20-%20EN%20PI%20(clean)%20Corr.1_files/image020.png"></span></span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt;text-transform:
uppercase'>&nbsp;</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all>
</span></b><br clear=ALL>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt;text-transform:
uppercase'>&nbsp;</span></b></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt;text-transform:
uppercase'>PART III: BETAFERON MEDICATION RECORD</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
style='font-size:11.0pt'>Instructions for keeping track of your injection sites
and dates</span></b></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>- Select an injection site for your first injection.</span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>-</span><span lang=EN-GB> </span><span lang=EN-GB
style='font-size:11.0pt'>Clean the injection site with an alcohol wipe and let
it air-dry.</span></p>

<p class=Smalltext120 style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>- After your injection, fill in the
used injection site and date on the table in your injection record (see the
example: Keeping track of your injection sites and dates).</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all>
</span>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=614 valign=top style='width:460.5pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
  style='font-size:11.0pt'>EXAMPLE OF A MEDICATION RECORD:</span></b></p>
  <p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 valign=top style='width:460.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center'><span
  lang=EN-GB style='font-size:11.0pt'><img border=0 width=603 height=855
  id="Bild 19"
  src="Betaferon%20II-130%20-%20EN%20PI%20(clean)%20Corr.1_files/image021.jpg"
  alt="How to fill_2a"></span></p>
  </td>
 </tr>
</table>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><b><u><span lang=EN-GB style='font-size:11.0pt'>---------------------------------------------------------------------------------------------------------------------------</span></u></b></p>

<p class=Smalltext120><b><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=Smalltext120><b><span lang=EN-GB style='font-size:11.0pt'>Separate
Annex: INTRODUCTORY LEAFLET FOR TITRATION PACK</span></b></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>Your doctor has
prescribed Betaferon to treat your MS. You will best tolerate Betaferon in the
beginning if you start with a low dose and gradually increase to the full
standard dose (see first part of the package leaflet, section 3. How to use
Betaferon). The syringes in this titration pack are marked accordingly with
the appropriate doses (0.25; 0.5; 0.75 or 1.0 ml).</span></p>

<p class=Para0s style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
style='font-size:11.0pt;background:yellow'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt'>&#9658; <b>Checking the content of the pack</b></span></p>

<p class=MsoNormal style='margin-bottom:0in'><b><span lang=EN-GB
style='font-size:11.0pt;background:yellow'>&nbsp;</span></b></p>

<p class=Smalltext120 style='margin-bottom:3.0pt'><span lang=EN-GB
style='font-size:11.0pt'>You will find in the Betaferon titration pack 4
differently coloured and numbered triple packs, each containing:</span></p>

<p class=Smalltext120 style='margin-left:28.4pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-size:11.0pt'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>3 Betaferon vials (with
powder for solution for injection)</span></p>

<p class=Smalltext120 style='margin-left:28.4pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-size:11.0pt'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>3 pre-filled syringes
with solvent for the Betaferon powder (sodium chloride solution 5.4 mg/ml
(0.54% <span style='layout-grid-mode:line'>w/v</span>))</span></p>

<p class=Smalltext120 style='margin-left:28.4pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-size:11.0pt'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>3 vial adapters with a
pre-attached needle</span></p>

<p class=Smalltext120 style='margin-top:0in;margin-right:0in;margin-bottom:
6.0pt;margin-left:28.4pt;text-indent:-14.2pt'><span lang=EN-GB
style='font-size:11.0pt'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>6 alcohol wipes for
skin and vial cleaning</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:30.0pt;text-indent:-30.0pt;text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'> <span style='color:black'>Each triple pack
contains the syringes you will require for preparing each dose. The syringes
have special markings for this dose. Please follow in detail the instructions
for use below. For each titration step use the complete amount of solvent for
reconstitution of the Betaferon powder, then draw up the required dose into the
syringe.</span></span></p>

<p class=MsoNormal style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt;color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:.25in;margin-right:0in'>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB style='font-size:11.0pt;color:black'>Start by
using the <b>yellow triple pack </b>which is clearly marked with a <b>1</b>
on the top right hand side of the box. </span></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB style='font-size:11.0pt;color:black'>This first
triple pack should be used for treatment days 1, 3 and 5. </span></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB style='font-size:11.0pt;color:black'>It contains
specially marked syringes with <b>0.25 ml </b>marking. This will help you to
inject the required dose only.</span></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB style='font-size:11.0pt;color:black'>After
finishing with the yellow pack, start using the <b>red triple pack </b>which is
clearly marked with a <b>&quot;2&quot; </b>on the top right hand side of the
box.</span></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB style='font-size:11.0pt;color:black'>This second
triple pack should be used for treatment days 7, 9 and 11.</span></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB style='font-size:11.0pt;color:black'>It contains
specially marked syringes with <b>0.50 ml</b> marking. This will help you to
inject the required dose only. </span></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB style='font-size:11.0pt;color:black'>After
finishing with the red pack, start using the <b>green triple pack </b>which is
clearly marked with a <b>&quot;3&quot; </b>on the top right hand side of the
box</span></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB style='font-size:11.0pt;color:black'>This third
triple pack should be used for treatment days 13, 15 and 17.</span></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB style='font-size:11.0pt;color:black'>It contains
specially marked syringes with <b>0.75 ml</b> marking. This will help you to
inject the required dose only. </span></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB style='font-size:11.0pt;color:black'>Finally,
after finishing with the green pack, start using the <b>blue triple pack </b>which
is clearly marked with a <b>&quot;4&quot; </b>on the top right hand side of the
box. This last triple pack should be used for treatment days 19, 21 and 23.</span></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB style='font-size:11.0pt;color:black'>It contains
syringes with <b>0.25, 0.5, 0.75 and 1.0 ml</b> markings. With triple pack 4
you can inject the full dose 1.0 ml. </span></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

</div>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;color:black;
background:yellow'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;color:black'>For
a description of how to prepare and use the Betaferon powder, please refer to
section 3. How to use Betaferon in the first part of the package leaflet and
to the Annex 'Self-injection procedure' in the second part of the package
leaflet. </span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;color:black;
background:yellow'>&nbsp;</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt'>In addition you
will need a disposal unit for used syringes and needles.</span></p>

<p class=Smalltext120><span lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

</div>

</body>

</html>
